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Hyaluronan is an abundant high-mo-
lecular weight polysaccharide in the 
extracellular matrix. Its accumulation 
is observed in several types of malig-
nancies. In this study, the mechanism 
of hyaluronan accumulation was 
clarified by analyzing the expression 
of hyaluronan synthesis (HAS1-3) 
and degradation (HYAL1-2) enzymes 
in normal, precancerous and can-
cerous states of human ovaries and 
endometria. Decreased HYAL1 levels 
were associated with increased tu-
moral hyaluronan content in ovarian 
and endometrial carcinomas. Fur-
thermore the decreased expression 
of HYAL1 was associated with more 
aggressive type of endometrial car-
cinoma and predicted early disease 
recurrence.
 
 
TIMO K. NYKOPP 
 
 
 
Expression of Hyaluronan Synthases and 
Hyaluronidases in  
Gynecological Malignancies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To be presented by permission of the Faculty of Health Sciences, University of Eastern Finland 
for public examination in Mediteknia Auditorium, Kuopio, on Friday, August 28th 2015, at 12 noon 
 
  
Publications of the University of Eastern Finland 
 Dissertations in Health Sciences  
Number 289 
 
 
Departments of Clinical Pathology and Forensic Medicine and Obstetrics and Gynecology,  
Institute of Clinical Medicine and Department of Anatomy, Institute of Biomedicine,  
School of Medicine, Faculty of Health Sciences, University of Eastern Finland 
Departments of Pathology and Gynecology and Obstetrics, Kuopio University Hospital 
Kuopio 
2015 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Grano Oy 
Kuopio, 2015 
 
Series Editors:  
Professor Veli-Matti Kosma, M.D., Ph.D. 
Institute of Clinical Medicine, Pathology 
Faculty of Health Sciences 
 
Professor Hannele Turunen, Ph.D. 
Department of Nursing Science 
Faculty of Health Sciences 
 
Professor Olli Gröhn, Ph.D. 
A.I. Virtanen Institute for Molecular Sciences 
Faculty of Health Sciences 
 
Professor Kai Kaarniranta, M.D., Ph.D. 
Institute of Clinical Medicine, Ophthalmology 
Faculty of Health Sciences  
 
Lecturer Veli-Pekka Ranta, Ph.D. (pharmacy) 
School of Pharmacy 
Faculty of Health Sciences 
 
Distributor:  
University of Eastern Finland 
Kuopio Campus Library 
P.O.Box 1627 
FI-70211 Kuopio, Finland 
http://www.uef.fi/kirjasto 
 
ISBN (print): 978-952-61-1814-7 
ISBN (pdf): 978-952-61-1815-4 
ISSN (print): 1798-5706 
ISSN (pdf): 1798-5714 
ISSN-L: 1798-5706 
 
			



)($&1'4&''04 %&("#(4$4)&&,4

)$%$4#*&'(,4$'%(!4

	4
	4
4
)%&*'$&'04 $#(4&(4#((!/4../4..4
%&("#(4$4,#$!$,4#4'((&'4

)$%$4#*&'(,4$'%(!4

	4
	4
4
$4&$##/4../4..4
	#'(()(4$4!#!4#2($!$,4
#*&'(,4$4'(&#4#!#4

	4
	4
4
&$''$&44""/4../4..4
	#'(()(4$4$"#2#($",4
#*&'(,4$4'(&#4#!#4

	4
	4
4
&$''$&4!3((4
$'"/4../4..4
	#'(()(4$4!#!4#2($!$,4
#*&'(,4$4'(&#4#!#4

	4
	4
4
*+&'04 $#(4## 4)&##/4../4..4
%&("#(4$4,#$!$,4#4'((&'4
)& )4#*&'(,4$'%(!4

4
	4
4
&$''$&4*4((/4..4
%&("#(4$4)&!4#4$&%$!$!4#'4
#*&'(,4$4	#')&4
4
	4
4
%%$##(04 &$''$&4!!4&%-#/4../4..4
%&("#(4$4($!$,4
#*&'(,4$4)& )4

4
	
IV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
V 
 
 
 
Nykopp, Timo K 
Expression of hyaluronan synthases and hyaluronidases in gynecological malignancies 
University of Eastern Finland, Faculty of Health Sciences 
Publications of the University of Eastern Finland. Dissertations in Health Sciences Number 289. 2015. 75 p. 
 
ISBN (print): 978-952-61-1814-7 
ISBN (pdf): 978-952-61-1815-4 
ISSN (print): 1798-5706 
ISSN (pdf): 1798-5706 
ISSN-L: 1798-5706 
 
ABSTRACT 
 
Hyaluronan is an abundant high-molecular weight polysaccharide in the extracellular matrix 
of various human tissues. Its accumulation is observed in many pathological conditions, 
including several types of malignancies of epithelial origin. Changes in hyaluronan content 
are a result of its metabolic dysregulation due to altered function and balance of hyaluronan 
synthesis and degradation enzymes. In human ovarian carcinoma, increased stromal 
hyaluronan is associated with poor outcome. Similarly, stromal hyaluronan accumulation 
has been observed in endometrial adenocarcinoma. In this study, the mechanism of 
hyaluronan accumulation in these gynecological malignancies was investigated by analyzing 
the expression of hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2), and their 
roles in tumorigenesis and invasion were clarified. 
Increased expression of HAS1-3 proteins was observed in ovarian and endometrial 
carcinomas without corresponding changes in mRNA levels, suggesting reduced protein 
turnover or altered post-transcriptional regulation. HYAL1 mRNA was significantly 
downregulated, which correlated with its enzymatic activity in ovarian serous carcinoma. 
Transcription of HYAL1 and HYAL2 mRNA was downregulated and correlated with 
decreased protein levels. The decreased HYAL1 mRNA levels were associated with increased 
tumoral hyaluronan content in both of these carcinoma types. 
 The expression of HYAL1 and HYAL2 protein in a larger set of histopathological samples 
of normal endometria, precancerous lesions, and endometrial adenocarcinomas were further 
examined. Increased HYAL2 expression was associated with the proliferative phase of the 
menstrual cycle. Decreased HYAL1 expression was associated with high carcinoma grade, 
deep myometrial invasion, large tumor size, lymphovascular invasion, and lymph node 
metastasis. HYAL1 was also an independent marker of early disease recurrence. In addition, 
the decreased expression of HYAL1 correlated with decreased tumoral E-cadherin levels, 
suggesting a potential role of HYAL1 in epithelial-to-mesenchymal transition (EMT).  
These results indicate that tumoral hyaluronan accumulation can be a consequence of 
decreased hyaluronidase function. The present results also indicate the importance of 
HYAL1 in endometrial cancer tumorigenesis, as its downregulation is associated with 
aggressive disease. 
 
National Library of Medicine Classification: QU 83, WP 540, WP 322, WP 460, QZ 202  
Medical Subject Headings: Hyaluronic Acid; Hyaluronan Synthase; Hyaluronoglucosaminidase; Menstrual 
Cycle; Ovarian Neoplasms; Endometrial Neoplasms; Cadherins; Epithelial-Mesenchymal Transition; 
Neoplasm Invasiveness 
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TIIVISTELMÄ
Hyaluronaani on soluväliaineen suurikokoinen sokerimolekyyli, jonka on todettu kertyvän
soluväliaineeseen epiteliaalista alkuperää olevissa syövissä. Hyaluronaanin kertymisen
taustalla on yleensä sen metabolian säätelyhäiriö, missä hyaluronaania rakentavien ja
hajottavien entsyymien toiminta on epätasapainossa. Munasarjan epiteliaaliset
pahanlaatuiset kasvaimet muodostavat huonoennusteisimman gynekologisten syöpien
ryhmän. Niissä hyaluronaanin kertyminen soluväliaineeseen liittyy aggressiiviseen
taudinkuvaan. Kohdun limakalvon syövässä, joka edustaa parempiennusteista
gynekologista syöpää, on myös todettu hyaluronaanin määrän lisääntyvän. Tämän
tutkimuksen tarkoituksena oli selvittää näissä kahdessa gynekologisessa syöpätaudissa niitä
mekanismeja jotka aiheuttavat hyaluronaanin kertymisen soluväliaineeseen tutkimalla
hyaluronaanisyntaasien (HAS1-3) ja hyaluronidaasien (HYAL1-2) ilmentymistä.
Munasarja- ja kohtusyövässä voitiin vaihtelevasti todeta hyaluronaanisyntaasien
ilmentymisen lisääntyneen proteiinitasolla, mutta ilman korrelaatiota vastaaviin lähetti-
RNA pitoisuuksiin. HYAL1 ali-ilmentyi ja korreloi hyaluronidaasi aktiivisuuden kanssa
seroosissa munasarjasyövässä. Kohtusyövässä sekä HYAL1, että HYAL2 ali-ilmentyivät
voimakkaasti ja tämä korreloi myös vastaavien geenien proteiinitasojen kanssa. Sekä
munasarja- että kohtusyövässä, alentunut HYAL1 lähetti-RNA taso korreloi kasvaneen
hyaluronaanipitoisuuden kanssa.
Koska tuloksemme osoittivat että hyaluronaanin kertymisen taustalla voi olla sen
alentunut hajotus, HYAL1 ja HYAL2 proteiinien ilmentymistä tutkittiin laajemmassa
kohtusyöpäaineistossa. Näissä tuloksissa HYAL2 liittyi enemmänkin eri kuukautiskierron
vaiheisiin. Kohtusyövässä HYAL1 oli ali-ilmentynyt ja korreloi vahvasti syövän
erilaistumisasteen kanssa. HYAL1 assosioitui aggressiiviseen kohtusyöpään liittyviin
piirteisiin, kuten syvään lihasinvaasioon, kasvaimen suureen kokoon, veri-imutieinvaasioon
ja imusolmukemetastaaseihin. Monimuuttuja-analyysissä alentunut HYAL1:n ilmentyminen
toimi itsenäisenä ennustekijänä kohtusyövän varhaisen uusiutumisen suhteen. HYAL1:n ali-
ilmentyminen liittyi myös epiteeli-mesenkyymi-transitioon, sillä se korreloi alentuneen E-
kadheriini tason kanssa.
Tämän väitöskirjatyön tulokset osoittivat että hyaluronaanin kertyminen syöpäkudoksiin
voi johtua sen alentuneesta hajotuksesta. Lisäksi tuloksemme osoittivat HYAL1:n
ennusteellisen merkityksen kohtusyövässä, sillä sen ali-ilmentyminen liittyi aggressiiviseen
tautiin.
Yleinen Suomalainen asiasanasto: Hyaluronaani; Kohtusyöpä; Munasarjasyöpä;
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”…we recognize that, unlike Beowulf at the hall of Hrothgar, we have not slain our enemy, the cancer 
cell, or figuratively torn the limbs from his body. In our adventures, we have only seen our monster 
more clearly and described his scales and fangs in new ways – ways that reveal a cancer cell to be, like 
Grendel, a distorted version of our normal selves. May this new vision and the spirit of tonight´s 
festivities inspire our band of biological warriors to inflict much greater wounds tomorrow.” 
Harold E. Varmus – speech at the Nobel Banquet, December 10, 1989  
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1 Introduction 
Cancer, the Emperor of all maladies (Mukherjee 2010), lives silently in our society, 
affecting human lives of all ages. There were 14.1 million new cancer cases, 8.2 million 
cancer deaths, and 32.6 million people living with cancer worldwide in 2012 
(GLOBOCAN 2012). Among gynecological malignancies, ovarian cancer is the 
leading cause of death in most Western countries, and the eighth most common type 
of cancer and the seventh most common cause of cancer-related death among women 
(Jemal et al. 2011). Endometrial cancer is the sixth most common cancer in women 
worldwide and the most common gynecological malignancy in developed countries. 
In contrast to ovarian cancer, most cases are diagnosed at an early stage and have a 
good prognosis (Siegel, Naishadham & Jemal 2013, Howlader et al. 2011).  
A major component of the local cancer cell microenvironment is extracellular 
matrix. This complex network of macromolecules has distinctive physical, 
biochemical, and biomechanical properties and plays a crucial role in cancer 
development and metastasis (Lu, Weaver & Werb 2012). Hyaluronan is a 
glycosaminoglycan (a linear polysaccharide) and one of the most abundant and 
ubiquitous components of the vertebrate extracellular matrix (Laurent, Fraser 1992). 
Hyaluronan synthases (HAS1-3) contribute to the biosynthesis of hyaluronan 
polymers that occurs transiently for cell division and motility (Itano et al. 1999). After 
synthesis, hyaluronan is rapidly degraded by endocytic uptake and hydrolyzed by 
hyaluronidases (Csoka, Frost & Stern 2001, McAtee, Barycki & Simpson 2014). In 
many human cancers, this normal hyaluronan metabolism is altered. In carcinomas of 
epithelial origin, hyaluronan accumulates in the tumor stroma, which can have 
devastating consequences (Tammi et al. 2008). 
In ovarian carcinoma, the high stromal hyaluronan level is significantly associated 
with poor differentiation, serous histological type, advanced stage, and large primary 
residual tumor. High stromal hyaluronan content is also an independent prognostic 
factor for short disease-free and overall survival (Anttila et al. 2000). Increased 
hyaluronan accumulation has also been shown in endometrial cancer (Afify et al. 
2005). 
In this thesis, the expression of hyaluronan synthesis (HAS1-3) and degradation 
(HYAL1-2) enzymes in serous ovarian adenocarcinomas and endometrial carcinomas 
was examined. By analyzing these genes, the possible alterations in hyaluronan 
metabolism that cause the increased hyaluronan content in tumors were investigated. 
Because the results suggest that decreased degradation could lead to tumoral 
hyaluronan accumulation, we analyzed the expression of hyaluronidases in a larger 
series of histopathological samples to elucidate their role in precancerous and 
malignant processes. 
2 
 
 
 
2 Review of the Literature 
2.1 OVARIAN CANCER 
2.1.1 Epidemiology and risk factors 
Ovarian cancer is the leading cause of death from all gynecological cancers in most 
Western countries, with more than 140,000 women dying from this disease each year 
worldwide. Thus, ovarian cancer is the eighth most common type of cancer and the 
seventh most common cause of cancer-related death among women. Ovarian cancer 
is uncommon before the age of 40, and the incidence increases until the age of 70-74 
(Jemal et al. 2011, Lowe et al. 2013). 
In Finland, ovarian cancer is the eleventh most common type of cancer in women, 
with 434 new ovarian cancer cases diagnosed in 2013. During the same period, 293 
women died due to ovarian cancer, making it the fifth most common cause of cancer 
death among women in Finland. For ovarian cancer, the age-adjusted incidence rate 
was 8.0 per 100 000 and mortality rate 4.1 per 100 000 (www.cancerregistry.fi). 
Nulliparity is associated with an increased risk of ovarian cancer, whereas 
pregnancy, lactation, oral contraceptive use, and tubal ligation are associated with 
reduced risk (Beral et al. 2008, Jordan et al. 2010, Hankinson et al. 1993). The most 
important risk factor for ovarian cancer is a strong family history (i.e., one or more 
first degree relatives with ovarian or breast cancer diagnosed under the age of 50) 
(Soegaard et al. 2009, Cannistra 2004). An identifiable genetic predisposition is present 
in 5-15% of cases (Boyd et al. 2000). Inherited mutations in tumor suppressor genes 
BRCA1 and BRCA2 are the most common cause of hereditary ovarian cancer. BRCA1 
and BRCA2 are located on chromosomes 17q and 13q, respectively, and their gene 
products are involved in DNA repair (King et al. 2003). In population-based studies, 
the lifetime risk for ovarian cancer in BRCA1 and BRCA2 mutation carriers is 24-39% 
and 8-22%, respectively (Chen et al. 2006, Risch et al. 2006). Approximately 15-30% of 
sporadic cases exhibit epigenetic hypermethylation of the BRCA1 promoter, leading 
to decreased protein expression (Baldwin et al. 2000).  
Lynch syndrome, also known as hereditary non-polyposis colorectal cancer 
syndrome (HNPPC), is a second familial disorder that carries an increased risk of 
ovarian cancer. It is an autosomal dominant cancer-susceptibility disorder caused by 
germline mutations in four mismatch repair (MMR) genes. Nearly 90% of the 
mutations are located in MLH1 and MSH2, and approximately 10% are located in 
MSH6 and PMS2.1 Carriers of MMR gene mutations are at high risk of early-onset 
colorectal, endometrial, and ovarian cancer. The Lynch syndrome spectrum also 
includes tumors of the small bowel, urothelium, biliary tract, and stomach (Lynch, de 
la Chapelle 2003). For ovarian cancer, the estimated cumulative cancer risk by 70 years 
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of age is 20% for MLH1, 24% for MSH2, and 1% for MSH6 mutations (Bonadona et al. 
2011). 
 
2.1.2 Pathogenesis 
Ovarian cancers are classified by histological appearance. Serous histology accounts 
for up to 80 - 85% of ovarian cancers. Mucinous and endometrioid tumors are less 
common (~10% each), followed by clear cell tumors and transitional, squamous, 
mixed, and undifferentiated subtypes (Soslow 2008). Borderline ovarian tumors are 
considered to be semi-malignant and are atypically proliferative without stromal 
invasion. Different histology is observed, but the majority of borderline tumors are 
serous or mucinous types (Silverberg et al. 2004). Classically, ovarian carcinomas are 
divided into three classes of histological nuclear grading, but a two class system (high-
grade and low-grade) is nowadays used, especially for serous carcinomas (Malpica et 
al. 2004).   
Recent morphological and molecular studies have changed the theory that ovarian 
cancer arises from the epithelium of the ovarian surface. Ovarian cancer is a 
heterogeneous disease. Serous tumors are thought to arise from the fallopian tube. 
Mucinous tumors are cystic tumors with a smooth lining of mucin-secreting epithelial 
cells resembling either endocervical or colonic epithelium, whereas endometrioid and 
clear cell lesions are thought to arise from dysregulated endometriosis (Wei et al. 
2013).  
The major histological subtypes of ovarian tumors are divided into type I and type 
II based on differences in histopathological features supported by molecular genetic 
changes. Type I tumors include low-grade serous carcinomas (LGSC), low-grade 
endometrioid carcinomas, clear cell carcinomas, Brenner tumors, and mucinous 
carcinomas. Type II tumors include high-grade serous carcinomas (HGSC), high-
grade endometrioid carcinomas, malignant mixed mesodermal tumors, and 
undifferentiated carcinomas (Shih, Kurman 2004, Hennessy, Coleman & Markman 
2009).  
LGSCs comprise a minority of epithelial ovarian carcinomas; at presentation, 70-
80% of patients have high-grade disease (Della Pepa et al. 2015). LGSCs have different 
epidemiology, histopathology, associated molecular changes, and clinical course than 
HGSCs (Diaz-Padilla et al. 2012). LGSCs arise in a stepwise manner from serous 
borderline tumors (SBLTs), in which KRAS or BRAF mutations are often present 
(Singer et al. 2003) or precede the development of SBLTs (Ho et al. 2004). Papillary 
tubal hyperplasia has been suggested to be a preceding lesion of SBLT closely related 
to an aberration in KRAS signaling that occurs very early in tumorigenesis (Kurman 
et al. 2011). Interestingly, in advanced stage LGSC, BRAF mutations are more rare 
(Wong et al. 2010) and may even prevent LGSC progression to more aggressive 
disease (Grisham et al. 2013).  
Low-grade endometrioid and clear cell carcinomas arise from dysregulated 
endometriosis, possibly due loss of tumor suppressor PTEN (Sato et al. 2000). 
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Mutations or inactivation of ARID1A are also associated with the development of 
endometrioid and clear cell carcinomas (Wiegand et al. 2010). 
The majority of ovarian carcinomas present as HGSC, harboring TP53 mutations in 
over 95% of cases, but mutations that are common in low-grade tumors are very rarely 
detected in high-grade tumors (Kurman 2013). HGSCs were first suggested to arise de 
novo in epithelial inclusion cysts, but their origin has been shown to be the fallopian 
tubes instead of the ovarian epithelium (Kurman 2013). The first evidence was found 
in gene expression studies demonstrating that the expression profiles of ovarian 
HGSCs more closely resemble fallopian tube epithelium (FTE) than ovarian surface 
epithelium (OSE) (Tone et al. 2008). In another study, investigators found that non-
invasive tubal carcinomas are associated with serous carcinomas, and these 
neoplasms were designated as serous tubal intraepithelial carcinoma (STIC) 
(Kindelberger et al. 2007).  STICs and concordant HGSCs involving the ovary have 
been shown to have identical TP53 mutations, supporting a clonal relationship (Kuhn 
et al. 2012). Moreover, studies of the human cancer genome atlas network showed this 
TP53 association in more than 97% of cases (Cancer Genome Atlas Research Network 
2011). 
 
2.1.3 Clinical features 
The symptoms of ovarian cancer are non-specific (e.g., nausea, general weakness, 
abdominal fullness), and most patients with early stage disease are asymptomatic. At 
the time of diagnosis, 70% of ovarian cancer patients have advanced disease 
presenting as stages III-IV. Ovarian cancer is staged on the basis of imaging, 
macroscopic findings in primary surgery, and histopathological samples taken for 
staging. The TNM and International Federation of Gynecology and Obstetrics (FIGO) 
criteria and classification of staging are presented in Table 1 (Edge et al. 2010b).  
The rates of long-term survival (> 5 years) in patients with early-stage disease 
(stages I-II) are 71-90%, 19-47% with advanced disease (stages III-IV) (Heintz et al. 
2006). In early-stage disease, the stage, rupture of the ovarian capsule, grade, 
histology, age, and pelvic fluid cytology have the best prognostic significance 
(Hennessy, Coleman & Markman 2009). In advanced stages, the presence of residual 
tumor and its size after surgical debulking has the strongest prognostic significance 
(du Bois et al. 2009).  Stage, histology, age, grade, and lymph node status are other 
important factors predicting survival in advanced disease (Hennessy, Coleman & 
Markman 2009). 
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Table 1. TNM and FIGO Classifications for Ovarian Cancer 2010 
 
 
 
 
 
 
 
 
 
 
 
 
 
TNM FIGO Definition
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 I Tumor limited to the ovaries (1 or both)
T1a IA Tumor limited to 1 ovary; capsule intact, no tumor on ovarian surface; no 
malignant cells in ascites or peritoneal washings
T1b IB Tumor limited to both ovaries; capsules intact, no tumor on ovarian 
surface; no malignant cells in ascites or peritoneal washings
T1c IC Tumor limited to 1 or both ovaries with any of the following: capsule 
ruptured, tumor on ovarian surface, malignant cells in ascites or 
peritoneal washings
T2 II Tumor involves 1 or both ovaries with pelvic extension
T2a IIA Extension and/or implants on the uterus and/or tube(s); no malignant 
cells in ascites or peritoneal washings
T2b IIB Extension to other pelvic tissues; no malignant cells in ascites or 
peritoneal washings
T2c IIC Pelvic extension (T2a or T2b) with malignant cells in ascites or 
peritoneal washings
T3 III Tumor involves 1 or both ovaries with microscopically confirmed 
peritoneal metastasis outside the pelvis
T3a IIIA Microscopic peritoneal metastasis beyond the pelvis (no macroscopic 
tumor)
T3b IIIB Macroscopic peritoneal metastasis beyond the pelvis 2 cm or less in 
greatest dimension
T3c IIIC Macroscopic peritoneal metastasis beyond the pelvis > 2 cm in greatest 
dimension and/or regional lymph node metastasis
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 IIIC Regional lymph node metastasis
M0 No distant metastasis
M1 IV Distant metastasis (excludes peritoneal metastasis)
Primary tumor (T)
Regional lymph nodes (N)
Distant metastasis (M)
The presence of nonmalignant ascites is not classif ied. The presence of ascites does not affect staging unless malignant 
cells are present.
Liver capsule metastasis is T3/stage III; liver parenchymal metastasis, M1/stage IV. Pleural effusion must have positive 
cytology for MI/stage IV.
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2.2 ENDOMETRIAL CANCER 
2.2.1 Epidemiology and risk factors 
Endometrial cancer is the sixth most common cancer in women worldwide and the 
most common gynecologic malignancy in developed countries, with an incidence of 
15-25 per 100,000 women annually. The majority of cases are diagnosed at an early 
stage of disease and have a good prognosis, as indicated by the overall 5-year survival 
rate of 80% (Siegel, Naishadham & Jemal 2013, Howlader et al. 2011).  
In Finland, endometrial cancer is the fifth most common type of cancer in women 
and 868 new endometrial cancer cases were diagnosed in 2013. During the same 
period, 189 women died due to endometrial cancer, making it the ninth most common 
cause of cancer death among women in Finland. For endometrial cancer, the age-
adjusted incidence rate was 13.8 per 100 000 and the mortality rate 2.1 per 100 000 
(www.cancerregistry.fi).  
The majority of endometrial cancers are estrogen-related, and estrogen-promoting 
factors increase the risk of disease. Unopposed exposure to estrogen is likely to cause 
endometrial hyperplasia and be a major risk factor for type I endometrial cancer. 
Increased risk can be significantly reduced by concomitant administration of a 
progestin (Voigt et al. 1991). Other risk factors are age, obesity and metabolic 
syndrome, diabetes, nulliparity, high years of menstruation, and tamoxifen (Amant et 
al. 2005). 
A familial tendency for endometrial cancer is found in first degree relatives 
(Lucenteforte et al. 2009). Interestingly, women with first degree relatives with 
colorectal cancer have a higher risk of developing endometrial cancer than those 
without a family history (Win, Reece & Ryan 2015). Women with Lynch syndrome 
have a high risk of endometrial cancer and are likely to develop the disease at a young 
age. With Lynch syndrome, the lifetime risk of endometrial cancer in women with 
MLH1 or MLH2 mutations is as high as 60%, with a median age of 49 years. Women 
with MSH6 mutations have a similar risk of endometrial cancer but a later age of 
diagnosis (Lu, Broaddus 2005, Lu, Daniels 2013). 
2.2.2 Pathogenesis 
Approximately 80% of endometrial cancers are endometrioid adenocarcinomas. 
Serous and clear cell carcinomas account for 1-5% and 5-10% of endometrial cancers, 
respectively. Mucinous, squamous cell, transitional cell, and small cell carcinomas 
compromise less than 2% of endometrial cancers (Clement, Young 2002, Boruta et al. 
2004). Endometrioid adenocarcinomas are divided into three classes in the histological 
nuclear grading system. Serous and clear cell carcinomas are classified as high-grade 
by definition (Prat 2004).  
There are two major subdivisions of endometrial cancer with different histological 
and genetic profiles. The most common carcinomas (type I) are estrogen-dependent, 
endometrioid-type, and present with a low histological grade (grades 1-2). Type I 
tumors usually develop in postmenopausal women and coexist with or are preceded 
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by complex and atypical endometrial hyperplasia. Women with atypical hyperplasia 
will have an approximately 50% risk of endometrial carcinoma (Bokhman 1983, 
Amant et al. 2005, Horn et al. 2004).  
Approximately 10% of endometrial carcinomas are type II tumors, which occur 
mainly in older postmenopausal women and are not dependent on estrogen. Most 
type II tumors are associated with endometrial atrophy, are more aggressive, and are 
mainly high-grade serous or clear cell carcinomas (non-endometrioid cancers) or 
poorly differentiated endometrioid carcinoma (grade 3). Type II carcinomas normally 
arise de novo, but occasionally they are associated with serous endometrial 
intraepithelial carcinoma in an atrophic endometrium or endometrial polyp. Forty 
percent of non-endometrial cancers are mixed tumors with an endometrioid 
component (Matias-Guiu, Prat 2013, Amant et al. 2005, Bokhman 1983). 
In type I carcinomas, mutations has been found in the PTEN, K-RAS, PIK3CA, and 
CTNNB1 genes, and tumors exhibit microsatellite instability (MI) (Matias-Guiu, Prat 
2013, Mutter et al. 2000, Kong et al. 1997, Lagarda et al. 2001, Rudd et al. 2011, Machin 
et al. 2002). In endometrial cancers associated with Lynch syndrome, MI has been 
reported in 75% of cases; MI has also been reported in 25-30% of sporadic carcinomas, 
occurring more frequently in type I cancers (Duggan et al. 1994). 
In contrast to type I carcinomas, 90% of type II non-endometrial carcinomas are 
associated with alterations in p53, and 80-90% of tumors have markedly reduced E-
cadherin expression. The expression of c-erb-B2 (HER-2) is also reduced, alterations in 
STK15 (mitotic spindle checkpoint) regulation are observed, and heterozygosity is lost 
at multiple loci, reflecting chromosomal instability (Lax et al. 2000, Tashiro et al. 1997, 
Hayes, Ellenson 2010, Morrison et al. 2006).  
Comprehensive genomic and transcriptomic analyses of endometrioid and serous 
carcinomas have revealed a new genomic classification for these endometrial 
carcinomas (Cancer Genome Atlas Research Network et al. 2013). On the basis of the 
integration of mutation spectra, copy number alterations, and MI status, endometrial 
carcinomas of endometrioid and serous histology are categorized into four genomic 
classes: 1) POLE (ultramutated) tumors characterized by very high mutation rates and 
hotspot mutations in the exonuclease domain of POLE (a subunit of DNA polymerase 
İ that plays a role in DNA replication), few copy-number aberrations, increased 
frequency of C Æ A transversions, mutations in PTEN, PIK3R1, PIK3CA, FBXW7, and 
KRAS, and favorable outcome; 2) an MI group of endometrioid tumors characterized 
by MI due to MLH1 promoter methylation, high mutation rates, few copy-number 
aberrations, recurrent RPL22 frameshift deletions, and KRAS and PTEN mutations; 3) 
low copy-number (endometrioid) tumors, comprising microsatellite-stable grade 1 
and 2 endometrioid cancers with low mutation rates characterized by frequent 
CTNNB1 mutations; and 4) high copy-number (serous-like) tumors characterized by 
extensive copy-number aberrations and low mutation rates, recurrent TP53, FBXW7, 
and PPP2R1A mutations, infrequent PTEN and KRAS mutations, and poor outcome 
(Murali, Soslow & Weigelt 2014, Cancer Genome Atlas Research Network et al. 2013). 
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2.2.3 Clinical features 
Abnormal uterine bleeding in postmenopausal women is the most frequent symptom 
of endometrial cancer. Diagnosis is usually made histologically from endometrial 
biopsy or curettage (Amant et al. 2005).  
Prognostic parameters for endometrial carcinoma can be divided into uterine and 
extrauterine factors. Uterine factors include histological type, histological grade, 
depth of myometrial invasion, vascular invasion, presence of atypical endometrial 
hyperplasia, cervical involvement, DNA ploidy and S-phase fraction, and hormone 
receptor status. Extrauterine factors include positive peritoneal cytology, adnexal 
involvement, pelvic and para-aortic lymph node metastasis, and peritoneal metastasis 
(Prat 2004). Endometrial cancer is staged on the basis of findings during primary 
surgery and in pathological samples. The TNM and FIGO (International Federation of 
Gynecology and Obstetrics) criteria and classification of staging are presented in Table 
2 (Edge et al. 2010a).  
FIGO stage is the single strongest prognostic parameter of endometrial carcinoma. 
The 5-year disease-free survival has been reported to be 85% for stage I, 75% for stage 
II, 45% for stage III, and 25% for stage IV (Amant et al. 2005). In low-stage endometrial 
carcinomas, myometrial invasion is an independent predictor of outcome. The 
previous iteration of the FIGO system subdivided stage I tumors into IA, IB, and IC 
tumors. Stage IA tumors were confined to the endometrial complex, stage IB tumors 
invaded only the inner half of the myometrium (<50% of the depth of the 
myometrium), and stage IC tumors invaded the outer half of the myometrium (≥50% 
of the depth of the myometrium). In the 2009 revised FIGO staging system, tumors 
confined to the endometrium and those invading the inner half of the myometrium 
are designated as stage IA tumors, and tumors invading the outer half of the 
myometrium are designated as stage IB tumors (Edge et al. 2010a). According to older 
FIGO classification for myometrial invasion, 5-year survival for low-grade IA lesions 
is 95%, whereas high-grade IC lesions had only 42% survival (Grigsby et al. 1992, 
Creutzberg et al. 2004, Amant et al. 2005). 
Histological type plays a critical role; type II cancers account for roughly 10% of all 
endometrial cancers but involve more than 50% of disease recurrence and deaths. The 
5-year survival rates for serous, clear cell, squamous, and undifferentiated carcinomas 
vary from 30% to 70% (Amant et al. 2005, Prat 2004). Histological grading of 
endometrioid endometrial carcinomas is prognostically important; the 5-year overall 
survival is 94% for grade 1 tumors, 84% for grade 2 tumors, and 72% for grade 3 
tumors (Zaino et al. 1991). 
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Table 2. TNM and FIGO Classifications for Endometrial Cancer 2010 
 
 
 
 
 
 
TNM FIGO Definition
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis* Carcinoma in situ (preinvasive carcinoma)
T1 I Tumor confined to corpus uteri
T1a IA Tumor limited to endometrium or invades less than one half of the 
myometrium
T1b IB Tumor invades one half or more of the myometrium
T2 II Tumor invades stromal connective tissue of the cervix but does not 
extend beyond uterus**
T3a IIIA Tumor involves serosa and/or adnexa (direct extension or 
metastasis)
T3b IIIB Vaginal involvement (direct extension or metastasis) or parametrial 
involvement
IIIC Metastases to pelvic and/or para-aortic lymph nodes
T4 IV Tumor invades bladder mucosa and/or bowel mucosa, and/or 
distant metastases
IVA Tumor invades bladder mucosa and/or bowel mucosa (bullous 
edema is not sufficient to classify a tumor as T4)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 IIIC1 Regional lymph node metastasis to pelvic lymph nodes
N2 IIIC2 Regional lymph node metastasis to para-aortic lymph nodes, with or 
without positive pelvic lymph nodes
M0 No distant metastasis
M1 IVB Distant metastasis (includes metastasis to inguinal lymph nodes, 
intraperitoneal disease, or lung, liver, or bone metastases; it 
excludes metastasis to para-aortic lymph nodes, vagina, pelvic 
serosa, or adnexa)
Distant metastasis (M)
Regional lymph nodes (N)
Primary tumor (T)
*FIGO no longer includes stage 0 (Tis)
**Endocervical glandular involvement should only be considered as stage I and no longer as stage II
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2.3. HYALURONAN 
2.3.1 Structure and biochemical properties of hyaluronan 
Hyaluronan (hyaluronic acid or hyaluronate) is a high molecular mass linear 
glycosaminoglycan (GAG). Hyaluronan is found predominantly in the extracellular 
matrix (ECM) between cells but can be found intracellularly and on the cell surface. 
Hyaluronan is a ubiquitous polymer consisting of D-glucuronic acid (GlcUA) and N-
acetyl-D-glucosamine (GlcNAc) with the repeating disaccharide structure of (–1,3-N-
acetyl-D-glucosamine–1,4-D-glucuronic acid–)n (Figure 1).  
 
 
 
 
Figure 1. Repeating disaccharide structure of the hyaluronan chain with its N-acetyl-D-
glucosamine (GlcNAc) and D-glucuronic acid (GlcA) repeating units linked via alternating 
β1->4 and β1->3 glycosidic bonds. 
 
The number of repeating units varies but can reach up to 25,000, corresponding to a 
molecular mass of 10 million Da (Stern 2008a). Hyaluronan has one carboxyl group, 
four hydroxyl groups, and an acetyl amine group per disaccharide repeating unit, 
making it a polyelectrolyte with a negative charge at neutral pH. Due to hydrogen 
bonding and mutual electrostatic repulsion between carboxyl groups, hyaluronan has 
unique hydrodynamic properties, such as the capacity to bind large amounts of water 
and form viscous gels at relatively low concentrations. In more concentrated solutions, 
hyaluronan molecules form a continuous but porous meshwork that can act as a filter, 
facilitating the diffusion of small molecules and excluding large molecules. When 
retained at the cell surface, this voluminous pericellular matrix has been termed the 
“glycocalyx” and is involved in structural and mechanochemical properties, the 
regulation of cell division and motility, and in cancer progression and metastasis. 
However, hyaluronan is more than a structural component of the ECM, as it also 
regulates cell behavior by interacting with cell surface receptors and initiating 
signaling pathways (Toole 2004, Tammi et al. 2008, Evanko et al. 2007, Itano, Kimata 
2002).   
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2.3.2 Biosynthesis of hyaluronan 
Although hyaluronan belongs to the family of GAGs that includes heparan sulfate 
and chondroitin sulfate, their synthesis differs greatly. Other GAGs are made as 
proteoglycans, but hyaluronan is synthesized as a free polysaccharide and not 
covalently bound to a protein core (Toole 2004). Hyaluronan is synthesized by one of 
the three hyaluronan synthase proteins (HAS 1-3), which are integral membrane 
proteins containing seven putative membrane-spanning regions. The large predicted 
cytoplasmic loop contains the UDP-binding motif and the catalytic sites for 
glycosyltransferases (Itano, Kimata 2002). Each HAS is capable of transferring the 
sugars from both UDP-GlcA and UDP-GlcNAc substrates in the presence of Mg2+ or 
Mn2+, and each is able to synthesize hyaluronan alone (Weigel, DeAngelis 2007). 
Hyaluronan is synthesized on the inner face of the plasma membrane, and the 
growing chain is extruded or translocated to the extracellular space (Itano, Kimata 
2002).  
HAS isoenzymes are highly homologous and independently active in hyaluronan 
synthesis, but they still differ from each other (Itano, Kimata 2002). The kinetic 
properties of the isoenzymes also differ. The affinity of HAS1 for its substrates is lower 
than that of HAS2, and HAS3 has the highest affinity implying a lower synthesis rate 
of hyaluronan. In cell culture, HAS1 transfectants have smaller pericellular coats than 
those of HAS2 and HAS3 (Itano et al. 1999). Furthermore, HAS1 requires a higher 
UDP-sugar concentration than HAS2 and HAS3, and HAS1 expression correlates with 
cellular UDP-sugar supply (Rilla et al. 2013). Interestingly, the cellular UDP-GlcNAc 
content controls HAS2 expression. High cellular UDP-GlcNAc decreases HAS2 
expression in keratinocytes, and a low cellular UDP-GlcNAc concentration increases 
HAS2 expression (Jokela et al. 2011). 
In mammals, HAS genes are highly homologous but located in different 
chromosomes. In humans, HAS1 is located on chromosome 19 q13.4, HAS2 on 
chromosome 8q24.12, and HAS3 on chromosome 16q22.1 (Spicer et al. 1997). HAS2 is 
the most important gene in the regulation of hyaluronan synthesis, as large changes 
in the rate of synthesis are noted with the use of stimulants that affect its expression 
(Tammi et al. 2011, Tien, Spicer 2005). In addition, deletion of only HAS2 results in a 
lethal phenotype in the knockout mouse model (Camenisch et al. 2000). The 
expression of HAS genes changes rapidly during embryonic development, and in 
adult tissues hyaluronan synthesis is stimulated by injury, inflammation, and 
neoplastic tumors (Tammi et al. 2011). Multiple growth factors and cytokines are 
involved in the transcriptional regulation of HAS genes, but the response depends on 
the cell type and treatment conditions (Tammi et al. 2011). Hyaluronan synthesis is 
also sensitive to prostaglandins and hormones. HAS2 expression is upregulated and 
the pericellular formation of hyaluronan increased by prostaglandins (Sussmann et al. 
2004). Corticosteroids have been shown to suppress HAS2 expression (Zhang et al. 
2000). In the uterine cervix of pregnant mice, progesterone increases HAS3 expression, 
whereas HAS1 and HAS2 expression are downregulated (Uchiyama, Sakuta & 
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Kanayama 2005). Moreover, the subcutaneous injection of estrogen in mice increases 
dermal hyaluronan with the induction of HAS3 (Rock et al. 2012). 
Post-translational regulation of hyaluronan synthases has also been reported. 
Cytokines, growth factors, and protein kinase C activators have immediate influence 
on HAS activity in addition to their stimulation of HAS transcription (Tammi et al. 
2011). Phosphorylation has been shown to influence HAS activity. Hyaluronan 
secretion is increased when HAS protein is phosphorylated using phorbol ester or 
interleukin (IL)-1beta (Vigetti et al. 2009). Activation of ERK1/2 and protein kinase-C 
has also been shown to activate HAS proteins (Bourguignon, Gilad & Peyrollier 2007, 
Wang, Hascall 2004). On the other hand, phosphorylation of HAS2 by AMKP reduces 
hyaluronan synthesis in human aortic smooth muscle cells (Vigetti et al. 2011). O-
GlcNacylation is a reaction in which ȕ-N-acetylglucosamine (O-GlcNAc) is linked to 
the side chain hydroxyl group of serine or threonine. After glucosamine treatments, 
HAS2 is O-GlcNacylated, increasing its activity in isolated membranes and cell 
cultures (Vigetti, Passi 2014, Vigetti et al. 2012). Proteins are led to proteosomal 
degradation when they are labeled with polyubiquitin chains. Mono-ubiquination is 
required for HAS2 activity, as its enzymatic activity is lost with site-directed 
lys190Arg mutation (Lys 190 is normally mono-ubiquinated) (Karousou et al. 2010). 
Intracellular trafficking can also control hyaluronan synthase function; Rab10-
mediated endocytosis has been shown to control HAS3 levels in the plasma membrane 
and change the cell surface hyaluronan coat and hyaluronan secretion (Deen et al. 
2014). 
 
2.3.3 Degradation of hyaluronan 
In human tissues, approximately 33% of total body hyaluronan turns over daily. This 
rapid process is mostly the result of hyaluronidases, enzymes that are primarily 
involved in the degradation of hyaluronan (Stern 2004). Alone or with hyaluronidase, 
hyaluronan can also be fragmented by reactive oxygen species (ROS) and free radicals 
(Agren, Tammi & Tammi 1997, Monzon et al. 2010a). Tight regulation of hyaluronan 
catabolism is crucial for normal homeostasis and embryonic development, wound 
healing, tissue regeneration, and repair (Stern, Jedrzejas 2006). Approximately 20% of 
total body hyaluronan is degraded in peripheral tissues, where the rest 80% goes to 
the lymphatic system, mainly to be degraded in the lymph nodes (85%). Fifteen 
percent of this lymphatic hyaluronan goes to the liver via the blood circulation where 
it is degraded in minutes (Laurent, Dahl & Reed 1991, Stern 2004, Jadin, Bookbinder 
& Frost 2012).  
Hyaluronan catabolism involves the binding of hyaluronan to a specific cell-surface 
receptor, such as CD44 in the peripheral tissues, LYVE-1 in the lymphnodes, and 
HARE in the liver. High molecular weight hyaluronan is fragmented by the 
membrane-associated HYAL-2. Hyaluronan is internalized by hyaluronan receptors 
or fluid phase endocytosis for lysosomal catabolism and fragmentation. The 
fragments are taken into vesicles, and eventually lysosomes, for complete degradation 
to monosaccharides (Stern 2004). HYAL-1 is a key enzyme involved in the lysosomal 
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degradation of hyaluronan by exoglycosidases (hexosaminodase and glucuronidase) 
(Gushulak et al. 2012). 
Hyaluronidases are endoglycosidases, as they break the ȕ-N-acetyl-D-glucosamine 
linkages in hyaluronan polymer (Figure 2). Hyaluronidases predominantly degrade 
hyaluronan, but they also have a limited ability to degrade chondroitin sulfate and 
chondroitin. 
 In the human genome, there are six hyaluronidase genes, and they are linked in 
two different clusters. HYAL-1, HYAL-2, and HYAL-3 are located in chromosome 
3p21.3, and HYAL-4, hyaluronidase pseudogene 1 (HYAL-P1), and PH-20 (SPAM1) 
are located in chromosome 7q31.3 (Csoka, Frost & Stern 2001). These two clusters of 
hyaluronidase genes may have arisen through gene duplication events, as they also 
share significant amino acid identity. Among the six mammalian hyaluronidases, 
HYAL-1, HYAL-2, and PH-20 are well characterized. HYAL-1 and HYAL-2 are the 
two major hyaluronidases involved in the degradation of hyaluronan (Stern, Jedrzejas 
2006). 
 
Figure 2. Hyaluronidase cleaves N-acetyl-D-glucosamine β(1->4) glycoside bonds in 
hyaluronan polymer   
 
HYAL-1 was the first hyaluronidase isolated and characterized from human 
plasma (Afify et al. 1993). HYAL-1 is generated by two endoprotease reactions that 
form a 57-kDa single polypeptide glycoprotein or a processed 45 kDa form. Both 
isoforms occur in urine and tissue extracts, but only the high-molecular weight 
isoform is present in circulation, with a low concentration of 60 ng/ml (Girish, 
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Kemparaju 2007, Stern, Jedrzejas 2006). Knockdown of Hyal-1 results in an 80% 
decrease in total acid hyaluronidase activity in the mouse liver, confirming that 
HYAL-1 plays a key role in HA catabolism in this organ (Boonen et al. 2014).  HYAL-
1 has high specific activity for the degradation of hyaluronan and is in an active form 
at acidic pH.  
HYAL-1 degrades high-molecular weight hyaluronan down to hexa- and 
tetrasaccharides in lysosomes (Stern 2004). HYAL-1 precursor traffics to endosomes 
via a mannose 6-phosphate-independent secretion/recapture mechanism involving 
the mannose receptor. Inside the endosomes, the precursor protein is processed into 
a form with a smaller molecular mass and transported to lysosomes, suggesting that 
non-covalent associations support the lysosomal activity of HYAL-1 (Puissant et al. 
2014).  
In humans, HYAL-1 deficiency can cause a lysosomal storage disease known as 
mucopolysaccharidosis IX (Triggs-Raine et al. 1999). HYAL-1 knockout mice are viable 
and fertile without elevated hyaluronan levels in the serum or non-skeletal tissues. As 
in mucopolysaccharidosis IX, HYAL-1-deficient mice develop osteoarthritis and 
exhibit hyaluronan accumulation in the joints (Martin et al. 2008). HYAL-1 also plays 
a role in the regulation of ovarian follicle development, showing an inter-relationship 
between this enzyme and the follistatin/activin/Smad3 pathway and the apoptotic 
process (Dumaresq-Doiron et al. 2012). High HYAL1 activity can result in apoptosis 
by increasing the expression of WOX1 (WW domain-containing oxidoreductase, 
WWOX) (Lokeshwar et al. 2005). WOX1 causes mitochondrial permeabilization and 
is an essential partner of p53 in cell death (Chang et al. 2001). Hyaluronidase can also 
cause apoptosis by inducing NAD+-linked 15-hydroxyprostaglandin dehydrogenase 
(15-PDGH), an enzyme that degrades prostaglandins and promotes apoptosis in lung 
carcinoma cells (Ding et al. 2005). Ectopic expression of HYAL1 has also been 
demonstrated to induce granulosa cell apoptosis (Dumaresq-Doiron et al. 2012). 
HYAL-2 is a glycosylphosphatidylinositol-anchored, lipid raft-associated 
hyaluronidase that is active under acidic conditions at the cell surface (Andre et al. 
2011). HYAL-2 has been suggested to initiate the degradation of hyaluronan, 
processing it to approximately 20 kDa products (50 disaccharide units), as HYAL-1 
and exoglycosidases (hexosaminodase) continue degradation the protein into smaller 
particles in lysosomes (Stern 2004, Gushulak et al. 2012). HYAL-2 can also act as a 
receptor on the cell surface for oncogenic sheep retroviruses, but it does not play a 
crucial role in cancer induction (Miller 2008). Studies in knockout mice have shown 
an essential role of HYAL-2 in hyaluronan catabolism. HYAL-2 knockout mice are 
viable and fertile despite a 10-fold increase in plasma hyaluronan levels and 2-fold 
increase in plasma hyaluronidase activity. No global accumulation of hyaluronan 
occurs in the tissues, though liver sinusoidal cells seem overloaded with high-
molecular weight hyaluronan. Mice also exhibit localized congenital defects in 
frontonasal and vertebral bone formation and suffer from mild thrombocytopenia and 
chronic hemolysis (Jadin et al. 2008). Outbred HYAL-2 knockout mice exhibit a more 
severe phenotype with increased mortality and an accumulation of extracellular 
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hyaluronan, leading to dramatic cardiopulmonary dysfunction. Serum hyaluronan 
levels in these HYAL-2 knockout mice increase continuously, reaching an average 27-
fold increase by the time of euthanasia (Chowdhury et al. 2013). 
The major HYAL-3 transcript is enzymatically inactive and appears to play only a 
supportive role in HYAL-1 expression (Hemming et al. 2008). HYAL-3 knockout mice 
also do not display any evidence of hyaluronan accumulation (Atmuri et al. 2008). 
Very little is known about HYAL-4, but its expression is limited, and it appears to be 
a chondroitinase with no activity against hyaluronan (Stern, Jedrzejas 2006). HYAL-
P1 is a pseudogene with active transcription but no translation in humans (Stern, 
Jedrzejas 2006). 
PH-20 is glycosylphosphatidylinositol-anchored hyaluronidase with activity at 
acidic and neutral pH. It is mainly a sperm-associated testicular hyaluronidase, but it 
is also expressed epididymis, breast, placenta, and fetal tissues (Stern, Jedrzejas 2006). 
PH-20 plays an important role during ovum fertilization, as it facilitates penetration 
of the sperm through the cumulus oophorus and zona pellucida of the ovum, and it 
also works as a receptor during fertilization (Cherr, Yudin & Overstreet 2001). 
There are different approaches in the regulation of hyaluronidases, as little is 
known about the exact mechanisms. Alternative splicing resulting in enzymatically 
inactive proteins is one mechanism of HYAL-1 regulation, and one of the splice 
variants (HYAL1-v1) has been shown to act as a negative regulator of tumor growth, 
invasion, and angiogenesis (Lokeshwar et al. 2002, Lokeshwar et al. 2006). HYAL-1 
expression has also been shown to be regulated epigenetically by the binding of 
different transcription factors (SP1, EGR-1, and AP-2) to the methylated and 
unmethylated HYAL-1 promoter (Lokeshwar et al. 2008). In human airway epithelial 
cells, pro-inflammatory cytokines (TNF-alpha and IL-1beta) have been shown to 
increase HYAL1-3 expression (Monzon et al. 2008), and ROS increase HYAL2 
expression and activity (Monzon et al. 2010b). In chondrocytes, HYAL-2 expression is 
constitutive and does not appear to respond to cytokines, growth factors, or cellular 
mediators (Chow, Knudson 2005).  
 
2.3.4 Hyaluronan binding proteins and receptors 
As hyaluronan is secreted to the cell surface and extracellular matrix, it interacts with 
different molecules and hyaluronan binding proteins, including receptors with 
signaling properties. This group of proteins is called hyaladherins. Most hyaladherins 
belong to the link module superfamily, with a hyaluronan binding domain of 100 
amino acids as a common feature. Hyaladherins can be extracellular, intracellular, or 
localize to the cell surface.  In addition to the link proteins, aggrecan, versican, 
brevican, neurocan, tumor necrosis factor alpha stimulated gene-6 (TSG-6), are 
members of the link protein superfamily are located extracellularly. Sialoprotein 
(SPACR) and sialoproteoglycan (SPACRCAN) also have extracellular locations, but 
they are not part of the link family. CD44, LYVE-1, and HARE, which are cell surface 
receptors for hyaluronan, belong to the link module superfamily (Day, Prestwich 
2002), whereas transmembrane hyaluronan receptor laylin does not have the link 
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module (Bono et al. 2001). Intracellular hyaluronan binding proteins include 
HABP)/P32 (hyaluronan binding protein), CDC37, and RHAMM (receptor for 
hyaluronan-mediated motility), and the latter is also found on the cell surface (Day, 
Prestwich 2002). As CD44 and RHAMM are the major receptors in cancer, they will 
be discussed in more detail. 
CD44 is by far the most characterized cell surface receptor for hyaluronan. It is a 
single-pass transmembrane glycoprotein expressed in most cell types (Toole 2009). 
CD44 is located in the short arm of chromosome 11. The regulation of CD44 is well 
known, occurring through promoter methylation, mRNA transcription, post-
translational glycosylation and phosphorylation, variable splicing, and ligand binding 
(Bourrguignon et al. 1995, Naor, Sionov & Ish-Shalom 1997). Hyaluronan is the 
principal ligand for CD44, but many other molecules, such as osteopontin, FGF, or 
selectin, have been shown to be able to bind CD44 (Toole 2009). With the help of CD44 
receptor, hyaluronan can anchor to the cell surface and form a pericellular matrix with 
associated aggregating proteoglycans (Evanko et al. 2007). CD44 is also involved in 
the endocytosis of hyaluronan (Thankamony, Knudson 2006). Most importantly, 
hyaluronan can activate intracellular signaling cascades associated with migration, 
proliferation, and invasion through its interaction with CD44 (Bourguignon 2008). 
RHAMM is located in chromosome 5, and the transcript is alternatively spliced into 
intracellular and cell surface variants (Zhang et al. 1998). RHAMM does not belong to 
the link module superfamily, as it uses special RHAMM-type hyaluronan binding 
motifs to interact with hyaluronan (Yang et al. 1994). RHAMM can be present in the 
cytoplasm, nucleus, or cell surface. In normal adult human tissues, RHAMM mRNA 
and protein expression is low. RHAMM expression is increased in wound repair 
(Samuel et al. 1993), and its genetic deletion results in slow healing skin wounds (Tolg 
et al. 2006). RHAMM has been suggested to control microtubule assembly during 
mitosis (Maxwell, McCarthy & Turley 2008). The hyaluronan-RHAMM interaction 
can initiate signaling cascades and activate CD44; moreover, RHAMM can co-operate 
with CD44 signaling through ERK1/2 and promote cancer cell motility (Toole 2009). 
2.4 HYALURONAN AND CANCER 
2.4.1 Altered tissue hyaluronan content and cancer 
Alterations in hyaluronan metabolism occur in many cancer types. Tumoral 
hyaluronan content can decrease or increase depending on the origin of the neoplastic 
process. A stratified epithelium that normally covers the hyaluronan-rich stroma goes 
through a dramatic change in hyaluronan content when carcinomas arise from its 
squamous cells (Tammi et al. 2008). This hyaluronan depletion has been shown with 
squamous cell carcinoma (SCC) of the mouth (Kosunen et al. 2004), larynx (Hirvikoski 
et al. 1999), lung (Pirinen et al. 1998), esophagus (Wang et al. 1996), vulva (Hamalainen 
et al. 2010), and skin (Karvinen et al. 2003).   
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In contrast, hyaluronan accumulation has been observed in carcinomas arising 
from epithelial cells that are normally devoid of hyaluronan and often surrounded by 
hyaluronan-poor connective tissue. High stromal hyaluronan levels have been found 
in many tumors of epithelial origin and correlate with poor prognosis (Tammi et al. 
2008). In ovarian carcinoma, the high stromal hyaluronan level is significantly 
associated with poor differentiation, serous histological type, advanced stage, and 
large primary residual tumor. Furthermore, high stromal hyaluronan content was 
found to be an independent prognostic factor for short disease-free survival and 
overall survival, even when a patient subgroup consisting of FIGO I and FIGO II 
stages was examined separately (Anttila et al. 2000). In the endometrium, the stromal 
hyaluronan level increases during the progression from hyperplasia to 
adenocarcinoma (Afify et al. 2005). Similarly, hyaluronan accumulation occurs in 
adenocarcinoma of the breast (Auvinen et al. 1997), lung (Pirinen et al. 2001), stomach 
(Setala et al. 1999), prostate (Lipponen et al. 2001), and pancreas (Cheng et al. 2013). 
The stromal accumulation of hyaluronan in adenocarcinomas is associated with more 
aggressive growth and poor differentiation, which is related to the increased 
capability to penetrate connective tissue capsules and invade lymph vessels and 
nerves (Tammi et al. 2008, Sironen et al. 2011). Hyaluronan accumulation is also 
involved in urothelial carcinoma of the bladder (Hautmann et al. 2001), B-cell 
lymphomas (Bertrand et al. 2005), and acute myeloid leukemia (Sundstrom et al. 
2005). 
 
2.4.2 Hyaluronan biosynthesis in cancer 
Accumulation of hyaluronan in cancer is due to its discoordinated metabolism. 
Increased hyaluronan levels can result from increased synthesis, decreased 
degradation, or both. Many studies have attempted to explain possible alterations in 
hyaluronan content due to altered synthesis.  
HAS1 mRNA expression is increased in bladder cancer and associated with 
metastases (Kramer et al. 2011). Elevated HAS1 mRNA levels have also been noted in 
renal cell carcinomas (Chi et al. 2012) and colon carcinoma (Yamada et al. 2004). In 
breast cancer, the HAS1-3 proteins are upregulated, and increased HAS1 and HAS3 
levels in stromal cells are associated with poor patient survival (Auvinen et al. 2014). 
Increased HAS1 protein levels are also associated with poor patient survival in 
ovarian cancer (Yabushita et al. 2004). HAS1 is aberrantly spliced in multiple myeloma 
and Waldenstrom macroglobulinemia (Adamia et al. 2013). Furthermore, inherited 
polymorphisms in HAS1 predict the risk for systemic B-cell malignancies, but not for 
solid tumors (Kuppusamy et al. 2014). 
Overexpression of HAS2 in the mammary glands of a transgenic mouse model 
induces hyaluronan overproduction in the intratumoral stroma, accelerated tumor 
angiogenesis, and poorly differentiated adenocarcinomas (Koyama et al. 2007). This 
hyaluronan-rich tumor-associated stroma has also been shown to promote 
intratumoral lymphangiogenesis in a tumor xenograft model (Koyama et al. 2008). In 
previous studies, overexpression of HAS2 in fibrosarcoma (Kosaki, Watanabe & 
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Yamaguchi 1999) and HAS 3 in prostate cancer (Liu et al. 2001) and mesothelioma (Li, 
Heldin 2001) cell lines resulted in hyaluronan accumulation and increased the 
tumorigenic ability of the cells. Other studies in osteosarcoma (Nishida et al. 2005), 
prostate (Simpson, Wilson & McCarthy 2002, Simpson et al. 2002), and breast cancer 
(Udabage et al. 2005b) cell lines showed that, when HAS2 and/or HAS3 expression is 
suppressed, hyaluronan production decreased and the tumorigenic potential was 
reduced (Itano, Kimata 2008). Moreover, in pancreatic cancer, hyaluronan 
accumulation by HAS3 favors cancer growth and modulates the pancreatic cancer 
microenvironment, decreasing epithelial cell adhesion (Kultti et al. 2014). HAS3 
induces the accumulation of hyaluronan in kidney cell cultures, resulting in possible 
premalignant changes, such as intraluminal invasion and disturbed organization of 
the epithelium likely mediated by mitotic spindle misorientation (Rilla et al. 2012). 
However, opposite effects have been seen in other models, suggesting that the effect 
of HAS overexpression depends on the cellular context. Thus, HAS2 overexpression 
reduces the tumorigenic potential of glioma cells (Enegd et al. 2002) and 
overexpression of all HAS isoforms reduces CHO cell migration (Brinck, Heldin 1999).   
 
2.4.3 Role of hyaluronidases in cancer 
Altered HYAL1 expression is found in many different cancer types, and its role as a 
biomarker has been widely studied. HYAL1 can be increased or decreased depending 
on the cell types arising from the neoplastic process. Interestingly, in prostate cancer, 
HYAL1 is a tumor promoter or suppressor depending on the concentration 
(Lokeshwar et al. 2005).  
HYAL1 expression is increased in prostate adenocarcinoma (Lokeshwar et al. 2001), 
and its expression in biopsy samples predicts its recurrence (Gomez et al. 2009). 
Blocking HYAL1 expression in an urothelial carcinoma cell line resulted in decreased 
cell growth (Lokeshwar, Cerwinka & Lokeshwar 2005). In line with this finding, 
HYAL1 was increased and its overexpression predicted metastasis and mortality in a 
human urothelial bladder carcinoma (Kramer et al. 2011). Importantly, high HYAL1 
expression correlated with muscle invasion, which is a crucial marker for radical 
surgery and poor prognosis (Kramer et al. 2010). HYAL1 is also an accurate urinary 
diagnostic marker for bladder cancer (Eissa et al. 2012).  
In human colorectal cancer, HYAL1-2 expression and hyaluronidase activity is 
increased, especially in advanced disease (Bouga et al. 2010). In contrast, findings in a 
rat colon carcinoma cell line and tumor transplantable rat model showed that HYAL1 
overexpression suppresses the growth rate of tumor cells (Jacobson et al. 2002).  
In breast cancer cells, HYAL1 mRNA and protein levels are overexpressed, and in 
human invasive ductal cancer tissues HYAL1 exhibits stronger staining compared to 
normal breast tissue. Blocking HYAL1 expression in breast cancer cells reduces tumor 
growth and invasion (Tan et al. 2011a). Moreover, in nude mice, forcing HYAL1 
expression induces breast cancer cell xenograft tumor growth and angiogenesis (Tan 
et al. 2011b). Interestingly, in a mouse syngenic breast tumor model, HYAL1 
overexpression promotes lung metastasis without affecting the accumulation of small 
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hyaluronan oligosaccharides (Schmaus, Sleeman 2015). In contrast, decreased HYAL1 
expression is also associated with short distant metastasis-free survival in human 
breast cancer (Heldin et al. 2013). 
 HYAL1 mRNA and protein expression is decreased in non-small cell carcinomas 
of the lung (Anedchenko et al. 2008, Wang et al. 2008) and kidney clear cell carcinoma 
(Chi et al. 2012, Wang et al. 2008). A recent study indicated that weak expression of 
HYAL1 is associated with poor survival in pancreatic ductal adenocarcinoma (Cheng 
et al. 2013). 
HYAL2 expression is also associated with cancer progression. HYAL2 
overexpression has been found in premalignant and malignant melanomas (Siiskonen 
et al. 2013) and is associated with the invasiveness of breast cancer (Udabage et al. 
2005a). In contrast, HYAL2 is deleted in human non-small cell lung cancer (Li et al. 
2007). HYAL2 expression is also decreased in B-cell non-Hodgkin lymphoma 
(Bertrand et al. 2005).  
 Interestingly, the methylation profile of HYAL2 is also altered in breast cancer, with 
a strong association between decreased HYAL2 methylation in the peripheral blood 
and an increased risk of breast cancer (Yang et al. 2015). Alterations in peripheral 
blood HYAL2 methylation status have also been found in head and neck squamous 
cell carcinoma (Langevin et al. 2012). 
 
2.4.4. Degradation products of hyaluronan and cancer  
Native hyaluronan (HMW-HA) is a large molecule, corresponding to a molecular 
mass of up to 10 million Da. (Stern 2008a). However, hyaluronan synthases can also 
produce end products with an altered size as a possible consequence of mutations to 
its gene or different availability of UDP-sugar precursors (Weigel, Baggenstoss 2012, 
Vigetti et al. 2014). The degradation of high-molecular weight hyaluronan by HYAL2 
yields intermediate-sizes particles ranging in size from 25 to 1000 disaccharides 
(LMW-HA), and HYAL1 creates HA-oligosaccharides (sHA) ranging from 2 to 25 
disaccharides in length. ROS degrade hyaluronan to intermediate-sized fragments 
(Agren, Tammi & Tammi 1997), perhaps in the tumor environment as well (Stern et 
al. 2007).   
Differently sized hyaluronan fragments and HMW-HA possess different biological 
properties in different diseases in a concentration-dependent manner (Schmaus, 
Bauer & Sleeman 2014). The accumulation of very high-molecular weight hyaluronan 
nearly double the average size of hyaluronan found in humans and other rodents was 
recently shown to be associated with exceptional longevity and cancer resistance in 
the naked mole rat. The ability to produce and accumulate this very high-molecular 
weight hyaluronan is due to decreased hyaluronidase activity and overexpression of 
HAS2 specific to the naked mole rat. Interestingly, when knocking down HAS2 or 
overexpressing HYAL2, naked mole rat cells become susceptible to malignant 
transformation and readily form tumors (Tian et al. 2013).  
sHA has been shown to have angiogenic potential in vitro (Cui et al. 2009, West, 
Kumar 1989); in vivo, it has been shown to increase blood vessels beneath the 
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epidermis where it is applied to the skin of rats (Sattar et al. 1994). sHA also increases 
endothelial cell proliferation, but only at low concentrations, whereas high 
concentrations of sHA have no effect on proliferation or are antiproliferative (Gao et 
al. 2010, Cui et al. 2009, Lokeshwar, Selzer 2000). Competition between HMW-HA and 
sHA for cellular hyaluronan receptors has also been suggested (Schmaus, Bauer & 
Sleeman 2014), as treatment with sHA results in decreased pericellular hyaluronan 
retention, leading to destruction and remodeling of the hyaluronan-rich pericellular 
matrices (Hosono et al. 2007, Knudson et al. 2000). Interestingly, HMW-HA-induced 
clustering of CD44 can be reversed by the addition of sHA (Yang et al. 2012). HMW-
HA has also been shown to promote complex formation between CXCR4 and CD44, 
leading to enhanced signaling, migration, and angiogenesis. These effects are blocked 
in the presence of sHA (Fuchs et al. 2013).  
Hyaluronan fragments play a role in inflammation during tumor development and 
progression, as they may be involved in activating the innate immune system and 
stimulate immune cells. Hyaluronan fragments also induce the expression of various 
cytokines that provide growth and survival signals for tumor cells (Schmaus, Bauer & 
Sleeman 2014). For example, sHA can induce cytokine expression in melanoma and 
breast tumor cells (Voelcker et al. 2008, Bourguignon et al. 2011). Controversially, 
cytokine expression was reported to be induced by HYAL2-cleaved intermediate-
sized hyaluronan in monocytes (de la Motte et al. 2009). Thus, a broad size range of 
hyaluronan may be pro-inflammatory. However, the hyaluronidases used in these 
studies were purified from animal tissues and contain endotoxins and other unrelated 
proteins. In a recent study, neither highly purified recombinant human hyaluronidase 
(rHuPH20) nor its directly generated hyaluronan catabolites had inflammatory 
properties (Huang et al. 2014). 
Matrix metalloproteinases (MMPs) are endopeptidases that can degrade 
components of the extracellular matrix and enable cells to invade surrounding tissues. 
They can also stimulate growth factors and cytokines and induce epithelial-to-
mesenchymal transition (EMT). Different sizes of hyaluronan fragments can also 
induce MMP expression (Orlichenko, Radisky 2008, Schmaus, Bauer & Sleeman 2014). 
The expression of MMP-9 and MMP-13 can be induced by sHA fragments, as well as 
intermediate-sized hyaluronan fragments, suggesting that metastasis-associated 
hyaluronan degradation in tumors can promote invasion by inducing MMP 
expression (Fieber et al. 2004). Controversially, in vivo studies have shown that, in 
wounded tissue, sHA represses the transcription of MMPs (Gao et al. 2010), 
suggesting that the effects of hyaluronan fragments are specific and context-
dependent. 
Hyaluronan fragments play an important role in tumorigenesis, when hyaluronan 
accumulation and variation in hyaluronidase expression are often present. However, 
the results of studies concerning tumors and hyaluronan fragments have been 
inconsistent, as the fragments have been reported to be tumor-promoting or inhibiting 
(Schmaus, Bauer & Sleeman 2014). In pancreatic carcinoma cells, sHA enhances CD44 
cleavage and tumor cell motility (Sugahara et al. 2006). In thyroid carcinoma cells, 
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sHA promotes cell proliferation and migration, inducing CXCR7 expression, and 
intratumorally injected sHA increases tumor growth in vivo (Dang et al. 2013). In 
contrast, sHA fragments can inhibit anchorage-dependent growth and promote 
apoptosis in vitro (Ghatak, Misra & Toole 2002). Hyaluronan oligosaccharides have 
been shown to suppress the progression of bone metastasis in breast carcinoma by 
interrupting the endogenous HA-CD44 interaction (Urakawa et al. 2012). 
Interestingly, sHA but not HMW-HA has been reported to reduce the growth of colon 
carcinoma cells; the effect was suggested to be achieved, in part, by stimulation of the 
immune system (Alaniz et al. 2009). 
 
2.4.5 Hyaluronan and epithelial-mesenchymal transition 
To acquire the ability to invade, tumor cells need to progress to an EMT. During this 
process, epithelial cells lose their polarity and cell-cell contacts and acquire a 
migratory phenotype, which results in a mesenchymal-like gene expression program 
(Colas et al. 2012). E-cadherin is a central cell adhesion molecule and plays a critical 
role in the suppression of tumor invasion and metastases. A critical molecular feature 
of EMT is the downregulation of E-cadherin expression (Thiery 2003). Several 
transcription factors capable of regulating this process have been identified, but Twist 
and Snail have emerged as the most promising candidates (Barrallo-Gimeno, Nieto 
2005, Yang et al. 2004).  
In endometrial cancer, downregulation of E-cadherin is often associated with high-
grade, non-endometrioid carcinomas (Holcomb et al. 2002, Moreno-Bueno et al. 2003). 
E-cadherin expression is also associated with tumor dedifferentiation and deep 
myometrial invasion (Sakuragi et al. 1994), possibly due to hypermethylation of the 
promoter region of its gene (Saito et al. 2003). E-cadherin has been shown to be an 
independent prognostic factor for disease progression and mortality in stage I-III 
endometrial cancer (Mell et al. 2004). 
Several findings support the conclusion that hyaluronan may facilitate the EMT. 
HAS2 knock-out prevents normal cardiac EMT in mice (Camenisch et al. 2000) via 
hyaluronan-augmented activation of ErbB2-ErbB3 receptors (Camenisch et al. 2002), 
whereas hyaluronan oligosaccharides prevent cardiac EMT via vascular endothelial 
growth factor (VEGF) activation (Rodgers et al. 2006). Increased hyaluronan content 
can also induce EMT in normal epithelial cells (Zoltan-Jones et al. 2003). Increased 
synthesis of hyaluronan is associated with the EMT in lung adenocarcinoma cells 
(Chow, Tauler & Mulshine 2010), and in pancreatic cancer cells, the accumulation of 
hyaluronan is associated with loss of E-cadherin. Interestingly, pegylated human 
recombinant hyaluronidase (PEGPH20) inhibits these changes (Kultti et al. 2014). In 
HAS2 transgenic mice, hyaluronan overproduction causes rapid development of 
aggressive breast carcinoma with a high incidence (Koyama et al. 2007); in further 
studies, this excess hyaluronan production was shown to drive cells towards the EMT. 
In particular, hyaluronan production made the plastic cancer cell population revert to 
stem cell states (Chanmee et al. 2014). 
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Overexpression of hyaluronan receptor CD44 was shown to downregulate E-
cadherin expression and induce EMT changes in colon carcinoma, whereas 
knockdown of CD44 reduced these events, suggesting that the influence of 
hyaluronan is mediated by this receptor (Cho et al. 2012). In contrast to these previous 
studies, Porsch et al. and Heldin et al. showed that transforming growth factor ȕ 
(TGFȕ)-induced HAS2 expression plays a regulatory role in EMT independent of the 
hyaluronan-producing activity of the HAS and hyaluronan receptor CD44 expressed 
in these cells (Heldin et al. 2014, Porsch et al. 2013). 
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3 Aims of the study
Stromal accumulation of hyaluronan has been well documented in human ovarian
and endometrial carcinomas, but the underlying mechanisms are not fully
understood.  The  aim  of  this  doctoral  thesis  was  to  elucidate  the  mechanisms  of
tumoral hyaluronan accumulation by investigating the expression and activity of the
key enzymes affecting hyaluronan turnover.
The specific aims of this thesis were:
1. To investigate the expression of hyaluronan synthase (HAS1-3) and
hyaluronidase genes (HYAL1-2) in ovarian and endometrial carcinomas and
study the correlation between possible changes in expression and tumoral
hyaluronan accumulation.
2. To examine the expression of HYAL1 and HYAL2 proteins in normal
endometria, precancerous lesions, and endometrial carcinomas and elucidate
their role in the pathology of endometrial cancer.
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4 Materials and Methods 
4.1 PATIENTS AND TISSUE SAMPLES (Studies I-III) 
4.1.1 Study I 
Thirty-nine ovarian tissue specimens from 39 patients were divided into five groups: 
normal ovaries (n = 5), serous cystadenomas (n = 10), serous borderline tumors (n = 4), 
low grade (grades 1 and 2) serous cystadenocarcinomas (n = 10), and high grade 
(grade 3) (n = 10) serous cystadenocarcinomas (Study I Table 1). All patients were 
diagnosed and treated at Kuopio University Hospital between 2002 and 2004. 
Histopathological tissue specimens for light microscopy were processed according to 
standard clinical protocol in the Pathology Department of Kuopio University 
Hospital. All samples were collected and handled identically. Tissue aliquots were 1) 
placed in RNAlater® (Ambion, Austin, TX) for mRNA analyses, 2) fixed in 10% 
buffered formalin, embedded in paraffin, or 3) homogenized in 1 mM sodium EDTA 
containing 1 mM benzamidine-HCl, 1 mM saccharic acid 1,4-lactone, 1 mM ȕ-
mercaptoethanol, 1 mM iodoacetate, and 0.5% Triton X-100 clarified by centrifugation 
at 4°C (1,000 × g for 15 min and 10,000 × g for 30 min). The extracts were stored at -
70°C until assayed. 
 
4.1.2 Study II 
Thirty-five endometrial tissue specimens from 35 patients were divided into five 
groups: proliferative and secretory endometrium (n = 10), post-menopausal 
proliferative endometrium (n = 5), complex atypical hyperplasia (n = 4), grade 1 (n = 
8) endometrioid adenocarcinomas, and grade 2+3 (n = 8) endometrioid 
adenocarcinomas. All patients were diagnosed and treated at Kuopio University 
Hospital between 2000 and 2006. Normal endometrium tissue specimens were 
obtained from hysterectomies for non-malignant diseases (e.g., leiomyoma or uterine 
prolapse). The tissue specimens collected in the operating room were prepared and 
evaluated by an experienced pathologist. All samples were collected and handled 
identically. Tissue aliquots were placed in RNAlater® (Ambion, Austin, TX) for mRNA 
analyses or fixed in 10% buffered formalin, and embedded in paraffin. 
 
4.1.3 Study III 
Endometrial tissue specimens were collected from 343 patients, including normal, 
atrophic, or premalignant (complex atypical hyperplasia) endometria and 
endometrial carcinomas (Study III Table 1). All patients were diagnosed and treated 
at Kuopio University Hospital between 2000 and 2012. The non-malignant 
endometrial samples were obtained from hysterectomies (e.g., due to leiomyoma or 
uterine prolapse). All patients with endometrial carcinoma underwent surgery. The 
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surgery included peritoneal cytology, total hysterectomy, bilateral salpingo-
oophorectomy, and pelvic and para-aortic lymph node sampling when considered 
necessary. No patient received chemotherapy or radiotherapy before surgery.  
Tissue samples were fixed in 10% buffered formalin and embedded in paraffin. 
Representative samples of carcinomas and hyperplastic endometria were cut into 3-
ȝm-thick sections for immunohistochemical analyses. Samples of normal endometria 
representing different phases of the menstrual cycle or atrophic endometrium were 
evaluated using tissue microarrays. For tissue microarrays, three regions of the 
endometrium were chosen from each sample and incorporated into microarrays (core 
diameter, 1.3 mm) with a tissue microarray I device (Beecher Instruments, Silver 
Spring, MD, USA). 
 
4.1.4 Histology (I-III) 
Histological typing and tumor grading were performed in Studies I-III according to 
WHO classifications (Kurman et al. 2003) and staged according to the International 
Federation of Gynecology and Obstetrics (FIGO) guidelines (Edge et al. 2010a). 
4.2 ANALYSIS OF HAS1-3 AND HYAL1-2 mRNA EXPRESSION 
(STUDIES I-II) 
4.2.1 RNA extraction and cDNA preparation 
Samples were frozen using liquid nitrogen and pulverized under pressure using a 
stainless steel cylinder and piston. Total RNA was isolated using Trizol® Reagent 
(Invitrogen, Carlsbad, CA) according to the manufacturer's protocol, quantified 
spectrophotometrically, and its integrity confirmed by agarose electrophoresis based 
on the appearance of the 18S and 28S RNA bands. First-strand cDNA was synthesized 
from 2.5 ȝg of total RNA using the High-Capacity cDNA Archive kit (Applied 
Biosystems, Foster City, CA) according to the manufacturer's protocol in a final 
volume of 50 ȝl.  
 
4.2.2 Quantitative real-time RT-PCR 
The PCR primers and fluorogenic probes for all target genes (HYAL1, HYAL2, HAS1–
3) and the endogenous control hypoxanthine phosphoribosyltransferase 1 (HPRT1) 
were purchased as TaqMan® Gene Expression Assays (Applied Biosystems): 
Hs00201046_m1 (HYAL1); Hs00186841_m1 (HYAL2); Hs00758053_m1 (HAS1); 
Hs00193435_m1 (HAS2); Hs00193436_m1 (HAS3); and Hs99999909_m1 (HPRT). The 
assays were supplied as a 20× mix of PCR primers and TaqMan MGB (minor groove 
binder) probes labeled with a 6-FAM dye and a non-fluorescent quencher at the 3' end 
of the probe. The primers were designed to span an exon-exon junction, eliminating 
the possibility of detecting genomic DNA. 
For each amplification, 6 ȝl of cDNA equivalent to 30 ng of total RNA was mixed 
with 1 ȝl of 20× Primer and Probe Mix and 10 ȝl of 2× TaqMan Universal Master Mix 
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in a final volume of 20 ȝl. Each sample was quantified using standard curves 
established by six series of 4-fold serial dilutions of cDNA obtained by reverse 
transcription of 2.5 ȝg Universal Human Reference RNA (Stratagene, La Jolla, CA). 
Standard curves and no-template negative controls (NTCs) were made for every plate. 
Triplicate reactions were used for each sample and each point of the standard curve. 
The reactions were performed in 96-well plates on the MX3000P real-time instrument 
(Stratagene, La Jolla, CA). The PCR conditions were as follows: 1 cycle at 95°C for 10 
min, followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min. 
HPRT1 was used for normalization as an accurate reference for quantitative gene 
expression assays in clinical tumor samples (de Kok et al. 2005). Relative gene 
expression values were calculated as the ratio between the target gene and HPRT1 
obtained for each sample from the standard curves. Finally, these values were divided 
by the mean value for normal ovaries. CT values were used to roughly compare the 
relative amount of HYAL1 and HYAL2 mRNA. 
4.3 HYALURONIDASE ASSAY (STUDY I) 
Hyaluronidase enzyme activities in tissue extracts were determined by the release of 
biotinylated hyaluronan coupled to the bottom of 96-well plates in triplicate reactions 
as described previously (Hiltunen et al. 2002). Briefly, aliquots of the tissue extracts 
and 0.001–10 units of hyaluronidase standards [Bovine Testes, type IV-S, H-3884 (pH 
6.0); Sigma] were diluted in incubation buffers [0.1 M Na-acetate (pH 6.0) for 
standards and 0.2 M NaCl in 0.1 M formate (pH 3.7 and pH 7.0) for tissue extracts] 
and kept in hyaluronan-coated wells at 37°C for 2 h. The standards contained the same 
concentrations of protease inhibitors as the samples. The wells were washed with 
0.05% Tween-PBS and the biotinylated hyaluronan remaining in the wells was 
quantitated using the avidin-biotin detection system. The hyaluronidase activity (mU) 
of each tissue extract was calculated using a logarithmic standard curve and the 
results normalized to protein concentration.  
4.4 HYALURONAN STAINING (STUDIES I-II) 
The level of hyaluronan accumulation in the present set of ovarian and endometrial 
tumors was scored in tissue sections using a biotinylated probe that specifically binds 
hyaluronan. This histological assay is closely correlated with biochemical quantitation 
of hyaluronan in ovarian tissues (Hiltunen et al. 2002). Deparaffinized 5-ȝm sections 
were stained for hyaluronan using our own preparation of biotinylated hyaluronan-
binding complex (bHABC) as described previously (Wang et al. 1996). Briefly, 
deparaffinized sections were rehydrated, washed with 0.1 M sodium PB (pH 7.4), 
treated with 1% hydrogen peroxide for 5 min to inactivate peroxidases, and blocked 
with 1% BSA in PB. The sections were incubated in bHABC (2.5 ȝg/ml, diluted in 1% 
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BSA) overnight at 4°C, washed with PB, and treated with avidin-biotin-peroxidase 
(ABC Vectastain Elite kit; Vector Laboratories). The sections were washed with PB and 
the color developed with 0.05% diaminobenzidine tetrahydrochloride (Sigma) and 
0.03% hydrogen peroxide in PB. The slides were counterstained with Mayer’s 
hematoxylin. Staining specificity was controlled by digesting some of the sections 
with Streptomyces hyaluronidase in the presence of protease inhibitors before staining 
or by pre-incubating the bHABC probe with hyaluronan oligosaccharides.  
All samples were scored by an observer blinded to the clinical data (M.A.). The 
intensity of hyaluronan positivity in the epithelium and stroma was graded into three 
categories (1, weak; 2, moderate; or 3, strong) and the percentage area of the strongest 
hyaluronan expression in the whole tumor section evaluated and used as an indicator 
of hyaluronan accumulation. 
4.5 IMMUNOHISTOCHEMISTRY (STUDIES I-III) 
4.5.1 HAS1-3 immunostaining (Studies I-II) 
Antigen retrieval was performed for HAS2 staining by microwave treatment (700 W, 
3 × 5 min) in citrate buffer. All deparaffinized sections were treated for 5 min with 1% 
H2O2 to block endogenous peroxidase, washed with 0.1 M Na-phosphate buffer pH 
7.4 (PB), and incubated in 1% bovine serum albumin (BSA) in PB for 30 min to block 
non-specific binding. The sections were then incubated overnight at 4°C with 
polyclonal antibodies for HAS1 (1:100 dilution in 1% BSA, Santa Cruz Biotechnology, 
Inc., Santa Cruz, CA), HAS2 (1:50, Santa Cruz), or HAS3 (1:100, Santa Cruz), followed 
by a 1 h incubation with biotinylated antigoat antibody (1:1000, Vector Laboratories). 
The bound antibodies were visualized using the avidin-biotin peroxidase method 
(1:200, Vectastain Kit, Vector Laboratories, Burlingame, CA). The sections were 
incubated for 5 min in 0.05% diaminobenzidine (Sigma) and 0.03% hydrogen peroxide 
in PB. After washing, the sections were counterstained with Mayer's hematoxylin for 
1 min, washed, dehydrated, and mounted in DPX (Gurr, BDH Laboratory Supplies, 
Poole, U.K.).  
All samples were scored by an observer blinded to the clinical data (K.R.). For study 
I, the percentage of area positive for each HAS was estimated in the stroma and 
epithelium for HAS1 and HAS3. The staining intensity for HAS2 in the epithelium 
was estimated by grading in three categories: 1, weak; 2, moderate; or 3, strong. 
For study II, the staining intensity of HAS1, HAS2, and HAS3 in the epithelium was 
graded into three categories: negative (n.d.), weak, or moderate. The intensity in the 
stroma was graded into two categories: negative (n.d.) or weak. The percentage of area 
positive for each HAS was estimated in both the stroma and epithelium. 
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4.5.2 HYAL1-2 immunostaining (Study III) 
Deparaffinized sections were incubated in 10 mM citrate buffer (pH 6.0) for 15 min in 
a pressure cooker at 120°C, washed with phosphate-buffered saline (PBS), and treated 
for 5 min with 1% H2O2 to block endogenous peroxidase activity. The sections were 
then incubated in 1% BSA, 0.05% Tween-20, and 0.1% gelatin (Sigma G-2500, Sigma) 
in PBS for 30 min to block non-specific binding. The sections were incubated with 
polyclonal primary antibodies against HYAL1 and HYAL2 overnight at 4°C, diluted 
in 1% BSA (HYAL1: HPA002112 Atlas Antibodies, Stockholm, Sweden, dilution 1:100; 
and HYAL2: Ab68608 Abcam, Cambridge, UK, dilution 1:100). This incubation was 
followed by 1-h incubation with biotinylated anti-rabbit antibody (1:200 dilution in 
1% powdered milk in PBS, Vector Laboratories, Burlingame, CA) at room 
temperature. Next, sections were washed with PBS, incubated with avidin-biotin 
peroxidase complexes (1:200, Vecta stain ABC Kit, Vector Laboratories, Burlingame, 
CA) for 1 h at room temperature (RT), and then washed again with PBS. The color was 
developed for 5 min with 0.05% diaminobenzidine (DAB; Sigma, St. Louis, MO) 
containing 0.03% H2O2. Next, the sections were washed with distilled water and 
counterstained with Mayer’s hematoxylin for 1 min, washed, dehydrated, and 
mounted in DPX (BDH Laboratory Supplies, Poole, UK). 
 
4.5.3 E-cadherin immunostaining (Study III) 
Deparaffinized and rehydrated sections were heated in a microwave oven in EDTA 
buffer (pH 8.0) for 2 × 5 min, and then incubated in the EDTA buffer for 18 min and 
washed twice in PBS for 5 min. Endogenous peroxidase activity was blocked by 
incubating the sections with 5% H2O2 for 5 min and then washing the sections twice in 
water for 5 min and twice in PBS for 5 min. Non-specific binding was blocked by 
incubating the sections with 1.5% normal horse serum in PBS for 45 min. The sections 
were incubated overnight at 4°C with the primary antibody for E-cadherin (mouse 
monoclonal anti-human E-cadherin, clone HECD-1; Invitrogen, California, USA; 1:100 
dilution). The negative control was incubated with 1% BSA in PBS without the 
primary antibody. Next, the sections were washed twice in PBS for 5 min and then 
incubated with the biotinylated secondary antibody (anti-mouse IgG; ABC Vectastain 
Elite kit, Vector Laboratories) for 45 min at RT. The sections were then washed twice 
in PBS for 5 min, incubated for 50 min in preformed avidin-biotinylated peroxidase 
complex (ABC Vectastain Elite kit, Vector Laboratories), washed, developed for color, 
counterstained, and mounted as described above. 
 
4.5.4 Evaluation of HYAL1-2 and E-cadherin staining (Study III) 
Two independent observers (TKN, RS) evaluated the sections for staining intensity 
and coverage in the epithelia and stroma. For the tissue microarray, triplicate cores 
were analyzed for each sample and median intensities and staining scores calculated. 
Specimens with less than two representative cores were excluded from the analysis. 
The stained portion of each section was estimated based on a five-level scoring system 
where 1 = less than 5% of positive cells, 2 = 6-25% of positive cells, 3 = 26-50% of 
29 
 
 
 
positive cells, 4 = 51-75% of positive cells, and 5 = 76-100% of positive cells. The 
intensity of the most prominently stained area was estimated based on a four-point 
scale of 0 to 3, where 0 = negative, 1 = weak, 2 = moderate, and 3 = strong (Siiskonen et 
al. 2013). In this study, negative and weak staining intensities were combined into one 
subgroup (score = 1). Epithelial expression scores (EESs) were calculated by 
multiplying the intensity score by the score corresponding to the proportion of 
positively stained cells. The final calculated EES ranged from 1 to 15. In the survival 
analysis, HYAL1 and HYAL2 expression levels were considered negative if EES ≤ 5 
and positive if EES > 5. 
4.6 STATISTICAL ANALYSES (STUDIES I-III) 
4.6.1 Study I 
Statistical analyses were carried out using SPSS 11.5 for Windows (SPSS, Chicago, IL). 
Differences between groups were analyzed by non-parametric Kruskal-Wallis test, 
followed by a non-parametric Mann-Whitney U-test for paired comparisons between 
the patient groups if the intial analysis was significant. Chi-square tests were used to 
evaluate HAS2 epithelial staining. Correlations between HAS3, HYAL1, and HYAL2 
gene expression, hyaluronidase activity, hyaluronan, and HAS staining were 
analyzed by Spearman's correlation test. A p-value ≤ 0.05 was considered significant. 
 
4.6.2 Study II 
Statistical analyses were carried out using SPSS 16.0 for Windows (SPSS, Chicago, IL). 
Differences between the patient groups were analyzed by a non-parametric Kruskal-
Wallis test, followed by a non-parametric Mann-Whitney U-test for further 
comparisons between the patient groups if the initial analysis was significant. 
Correlations between gene expression data, hyaluronan staining, and 
immunostaining scores were analyzed by Spearman's correlation test. Chi-square tests 
were used to analyze the association between hyaluronan staining and 
immunostaining scores. A p-value ≤ 0.01 was considered significant. 
 
4.6.3 Study III 
Statistical analyses were carried out using SPSS version 19 (SPSS, Chicago, IL). 
Associations between staining scores and clinicopathological parameters were 
evaluated using chi-square, Kruskal-Wallis, or Mann-Whitney U-tests. Correlations 
between E-cadherin, HYAL1, and HYAL2 EES values were determined using 
Spearman’s rank correlation test. Recurrence-free survival was calculated from the 
date of diagnosis to the date of recurrence. Univariate analyses for overall survival 
were conducted using the Kaplan–Meier method, and the significance of differences 
between groups was assessed by the log-rank test. Multivariate analyses were 
conducted with the Cox regression model. A p-value < 0.05 was considered significant, 
except in pair-wise comparisons, where a p-value < 0.01 was preferred. 
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4.7 ETHICAL CONSIDERATIONS (STUDIES I-III) 
The ethics committee of Kuopio University Hospital approved the study protocol, and 
all patients provided signed informed consent. 
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5 Results 
5.1 HYALURONAN IN OVARIAN AND ENDOMETRIAL TUMORS 
(STUDIES I-II) 
The hyaluronan content of benign ovarian cystadenomas was close to that of normal 
ovarian tissue. Malignant tumors had markedly increased levels (malignant tumors 
vs. other lesions, p = 0.00026) (Figure 3 and Study I Figure 1A) 
The epithelial and stromal hyaluronan intensity scores were significantly elevated 
(p = 0.0001 and p = 0.006, respectively) in endometrioid endometrial tumors compared 
to normal endometrium (Figure 4, Study II Figure 3 G, H, and Study II Table 3). 
 
 
Figure 3. Hyaluronan accumulation in ovarian serous carcinoma. An example of the 
biological heterogeneity among tumors is demonstrated with a low stromal hyaluronan 
intensity in a and high stromal hyaluronan staining in b. 
 
 
Figure 4. Hyaluronan accumulation in endometrial adenocarcinoma. Low tumoral 
hyaluronan staining is present in a and high hyaluronan staining in b. 
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5.2 EXPRESSION OF HYALURONAN SYNTHASES (STUDIES I-II) 
5.2.1 Expression of HAS1-3 mRNA 
In both ovarian and endometrial tissue specimens, HAS1 transcripts were detected at 
such a low level that reliable quantitation was not possible. 
The expression of HAS2 was similar between benign and borderline ovarian 
tumors (Study I Figure 1B). The median for HAS2 mRNA was 51–61% higher in 
malignant tumors compared to normal ovaries, but the variance between individual 
tumors was extensive (Study I Figure. 1B). Overall, HAS2 mRNA expression was not 
significantly different between the groups (p = 0.387). HAS3 expression was increased 
in benign tumors compared to normal ovaries (median +60%, p = 0.0039) and mRNA 
expression tended to be decreased in high grade (grade III) carcinomas (-44%) (Study 
I Figure 1C). No correlations were found between the levels of HAS2 or HAS3 mRNA 
and hyaluronan content in normal, benign, or borderline ovaries or serous ovarian 
carcinomas (Table 3).  
  HAS2 expression remained unaltered in postmenopausal or hyperplastic tissues 
of the endometria and malignant endometrioid adenocarcinomas compared to 
premenopausal endometria (Study II Figure 1A). HAS3 expression was increased 
more than 4-fold in postmenopausal endometrium (p = 0.003) compared to 
premenopausal endometrium (Study II Figure 1B). Moreover, HAS3 expression was 
elevated (1.5-fold increase) in grade I endometrioid adenocarcinomas compared to 
normal endometrium (p = 0.033) (Study II Figure 1B). No correlations were found 
between HAS2 or HAS3 mRNA levels and the hyaluronan content of normal or 
hyperplastic endometria and endometrioid adenocarcinoma (Table 3). 
 
5.2.2 HAS1-3 immunostaining (Studies I-II) 
No HAS1-positive cells were detected in the epithelia or stroma of normal ovaries, 
and staining remained very low in benign and borderline ovarian tumors. However, 
41% of ovarian carcinomas exhibited a low level of epithelial HAS1-positivity (Study 
I Figure 3 and Table 2). The percentage of HAS1-positive cells did not correlate with 
the HAS1 mRNA levels, hyaluronan content, histological types, or carcinoma grades 
(Table 3). The anti-HAS2-antibody resulted in more widespread staining and, in 
contrast to HAS1 and HAS3 antibodies, stained both epithelial and stromal cells 
(Study I Figure 3). All epithelial cells exhibited weak HAS2 staining in normal ovaries. 
The HAS2 signal in the epithelial cells of carcinomas was more variable. In addition 
to samples with weakly stained epithelial tissue similar to normal ovaries, 64% of 
tumor samples exhibited more intense epithelial HAS2 immunostaining. The highest 
HAS2 staining intensity was detected in benign tumors and grade I serous carcinomas, 
and the intensities were significantly different in the histological subgroups (p = 
0.003). Of the stromal cells, 25–37% were HAS2-positive in both normal ovaries and 
tumor specimens, but the proportion of HAS2-positive stromal cells did not correlate 
with the HAS2 mRNA level, hyaluronan staining intensity, or histological groups 
(Table 3 and Study I Table 2). No positive HAS3 signal was observed in normal 
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ovaries, but 46% of serous ovarian carcinomas presented with generally low numbers 
of HAS3-positive cancer epithelial cells (Study I Figure 3 and Table 2). An analysis 
including both normal and different tumor specimens indicated that the proportion 
(%) of HAS3-positive cells among all epithelial cells correlated with hyaluronan 
staining in the stroma (r = 0.424, p = 0.008). HAS3 immunostaining did not correlate 
with HAS3 mRNA levels, histological type, or tumor grade (Table 3). 
 
Table 3. Expression of hyaluronan synthases (HAS1-3) and their correlation to hyaluronan 
accumulation (I, II) 
 
 
Positive HAS1 staining in the epithelium and stroma of normal endometrium was 
observed in a minority of cases and was completely absent in postmenopausal 
endometria. HAS1 staining was also generally negative or weak in atypical 
hyperplasia, but more consistent and significantly intense staining was noticed in 
endometrial adenocarcinomas compared to normal endometria (Study II Figure 3 A, 
B, and Study II Table 2) (p = 0.001). HAS1 immunostaining did not correlate with HAS1 
mRNA, tumor grade, or hyaluronan accumulation (Table 3). Epithelial and stromal 
HAS2 staining was negative or weak in premenopausal and postmenopausal 
endometria, and staining patterns were similar in hyperplastic endometria. However, 
epithelial HAS2 immunostaining was more intense in endometrioid adenocarcinomas 
compared to normal endometrium (Study II Figure 3 C, D and Study II Table 2) (p = 
0.004), and a correlation was also found with epithelial hyaluronan staining (p = 0.009). 
Despite signs of a connection to hyaluronan accumulation, HAS2 did not correlate 
with HAS2 mRNA levels or tumor grade (Table 3). HAS3 had a similar staining 
pattern as HAS1 and HAS2 in normal and hyperplastic endometria. The epithelial 
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intensity of HAS3 (Study II Figure 3 E, F) immunostaining was significantly stronger 
in endometrial adenocarcinomas compared to normal endometrium (p = 0.003) (Study 
II Table 2). The HAS3 staining intensities did not correlate with tumor grade, and no 
significant correlations were found between HAS3 mRNA levels and hyaluronan 
accumulation (Table 3). 
5.3 HYALURONIDASE ACTIVITY (STUDY I) 
Hyaluronidase activity is present at pH 3.7 in ovarian tissues, with a tendency to 
decrease in malignant tumors (Hiltunen et al. 2002). The median hyaluronidase 
activity in borderline and malignant tumors was 58-40% lower than in normal ovary, 
but the difference did not reach significance (p = 0.076) (Study I Figure 2A). However, 
decreased hyaluronidase activity correlated inversely with hyaluronan accumulation 
(r = -0.5, p = 0.003) (Table 4). 
5.4 HYALURONIDASE EXPRESSION (STUDIES I-II) 
As two ubiquitous hyaluronidases, HYAL1 and HYAL2, likely account for the 
hyaluronidase activity, we quantified mRNA levels by real-time RT-PCR. A gradual 
decline in HYAL1 expression was measured in benign and borderline tumors 
compared to normal ovaries (Study I Figure 2B), with significant differences between 
the groups (p = 0.022). A pair-wise analysis indicated decreased HYAL1 in all non-
benign tumors compared to normal ovaries (borderline: -58% (median), p = 0.05; 
grades I+II: -79%, p = 0.05; grade III: -69%, p = 0.01). Malignant grade I+II and grade III 
tumors also expressed significantly less HYAL1 than benign tumors (p = 0.034 and p = 
0.028, respectively) (Table 4 and Study I Figure 2B). HYAL2 mRNA expression was 
increased in benign ovarian cystadenomas compared to normal ovaries (+76%, p = 
0.037), whereas a decrease was noted in grade III ovarian serous carcinomas (p = 
0.0156) (Study I Figure 2C). HYAL1 transcript levels correlated with hyaluronan 
content (r = -0.4; p = 0.025) and hyaluronidase activity (r = 0.5; p = 0.006), suggesting 
that HYAL1 dominated the differences in hyaluronidase activity and contributed to 
the accumulation of hyaluronan in ovarian cancers (Table 4). Interestingly, HYAL2 
expression did not correlate with hyaluronidase activity, even though its mRNA level 
was two to three orders of magnitude higher than that of HYAL1, as suggested by real-
time RT-PCR. A correlation with hyaluronan accumulation was not found with 
HYAL2. 
 
 
 
 
 
 
35 
 
 
 
Table 4. Expression of hyaluronidases (HYAL1 and HYAL2) and their correlation to 
hyaluronan accumulation (I, II) 
 
 
A significant decline in HYAL1 expression was measured from normal 
endometrium to endometrioid adenocarcinoma (p = 0.002). A 10-fold higher 
expression of HYAL1 mRNA was found in the normal endometrium compared to both 
grade I and grade II + III endometrial adenocarcinomas (p = 0.004 and p = 0.006, 
respectively). Values more than 15-fold higher were measured in normal post-
menopausal endometrium (p = 0.002) (Study II Figure 2A). A similar trend to HYAL1 
was noted for HYAL2 expression in grade I and grade II + III adenocarcinomas 
compared to normal endometrium (p = 0.020) (Study II Figure 2B). HYAL1 transcript 
levels significantly inversely correlated with epithelial (r = -0.6, p = 0.001) and stromal 
hyaluronan staining (r = -0.4, p = 0.01). For endometrial material, we also analyzed 
HYAL1 and HYAL2 protein levels using immunohistochemistry. HYAL1 epithelial 
staining intensity correlated significantly with HYAL1 mRNA levels (p = 0.0009, n = 
33) and inversely correlated with epithelial and stromal hyaluronan staining (p = 0.021 
and p = 0.013, respectively) (unpublished result). HYAL2 transcript levels correlated 
with epithelial hyaluronan staining (r = -0.4, p = 0.01). HYAL2 epithelial staining 
intensity correlated with HYAL2 mRNA levels (p = 0.045, n = 33) and inversely 
correlated with epithelial hyaluronan staining (p = 0.005) (unpublished result). 
 A significant correlation was found between HYAL1 and HYAL2 mRNA levels in 
ovarian and endometrial tissue specimens (r = 0.5, p = 0.0013 and r = 0.8, p = 0.0001, 
respectively). The HAS3 epithelial staining intensity was also found to correlate 
inversely with HYAL1 mRNA in both ovarian and endometrial samples (r = -0.438, p 
= 0.005 and r = -0.5, p = 0.004, respectively). 
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5.5 HYAL1-2 IN ENDOMETRIUM AND ENDOMETRIAL TUMORS 
(STUDY III) 
Because our previous results suggested that hyaluronan accumulation can be a result 
of decreased hyaluronan degradation, we analyzed HYAL1 and HYAL2 protein 
expression in a larger set of samples representing tissues from normal and 
precancerous endometria and endometrial carcinomas. 
In premenopausal endometria, both HYAL1 and HYAL2 were predominantly 
expressed in the cytoplasm of glandular epithelial cells. Endometrial stromal cells 
were negative for HYAL1 and HYAL2, regardless of the phase of the endometrial 
cycle. This expression pattern was also evident in atrophic postmenopausal 
endometria and a similar distribution was observed in atypical complex hyperplasia 
and endometrial carcinomas, regardless of the carcinoma type or grade (Study III 
Table 2 and Figure 1). HYAL1 and HYAL2 localized mainly in the cytoplasm, but we 
also occasionally observed plasma membrane staining (Study III Figure 1). 
The epithelial HYAL1 staining intensity was strong in the majority of 
premenopausal endometria (42/52, 80.8%), regardless of the phase of the endometrial 
cycle. Similarly, HYAL1 staining was strong in atrophic endometria (13/14, 92.9%) and 
atypical complex hyperplasia (21/26, 80.8%). In contrast, the intensity of HYAL1 
staining and EES were reduced in the epithelia of endometrioid adenocarcinomas. 
Moreover, HYAL1 staining intensity was significantly negatively associated with the 
tumor grade (p < 0.0001). Thus, none of the poorly differentiated (grade III) 
endometrioid adenocarcinomas (0/33) exhibited strong HYAL1 staining, and in 21/33 
(63.6%) cases it was negative or weak. In serous carcinomas, 9/12 (75%) cases exhibited 
a negative or weak HYAL1 staining intensity (Figure 5 and Study III Table 2).  
In contrast to HYAL1 expression, premenopausal endometria exhibited strong 
HYAL2 intensity only in 5/52 (9.6%) samples. Furthermore, the expression of HYAL2 
varied according to the phases of the endometrial cycle; the HYAL2 staining intensity 
was significantly stronger in the proliferative phase than in the secretory phase 
(Figure 5 and Study III Table 2). The HYAL2 staining intensity was not significantly 
different in normal endometria, complex atypical hyperplasia, or any grade of 
endometrioid adenocarcinoma. However, HYAL2 expression was significantly 
stronger in atrophic endometria than endometrioid endometrial carcinomas. In serous 
carcinoma, 4/11 (36.4%) cases had strong HYAL2 epithelial staining, which was 
significantly different from the proportion of strong staining found in normal 
endometria (p = 0.0044) (Figure 5 and Study III Table 2). 
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Figure 5. Distribution of different HYAL1 and HYAL2 epithelial staining intensities in the 
endometrium and its tumors (total n = 343). Significant differences between groups are 
indicated by asterisks: * p < 0.01, ** p < 0.001, *** p < 0.0001. 
5.6 HYAL1-2 AND CLINICOPATHOLOGICAL FACTORS (STUDY III) 
Reduced HYAL1 epithelial staining intensity and EES were significantly associated 
with large tumor size, lymphovascular invasion, and lymph node metastases in 
endometrial carcinoma (Study III Table 3). In particular, reduced HYAL1 expression 
strongly correlated with deep myometrial invasion (i.e., tumor invasion of one half or 
more of the myometrium) (p < 0.0001). In addition, HYAL1 staining intensity and EES 
were associated with the absolute depth of invasion. In tumors with negative or weak 
staining intensity, the median depth of invasion was 8.0 mm (range: 0-31 mm). 
Invasion was less profound for moderate or strong staining intensity [4.0 mm (range: 
0-22 mm) and 1.5 mm (range: 0-15 mm), respectively; p < 0.0001]. In tumors with 
negative (EES ≤ 5) or positive (EES > 5) HYAL1 expression profiles, the absolute 
invasion depth was 7.5 mm (range: 0-31 mm) and 3.0 mm (range: 0-22 mm), 
respectively (p < 0.0001). 
Weak HYAL2 staining intensity and EES were also associated with deep 
myometrial invasion, but not with the absolute depth of invasion or the other above-
mentioned clinicopathological factors (Study III Table 3).  
Follow-up data were available from 173 patients in this study. The patients were 
followed up for a maximum of 48 months (median 37 months, range: 16-48 months). 
Recurrence occurred in 13/173 (7.5%) patients, and the median disease-free survival 
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was 17 months (range: 5-23 months). In univariate analysis, the HYAL1 epithelial 
staining intensity and HYAL1 expression were associated with disease-free survival 
(Study III Figure 2). Because no recurrent events were observed in the group with 
strong epithelial staining, we subjected the EES to multivariate analysis. In the 
multivariate Cox regression model, age, lymphovascular invasion, myometrial 
invasion, cervical invasion, and tumor grade (low-grade vs. high-grade) were 
included as variables. We found that negative HYAL1 expression was an independent 
prognostic factor for early disease recurrence (HR 5.13, 95% CI 1.131 – 23.270, p = 
0.034). 
5.7 E-CADHERIN AND HYAL1 EXPRESSION (STUDY III) 
Loss of E-cadherin expression is a key event in EMT. Therefore, we used E-cadherin 
as an indicator of EMT and analyzed its expression in endometrial cancer samples to 
determine whether it is associated with the previously reported reduction in HYAL1 
expression.  
Reduced E-cadherin expression was associated with high-grade endometrioid 
adenocarcinomas (Study III Table 4). The E-cadherin EES also exhibited a strong 
association with deep myometrial invasion, lymphovascular invasion, cervical 
invasion, and tumor size in endometrial carcinoma (Study III Table 3). We noted a 
significant positive correlation between HYAL1 and E-cadherin epithelial staining 
intensity (p<0.0001). Thus, in 21/25 (84%) cases with negative or weak E-cadherin 
epithelial staining intensity, the HYAL1 intensity was also negative or weak; 
conversely, in 32/34 (94.1%) cases with strong HYAL1 intensity, E-cadherin also had a 
strong pattern of epithelial staining. A significant correlation was also found between 
the EES for E-cadherin and HYAL1 (r = 0.5, p < 0.0001). 
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6 Discussion 
6.1 ROLE OF HYALURONAN SYNTHASES IN HYALURONAN 
ACCUMULATION 
6.1.1 HAS1-3 in serous ovarian carcinoma (Study I) 
Little HAS1 mRNA and no consistent upregulation of HAS2 were observed in the 
cancers, and the median levels of HAS3 mRNA were actually lower in cancers than 
controls. Immunohistochemical staining of HAS proteins revealed a low level of 
HAS1, a slightly elevated level of HAS3 in the tumor epithelia, and a variable elevation 
of HAS2 immunostaining in tumor epithelial cells, which is in agreement with the 
mRNA assays. In stromal cells, no difference was observed with the HAS2 
immunoreactivity in normal ovaries and malignant tumors, an unexpected result 
considering the strong accumulation of hyaluronan in serous adenocarcinomas.  
As HAS2 and HAS3 did not exhibit a consistent increase in their expression in 
serous ovarian cancers and HAS1 mRNA was virtually absent, changes in the 
transcriptional activity of the HAS genes seemed to not be the main factor in the 
increased hyaluronan content of these tumors. A few of the serous adenocarcinoma 
specimens had high HAS2 expression levels, but most of the cancers had no elevation 
in the expression of any of HAS genes. 
Immunohistochemical staining confirmed that the HAS1 and HAS3 levels were 
relatively low in ovarian cancers, whereas the signal for HAS2 was more widespread, 
which is in line with the real-time RT-PCR analysis. Though stromal cells were 
positive for HAS2, the staining intensity did not correlate with that of stromal 
hyaluronan or the tumor type or grade. Unexpectedly, the HAS2 antibody stained 
normal, benign, and malignant ovarian epithelial cells, all of which were largely 
negative when using the hyaluronan probe. Taken together, these findings suggest 
that the epithelium somehow contributes to stromal hyaluronan. Theoretically, this 
would be possible if the epithelial cells were unable to hold and take up the 
synthesized hyaluronan via a receptor like CD44. In support of this idea, the 
expression of CD44 was reported to be reduced in high-grade ovarian cancers 
(Sillanpaa et al. 2003), and the released hyaluronan can be trapped in the stroma by 
complexing with versican (Voutilainen et al. 2003). Even if the epithelial HAS 
contributes to stromal hyaluronan, it would not explain the hyaluronan accumulation 
in high-grade tumors because the epithelial HAS2 staining intensity was highest in 
benign and well-differentiated tumors. 
Taken together, the data suggest that, although a high HAS2/HAS3 level may 
contribute to hyaluronan accumulation in some ovarian tumors, stromal hyaluronan 
accumulation is not explained by the increased expression of any of the HASs in the 
majority of cases, particularly high-grade tumors. 
40 
 
 
 
6.1.2 HAS1-3 in endometrial adenocarcinoma (Study II) 
Except for a trend of increased HAS3 expression in grade 1 carcinomas, we did not 
find a clear pattern of increased HAS1-3 mRNA in endometrial cancer compared to 
normal endometrium. This finding is somewhat similar to the enhanced HAS3 mRNA 
level observed in benign, but not malignant, ovarian tumors in study I. Our results 
suggest that transcriptional upregulation of HAS expression is not the main 
contributor to the increased hyaluronan content in these tumors. 
Despite minor changes in mRNA levels, the immunoreactivity for all HASs was 
stronger in cancer cells than normal endometrium, although the density of staining 
did not significantly correlate with tumor grade. A similar discordance between the 
levels of HAS mRNA and HAS immunoreactivity was found in ovarian cancer in 
study I. Interestingly, the significance of the cancer-associated increase in HAS 
immunoreactivity was strongest for HAS1, though real-time RT-PCR suggested very 
low transcription of this gene. Similar to the present study, Yabushita et al. (Yabushita 
et al. 2005) found that HAS1 immunoreactivity is strongly associated with endometrial 
cancer. Moreover, among all HASs, HAS1 had the strongest prognostic power for 
short survival in breast cancer (Auvinen et al. 2014). 
HAS2 is the only HAS gene in which deletion causes a clear (lethal) phenotype 
(Camenisch et al. 2000), and it has been suggested to be the most important gene for 
hyaluronan synthesis, at least in fibroblasts (Kobayashi et al. 2010). In line with this 
idea, the immunohistochemical signal of epithelial HAS2 correlated with the epithelial 
hyaluronan staining score in the endometrium. 
Because the expression of HAS genes in tumor tissues poorly correlated with the 
levels of the respective HAS proteins, the turnover of HAS proteins must be slower in 
cancer cells. One explanation for this is the availability of hyaluronan precursor sugar, 
UDP-ClcNAc. After glucosamine treatments, UDP-ClcNAc increases, HAS2 is O-
GlcNacylated, and its activity is increased in isolated membranes and cell cultures 
(Vigetti, Passi 2014, Vigetti et al. 2012). Interestingly, cellular UDP-GlcNAc content 
controls HAS2 mRNA expression. High cellular UDP-GlcNAc decreases HAS2 
expression in keratinocytes, and a low cellular UDP-GlcNAc concentration increases 
its expression (Jokela et al. 2011). Recent results have shown that UDP-GlcNAc 
concentrations in breast and ovarian cancer tissues are elevated over 10-fold 
compared to normal tissues (Tammi M, personal communication). The duration of the 
functional work life of HAS proteins in ovarian and endometrial carcinomas is not 
known, but if extended, it may have a major influence on hyaluronan synthesis.  
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6.2 HYALURONIDASES IN HYALURONAN ACCMULATION AND 
CANCER 
6.2.1 Altered HYAL 1-2 expression (Studies I-III)  
In study I, HYAL1 mRNA expression was consistently decreased in serous ovarian 
carcinoma specimens with a concomitant trend of reduced hyaluronidase enzyme 
activity and an inverse correlation to hyaluronan accumulation. In terms of the cellular 
mRNA content, the dominant hyaluronidase in these tissues was HYAL2. However, 
only HYAL1 mRNA correlated with the measured hyaluronidase activity, and it 
inversely correlated with hyaluronan accumulation, suggesting higher enzymatic 
activity of HYAL1 and more importance in hyaluronan catabolism. There was also a 
trend of low HYAL2 expression in the most aggressive grade 3 tumors, similar to 
diffuse large B-cell lymphomas (DLBCLs) (Bertrand et al. 2005). As in ovarian cancer, 
hyaluronidase activity in DLBCL tissue extracts was found to not correlate with 
HYAL2 expression. In line with this, the ability of HYAL2 to degrade hyaluronan is 
less than that of HYAL1 (Vigdorovich, Miller & Strong 2007). 
As in serous ovarian carcinomas, we found similar but more pronounced signs of 
HYAL1 mRNA downregulation in endometrial endometrioid carcinoma in study II. 
We found a more than 10-fold decrease in HYAL1 mRNA in endometrioid 
adenocarcinomas compared to normal endometria, and the expression inversely 
correlated with hyaluronan accumulation. HYAL2 mRNA expression also declined in 
cancerous tissues, and there was a strong correlation between HYAL1 and HYAL2 
mRNA levels. The expression of HYAL1 and HYAL2 also correlated with the protein 
levels determined by immunohistochemistry, suggesting that their expression is 
transcriptionally regulated. 
Our results suggested that hyaluronan accumulation in endometrial endometrioid 
adenocarcinomas results from decreased degradation of hyaluronan; thus, we further 
analyzed HYAL1 and HYAL2 protein expression in a large sample representing cases 
from normal, precancerous, and cancerous endometria in study III. This study showed 
that HYAL2 expression was altered in healthy endometria during the phases of the 
menstrual cycle, whereas HYAL1 expression remained strong and constant. Our 
finding that HYAL2 expression was strong in the proliferative phase and declined in 
the secretory phase was consistent with a previous report describing increased 
hyaluronan content during the secretory phase (Afify et al. 2005). The data suggest 
that HYAL2 enzymatic activity regulates endometrial hyaluronan content during the 
menstrual cycle.  
In endometrial adenocarcinomas, HYAL2 expression generally remained stable, 
and we found no signs of altered expression compared to normal endometrium or 
precancerous hyperplastic lesions. However, in serous endometrial cancer, HYAL2 
expression was increased compared to normal endometrium. In addition, atrophic 
endometrium had a stronger HYAL2 staining pattern than normal samples. Because 
endometrial intraepithelial carcinoma typically arises from a background of atrophic 
endometrium (Acharya et al. 2005), this raises the question of whether HYAL2 plays 
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a role in malignant progression from atrophic endometrium, which is to be clarified 
in future studies. 
The fact that HYAL1 staining was generally strong in normal, atrophic, and 
hyperplastic endometria but reduced in all types of cancers (endometrioid, serous, 
and clear cell) suggested that HYAL1 can significantly contribute to the progression 
of malignancy. This hypothesis was further supported by HYAL1 levels significantly 
decreasing as the tumor grade increases from I to III. 
The exact mechanism of decreased HYAL1 and HYAL2 expression is not 
completely understood, but genomic alterations, transcriptional regulation, or 
epigenetic regulation may play a crucial role. Allelic imbalance and deletions are 
frequent in the tumor suppressor gene region of 3p21.3 containing HYAL1 and 
HYAL2, suggesting that this site is important in ovarian (Tuhkanen et al. 2004) and 
other cancers (Csoka, Frost & Stern 2001, Stern 2008b). The positive correlation that 
existed between the expression of HYAL1 and HYAL2 may be explained by 
concomitant deletion of these closely mapped genes. Epigenetic regulation of this 
tumor suppressor gene cluster flanking RASSF1 has been studied in epithelial breast 
cancer cell lines; after demethylation treatment, HYAL1 was significantly 
overexpressed, demonstrating that epigenetic repression is involved in the 
downregulation of its expression (da Costa Prando, Cavalli & Rainho 2011). 
Interestingly, hypermethylation of RASSF1 and its promoter element has also been 
shown in endometrial cancer (Visnovsky et al. 2013, Fiolka et al. 2013) and is 
associated with aggressive disease. The methylation status of HYAL1 has not been 
examined in endometrial cancer.  
 
6.2.2 Hyaluronidase and clinicopathological factors 
In study III, reduced HYAL1 expression in endometrial cancer was associated with 
lymphovascular invasion, large tumor size, lymph node metastasis, and deep 
myometrial invasion, all of which are properties of a more aggressive phenotype of 
cancer. Furthermore, as a possible consequence of this aggressive phenotype, 
decreased HYAL1 expression is associated with early disease recurrence in 
endometrial carcinoma.   
The present findings of reduced HYAL1 expression are consistent with findings in 
cancers of the lung (Anedchenko et al. 2008, Wang et al. 2008) and kidney (Chi et al. 
2012, Wang et al. 2008). Interestingly, Yoffou et al. (2011) showed subtype-specific 
overexpression of HYAL1 mRNA in ovarian carcinomas representing clear cell or 
mucinous histology. However, in line with our findings, HYAL1 expression was more 
likely to decline in serous carcinomas, but the decrease was not significant (Yoffou et 
al. 2011). Also in line with our findings are results in pancreatic ductal 
adenocarcinoma; weak HYAL1 expression was an independent factor of survival 
together with hyaluronan accumulation (Cheng et al. 2013). In silico mRNA studies 
have also revealed that decreased HYAL1 expression in breast cancer is associated 
with distant metastasis-free survival (Heldin et al. 2013). 
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In a strong contrast to our results, increased HYAL1 expression in poorly 
differentiated prostate and bladder tumors is associated with advanced disease and 
unfavorable prognosis (Lokeshwar et al. 2005, Kramer et al. 2010). Malignancies 
arising from different cell types appear to utilize distinct strategies to survive and 
progress. Increased hyaluronan may contribute to tumor growth and invasiveness by 
providing an expanded, loose matrix for cancer cells, protecting the tumor from 
immune reactions and apoptosis, stimulating tumor cell migration, and increasing cell 
proliferation (Tammi et al. 2008). The relative importance of the opposite roles of 
hyaluronidase function in a particular type of cancer may determine the outcome. The 
exact expression level is also important; transfection of HYAL1 can either promote or 
suppress malignant growth in a single cell type depending on the resulting enzyme 
activity (Lokeshwar et al. 2005). 
 
6.2.3 Decreased HYAL1 expression and invasion 
In study III, decreased HYAL1 expression was associated with deep and absolute 
myometrial invasion in endometrial carcinoma. Invasion over half of the myometrium 
is a well-known predictor of recurrence and usually a marker for adjuvant treatments. 
Recently, the absolute depth of invasion was suggested to have better predictive value 
for aggressive disease. An optimal cut of 4 mm has been presented (Geels et al. 2013). 
As our results show, endometrial tumors with strong HYAL1 staining have a median 
depth of invasion of only 1.5 mm.  
As decreased HYAL1 expression was associated with invasive features in 
endometrial carcinoma, we further elucidated its role in EMT, a process that initiates 
invasion and metastasis in cancer. Because decreased E-cadherin expression is the key 
event in EMT, we analyzed and correlated its expression levels with HYAL1. 
Decreased E-cadherin was associated with tumor grade, and we found a strong 
significant association with deep myometrial invasion, lymphovascular invasion, 
cervical invasion, and tumor size. Our findings are quite similar to previous reports 
of E-cadherin and endometrial cancer (Holcomb et al. 2002, Moreno-Bueno et al. 2003, 
Sakuragi et al. 1994). In line with our hypothesis, decreased E-cadherin was associated 
with decreased HYAL1 expression in study III. One explanation for this could be the 
accumulation of hyaluronan due to decreased HYAL1 expression. Increased 
hyaluronan content can induce EMT in normal epithelial cells (Zoltan-Jones et al. 
2003). Recently, the accumulation of hyaluronan in pancreatic cells was associated 
with a loss of E-cadherin. Interestingly, pegylated human recombinant hyaluronidase 
(PEGPH20) inhibits these changes (Kultti et al. 2014).  
 
6.2.4 Hyaluronan degradation products 
Because our results suggest that HYAL1 expression is decreased in endometrial 
carcinomas, the accumulating hyaluronan in tumor stroma may predominantly be 
HMW-HA, or in some cases intermediate-sized hyaluronan cleaved by HYAL2, due 
to impaired function of HYAL1 protein. We can also hypothesize that the amount of 
44 
 
 
 
small hyaluronan oligosaccharides is relatively low in carcinomas with decreased 
HYAL1. 
HMW-HA accumulation in tumor stroma can cause dramatic changes in the cancer 
cell microenvironment purely by its chemical properties. HMW-HA has the capacity 
to bind a large amount of water and form viscous gels at relatively low concentrations. 
In more concentrated solutions, hyaluronan molecules can form a continuous but 
porous meshwork that can act as a filter, facilitating the diffusion of small molecules 
and excluding large molecules (Stern 2008b). This hyaluronan barrier can decrease the 
uptake of chemotherapeutic drugs and be one cause of chemoresistance in cancer. 
Baumgartner et al. (Baumgartner et al. 1998) first showed that hyaluronidase 
treatments can enhance the actions of various chemotherapeutic agents, especially 
when used locally. Hyaluronan has been shown to be the primary matrix determinant 
for these barriers, forming desmoplastic reactions and causing high interstitial fluid 
pressures in the tumor microenvironment (Provenzano et al. 2012). Using synthetic 
hyaluronidase (PEGPH20), this stromal hyaluronan was degraded, causing 
normalization of tumor IFP and re-expansion of the microvasculature (Provenzano et 
al. 2012). The same results were achieved in another study in which an animal model 
of HMW-HA accumulation in tumor stroma in pancreatic cancer was degraded by 
PEGPH20, improving vascular patency and increased chemotherapeutic delivery. In 
the same study, combination therapy with PEGPH20 and gemcitabine inhibited tumor 
growth and significantly extended survival (Jacobetz et al. 2013). However, there is 
more than one hyaluronan “barrier”; CD44 signaling promotes drug resistance, and 
disruption of this endogenous hyaluronan-induced signaling suppresses cell 
resistance to chemotherapeutics (Misra et al. 2003).  
sHA is known to promote angiogenesis, which is a key component of tumor growth 
and progression (Toole 2004). However, administration of sHA to several types of 
tumor xenografts inhibited rather than stimulated tumor growth (Ghatak, Misra & 
Toole 2002, Zeng et al. 1998). Chemokine CXCL12 and its receptor CXCR4 are known 
to promote tumor growth and stimulate angiogenesis (Kryczek et al. 2007). 
Interestingly, HMW-HA and sHA were recently shown to have opposing effects on 
CXCR-induced signaling (Fuchs et al. 2013). In particular, HMW-HA promotes 
CXCL12-induced CXCR4 activation, whereas sHA inhibits it. This significant finding 
supports our results and suggests that carcinomas that accumulate HMW-HA, 
possibly due to decreased HYAL1, induce CXCR4 signaling, promoting tumor cell 
dissemination, angiogenesis, and potentially the growth of tumors and their 
metastatic spread.  
The exact size or molecular weight of hyaluronan that accumulates in cancer is 
difficult to determine. The measurable sHA concentration can be low, as it is rapidly 
”thrown” to the systemic circulation or is locally endocytosed. Histologically 
detectable hyaluronan may be HMW-HA, as small fragments escape fixation and the 
affinity of the hyaluronan probe is weaker towards hyaluronan fragments (Yuan et al. 
2013). Schmaus et. al. (Schmaus, Sleeman 2015) first hypothesized that accumulation 
of sHA accounts for the association between HYAL1 expression and metastasis, and 
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their study showed that HYAL-1 expression promotes lung metastasis in mouse 
tumor models, but without sHA accumulation.  
Despite the downregulation of HYAL1, we can assume that some hyaluronidase 
function is left to produce low concentrations of sHA. Low concentrations of sHA can 
increase endothelial cell proliferation, but high levels of sHA can be antiproliferative 
(Gao et al. 2010, Lokeshwar, Selzer 2000, Cui et al. 2009). Intermediate-sized 
hyaluronan can also induce cytokine expression to provide stimulating growth signals 
to tumor cells (de la Motte et al. 2009). Concerning our results, this could occur in 
serous endometrial carcinomas, where the concentrations of intermediate-sized 
hyaluronan can be even higher due to HYAL2 upregulation.  
It would be interesting to know the consequences that restoration of HYAL1 
function could have on HYAL1-depleted carcinomas. Increasing sHA concentration 
could slow down proliferation and further reduce tumor growth as shown in colon 
carcinoma (Alaniz et al. 2009). Increased sHA could also silence CXCR signaling 
(Fuchs et al. 2013). Suppression of cancer progression could be achieved by 
interrupting endogenous HA-CD44 interactions via sHA as shown in bone metastasis 
of breast cancer (Urakawa et al. 2012). Furthermore, the HMW-HA that occupies cell 
surface CD44 receptors may maintain p-Akt- and PI3K-dependent signals that 
prevent cancer cell apoptosis, returning hyaluronidase function, and the sHA created 
by hyaluronidase could block these cell survival signals (Ghatak, Misra & Toole 2002).  
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7 Summary and Conclusions 
The main findings of this thesis are that: 
 
x Hyaluronan synthases (HAS1-3) are associated with ovarian and endometrial 
tumors without a correlation with their mRNA levels. 
 
x HYAL1 mRNA levels are downregulated in serous ovarian carcinoma and 
associated with decreased hyaluronidase activity. Hyaluronan accumulation 
is related to decreased expression of HYAL1 but not to the increased expression 
of hyaluronan synthases (HAS1-3). 
 
x HYAL1 and HYAL2 mRNA and protein levels evaluated by 
immunohistochemistry are downregulated in endometrioid endometrial 
carcinoma and inversely correlate with hyaluronan accumulation. 
 
x Decreased HYAL1 expression is associated with aggressive features of 
endometrial carcinoma and is an independent prognostic marker of early 
disease recurrence. 
 
x Decreased HYAL1 in endometrial cancer may be associated with epithelial-
mesenchymal transition, as its expression correlates with decreased E-
cadherin expression. 
 
This thesis provides new knowledge about genes affecting hyaluronan metabolism 
and their role in hyaluronan accumulation. We initially identified decreased 
hyaluronidase expression as a possible mechanism or cause of increased hyaluronan 
in ovarian and endometrial cancer, and further elucidated the clinical consequences. 
This thesis opens new directions for research concerning hyaluronan metabolism in 
diagnosis and treatment. In the future, we may study the use of HYAL1 as a marker 
in endometrial biopsies to aid in clinical decision making for adjuvant treatments. This 
thesis also encourages the investigation of recombinant hyaluronidase in 
hyaluronidase-depleted cancers to answer questions such as: Is there a way to 
manipulate hyaluronan metabolism to stop or prevent cancer invasion and keep the 
tumor localized for surgical therapies and better prognosis?  
 
 
 
47 
 
 
 
8 References 
Acharya, S., Hensley, M.L., Montag, A.C. & Fleming, G.F. 2005, "Rare uterine 
cancers", The lancet oncology, vol. 6, no. 12, pp. 961-971. 
Adamia, S., Pilarski, P.M., Belch, A.R. & Pilarski, L.M. 2013, "Aberrant splicing, 
hyaluronan synthases and intracellular hyaluronan as drivers of oncogenesis 
and potential drug targets", Current cancer drug targets, vol. 13, no. 4, pp. 347-361. 
Afify, A.M., Stern, M., Guntenhoner, M. & Stern, R. 1993, "Purification and 
characterization of human serum hyaluronidase", Archives of Biochemistry and 
Biophysics, vol. 305, no. 2, pp. 434-441. 
Afify, A.M., Craig, S., Paulino, A.F.G. & Stern, R. 2005, "Expression of hyaluronic 
acid and its receptors, CD44s and CD44v6, in normal, hyperplastic, and 
neoplastic endometrium", Annals of Diagnostic Pathology, vol. 9, no. 6, pp. 312-
318. 
Agren, U.M., Tammi, R.H. & Tammi, M.I. 1997, "Reactive oxygen species contribute 
to epidermal hyaluronan catabolism in human skin organ culture", Free radical 
biology & medicine, vol. 23, no. 7, pp. 996-1001. 
Alaniz, L., Rizzo, M., Malvicini, M., Jaunarena, J., Avella, D., Atorrasagasti, C., 
Aquino, J.B., Garcia, M., Matar, P., Silva, M. & Mazzolini, G. 2009, "Low 
molecular weight hyaluronan inhibits colorectal carcinoma growth by 
decreasing tumor cell proliferation and stimulating immune response", Cancer 
letters, vol. 278, no. 1, pp. 9-16. 
Amant, F., Moerman, P., Neven, P., Timmerman, D., Van Limbergen, E. & Vergote, I. 
2005, "Endometrial cancer", The Lancet, vol. 366, no. 9484, pp. 491-505. 
Andre, B., Duterme, C., Van Moer, K., Mertens-Strijthagen, J., Jadot, M. & Flamion, 
B. 2011, "Hyal2 is a glycosylphosphatidylinositol-anchored, lipid raft-associated 
hyaluronidase", Biochemical and biophysical research communications, vol. 411, no. 
1, pp. 175-179. 
Anedchenko, E.A., Dmitriev, A.A., Krasnov, G.S., Kondrat'eva, T.T., Kopantsev, E.P., 
Vinogradova, T.V., Zinov'eva, M.V., Zborovskaia, I.B., Polotskii, B.E., Sakharova, 
O.V., Kashuba, V.I., Zabarovskii, E.R. & Senchenko, V.N. 2008, "Down-
regulation of RBSP3/CTDSPL, NPRL2/G21, RASSF1A, ITGA9, HYAL1 and 
48 
 
 
 
HYAL2 genes in non-small cell lung cancer", Molekuliarnaia biologiia, vol. 42, no. 
6, pp. 965-976. 
Anttila, M.A., Tammi, R.H., Tammi, M.I., Syrjanen, K.J., Saarikoski, S.V. & Kosma, 
V.M. 2000, "High levels of stromal hyaluronan predict poor disease outcome in 
epithelial ovarian cancer", Cancer research, vol. 60, no. 1, pp. 150-155. 
Atmuri, V., Martin, D.C., Hemming, R., Gutsol, A., Byers, S., Sahebjam, S., Thliveris, 
J.A., Mort, J.S., Carmona, E., Anderson, J.E., Dakshinamurti, S. & Triggs-Raine, 
B. 2008, "Hyaluronidase 3 (HYAL3) knockout mice do not display evidence of 
hyaluronan accumulation", Matrix biology : journal of the International Society for 
Matrix Biology, vol. 27, no. 8, pp. 653-660. 
Auvinen, P., Rilla, K., Tumelius, R., Tammi, M., Sironen, R., Soini, Y., Kosma, V.M., 
Mannermaa, A., Viikari, J. & Tammi, R. 2014, "Hyaluronan synthases (HAS1-3) 
in stromal and malignant cells correlate with breast cancer grade and predict 
patient survival", Breast cancer research and treatment, vol. 143, no. 2, pp. 277-286. 
Auvinen, P.K., Parkkinen, J.J., Johansson, R.T., Agren, U.M., Tammi, R.H., Eskelinen, 
M.J. & Kosma, V.M. 1997, "Expression of hyaluronan in benign and malignant 
breast lesions", International journal of cancer, vol. 74, no. 5, pp. 477-481. 
Baldwin, R.L., Nemeth, E., Tran, H., Shvartsman, H., Cass, I., Narod, S. & Karlan, 
B.Y. 2000, "BRCA1 promoter region hypermethylation in ovarian carcinoma: a 
population-based study", Cancer research, vol. 60, no. 19, pp. 5329-5333. 
Barrallo-Gimeno, A. & Nieto, M.A. 2005, "The Snail genes as inducers of cell 
movement and survival: implications in development and cancer", Development 
(Cambridge, England), vol. 132, no. 14, pp. 3151-3161. 
Baumgartner, G., Gomar-Hoss, C., Sakr, L., Ulsperger, E. & Wogritsch, C. 1998, "The 
impact of extracellular matrix on the chemoresistance of solid tumors--
experimental and clinical results of hyaluronidase as additive to cytostatic 
chemotherapy", Cancer letters, vol. 131, no. 1, pp. 85-99. 
Beral, V., Doll, R., Hermon, C., Peto, R. & Reeves, G. 2008, "Ovarian cancer and oral 
contraceptives: collaborative reanalysis of data from 45 epidemiological studies 
including 23,257 women with ovarian cancer and 87,303 controls", Lancet, vol. 
371, no. 9609, pp. 303-314. 
Bertrand, P., Courel, M.N., Maingonnat, C., Jardin, F., Tilly, H. & Bastard, C. 2005, 
"Expression of HYAL2 mRNA, hyaluronan and hyaluronidase in B-cell non-
Hodgkin lymphoma: relationship with tumor aggressiveness", International 
journal of cancer, vol. 113, no. 2, pp. 207-212. 
49 
 
 
 
Bokhman, J.V. 1983, "Two pathogenetic types of endometrial carcinoma", Gynecologic 
oncology, vol. 15, no. 1, pp. 10-17. 
Bonadona, V., Bonaiti, B., Olschwang, S., Grandjouan, S., Huiart, L., Longy, M., 
Guimbaud, R., Buecher, B., Bignon, Y.J., Caron, O., Colas, C., Nogues, C., 
Lejeune-Dumoulin, S., Olivier-Faivre, L., Polycarpe-Osaer, F., Nguyen, T.D., 
Desseigne, F., Saurin, J.C., Berthet, P., Leroux, D., Duffour, J., Manouvrier, S., 
Frebourg, T., Sobol, H., Lasset, C., Bonaiti-Pellie, C. & French Cancer Genetics 
Network 2011, "Cancer risks associated with germline mutations in MLH1, 
MSH2, and MSH6 genes in Lynch syndrome", JAMA : the journal of the American 
Medical Association, vol. 305, no. 22, pp. 2304-2310. 
Bono, P., Rubin, K., Higgins, J.M. & Hynes, R.O. 2001, "Layilin, a novel integral 
membrane protein, is a hyaluronan receptor", Molecular biology of the cell, vol. 12, 
no. 4, pp. 891-900. 
Boonen, M., Puissant, E., Gilis, F., Flamion, B. & Jadot, M. 2014, "Mouse liver 
lysosomes contain enzymatically active processed forms of Hyal-1", Biochemical 
and biophysical research communications, vol. 446, no. 4, pp. 1155-1160. 
Boruta, D.M.,2nd, Gehrig, P.A., Groben, P.A., Bae-Jump, V., Boggess, J.F., Fowler, 
W.C.,Jr & Van Le, L. 2004, "Uterine serous and grade 3 endometrioid 
carcinomas: is there a survival difference?", Cancer, vol. 101, no. 10, pp. 2214-
2221. 
Bouga, H., Tsouros, I., Bounias, D., Kyriakopoulou, D., Stavropoulos, M.S., 
Papageorgakopoulou, N., Theocharis, D.A. & Vynios, D.H. 2010, "Involvement 
of hyaluronidases in colorectal cancer", BMC cancer, vol. 10, pp. 499-2407-10-499. 
Bourguignon, L.Y., Gilad, E. & Peyrollier, K. 2007, "Heregulin-mediated ErbB2-ERK 
signaling activates hyaluronan synthases leading to CD44-dependent ovarian 
tumor cell growth and migration", The Journal of biological chemistry, vol. 282, no. 
27, pp. 19426-19441. 
Bourguignon, L.Y., Wong, G., Earle, C.A. & Xia, W. 2011, "Interaction of low 
molecular weight hyaluronan with CD44 and toll-like receptors promotes the 
actin filament-associated protein 110-actin binding and MyD88-NFkappaB 
signaling leading to proinflammatory cytokine/chemokine production and 
breast tumor invasion", Cytoskeleton (Hoboken, N.J.), vol. 68, no. 12, pp. 671-693. 
Bourguignon, L.Y.W. 2008, "Hyaluronan-mediated CD44 activation of RhoGTPase 
signaling and cytoskeleton function promotes tumor progression", Seminars in 
cancer biology, vol. 18, no. 4, pp. 251-259. 
50 
 
 
 
Bourrguignon, L.Y., Iida, N., Welsh, C.F., Zhu, D., Krongrad, A. & Pasquale, D. 1995, 
"Involvement of CD44 and its variant isoforms in membrane-cytoskeleton 
interaction, cell adhesion and tumor metastasis", Journal of neuro-oncology, vol. 
26, no. 3, pp. 201-208. 
Boyd, J., Sonoda, Y., Federici, M.G., Bogomolniy, F., Rhei, E., Maresco, D.L., Saigo, 
P.E., Almadrones, L.A., Barakat, R.R., Brown, C.L., Chi, D.S., Curtin, J.P., 
Poynor, E.A. & Hoskins, W.J. 2000, "Clinicopathologic features of BRCA-linked 
and sporadic ovarian cancer", JAMA : the journal of the American Medical 
Association, vol. 283, no. 17, pp. 2260-2265. 
Brinck, J. & Heldin, P. 1999, "Expression of recombinant hyaluronan synthase (HAS) 
isoforms in CHO cells reduces cell migration and cell surface CD44", 
Experimental cell research, vol. 252, no. 2, pp. 342-351. 
Camenisch, T.D., Schroeder, J.A., Bradley, J., Klewer, S.E. & McDonald, J.A. 2002, 
"Heart-valve mesenchyme formation is dependent on hyaluronan-augmented 
activation of ErbB2-ErbB3 receptors", Nature medicine, vol. 8, no. 8, pp. 850-855. 
Camenisch, T.D., Spicer, A.P., Brehm-Gibson, T., Biesterfeldt, J., Augustine, M.L., 
Calabro, A.,Jr, Kubalak, S., Klewer, S.E. & McDonald, J.A. 2000, "Disruption of 
hyaluronan synthase-2 abrogates normal cardiac morphogenesis and 
hyaluronan-mediated transformation of epithelium to mesenchyme", The Journal 
of clinical investigation, vol. 106, no. 3, pp. 349-360. 
Cancer Genome Atlas Research Network 2011, "Integrated genomic analyses of 
ovarian carcinoma", Nature, vol. 474, no. 7353, pp. 609-615. 
Cancer Genome Atlas Research Network, Kandoth, C., Schultz, N., Cherniack, A.D., 
Akbani, R., Liu, Y., Shen, H., Robertson, A.G., Pashtan, I., Shen, R., Benz, C.C., 
Yau, C., Laird, P.W., Ding, L., Zhang, W., Mills, G.B., Kucherlapati, R., Mardis, 
E.R. & Levine, D.A. 2013, "Integrated genomic characterization of endometrial 
carcinoma", Nature, vol. 497, no. 7447, pp. 67-73. 
Cannistra, S.A. 2004, "Cancer of the ovary", The New England journal of medicine, vol. 
351, no. 24, pp. 2519-2529. 
Chang, N.S., Pratt, N., Heath, J., Schultz, L., Sleve, D., Carey, G.B. & Zevotek, N. 
2001, "Hyaluronidase induction of a WW domain-containing oxidoreductase 
that enhances tumor necrosis factor cytotoxicity", The Journal of biological 
chemistry, vol. 276, no. 5, pp. 3361-3370. 
Chanmee, T., Ontong, P., Mochizuki, N., Kongtawelert, P., Konno, K. & Itano, N. 
2014, "Excessive Hyaluronan Production Promotes Acquisition of Cancer Stem 
51 
 
 
 
Cell Signatures through the Coordinated Regulation of Twist and the 
Transforming Growth Factor beta (TGF-beta)-Snail Signaling Axis", The Journal 
of biological chemistry, vol. 289, no. 38, pp. 26038-26056. 
Chen, S., Iversen, E.S., Friebel, T., Finkelstein, D., Weber, B.L., Eisen, A., Peterson, 
L.E., Schildkraut, J.M., Isaacs, C., Peshkin, B.N., Corio, C., Leondaridis, L., 
Tomlinson, G., Dutson, D., Kerber, R., Amos, C.I., Strong, L.C., Berry, D.A., 
Euhus, D.M. & Parmigiani, G. 2006, "Characterization of BRCA1 and BRCA2 
mutations in a large United States sample", Journal of clinical oncology : official 
journal of the American Society of Clinical Oncology, vol. 24, no. 6, pp. 863-871. 
Cheng, X.B., Sato, N., Kohi, S. & Yamaguchi, K. 2013, "Prognostic impact of 
hyaluronan and its regulators in pancreatic ductal adenocarcinoma", PloS one, 
vol. 8, no. 11, pp. e80765. 
Cherr, G.N., Yudin, A.I. & Overstreet, J.W. 2001, "The dual functions of GPI-
anchored PH-20: hyaluronidase and intracellular signaling", Matrix biology : 
journal of the International Society for Matrix Biology, vol. 20, no. 8, pp. 515-525. 
Chi, A., Shirodkar, S.P., Escudero, D.O., Ekwenna, O.O., Yates, T.J., Ayyathurai, R., 
Garcia-Roig, M., Gahan, J.C., Manoharan, M., Bird, V.G. & Lokeshwar, V.B. 2012, 
"Molecular characterization of kidney cancer: association of hyaluronic acid 
family with histological subtypes and metastasis", Cancer, vol. 118, no. 9, pp. 
2394-2402. 
Cho, S.H., Park, Y.S., Kim, H.J., Kim, C.H., Lim, S.W., Huh, J.W., Lee, J.H. & Kim, 
H.R. 2012, "CD44 enhances the epithelial-mesenchymal transition in association 
with colon cancer invasion", International journal of oncology, vol. 41, no. 1, pp. 
211-218. 
Chow, G. & Knudson, W. 2005, "Characterization of promoter elements of the 
human HYAL-2 gene", The Journal of biological chemistry, vol. 280, no. 29, pp. 
26904-26912. 
Chow, G., Tauler, J. & Mulshine, J.L. 2010, "Cytokines and growth factors stimulate 
hyaluronan production: role of hyaluronan in epithelial to mesenchymal-like 
transition in non-small cell lung cancer", Journal of biomedicine & biotechnology, 
vol. 2010, pp. 485468. 
Chowdhury, B., Hemming, R., Hombach-Klonisch, S., Flamion, B. & Triggs-Raine, B. 
2013, "Murine hyaluronidase 2 deficiency results in extracellular hyaluronan 
accumulation and severe cardiopulmonary dysfunction", The Journal of biological 
chemistry, vol. 288, no. 1, pp. 520-528. 
52 
 
 
 
Clement, P.B. & Young, R.H. 2002, "Endometrioid carcinoma of the uterine corpus: a 
review of its pathology with emphasis on recent advances and problematic 
aspects", Advances in Anatomic Pathology, vol. 9, no. 3, pp. 145-184. 
Colas, E., Pedrola, N., Devis, L., Ertekin, T., Campoy, I., Martinez, E., Llaurado, M., 
Rigau, M., Olivan, M., Garcia, M., Cabrera, S., Gil-Moreno, A., Xercavins, J., 
Castellvi, J., Garcia, A., Ramon y Cajal, S., Moreno-Bueno, G., Dolcet, X., 
Alameda, F., Palacios, J., Prat, J., Doll, A., Matias-Guiu, X., Abal, M. & Reventos, 
J. 2012, "The EMT signaling pathways in endometrial carcinoma", Clinical & 
translational oncology : official publication of the Federation of Spanish Oncology 
Societies and of the National Cancer Institute of Mexico, vol. 14, no. 10, pp. 715-720. 
Creutzberg, C.L., van Putten, W.L., Warlam-Rodenhuis, C.C., van den Bergh, A.C., 
de Winter, K.A., Koper, P.C., Lybeert, M.L., Slot, A., Lutgens, L.C., Stenfert 
Kroese, M.C., Beerman, H., van Lent, M. & postoperative Radiation Therapy in 
Endometrial Carcinoma Trial 2004, "Outcome of high-risk stage IC, grade 3, 
compared with stage I endometrial carcinoma patients: the Postoperative 
Radiation Therapy in Endometrial Carcinoma Trial", Journal of clinical oncology : 
official journal of the American Society of Clinical Oncology, vol. 22, no. 7, pp. 1234-
1241. 
Csoka, A.B., Frost, G.I. & Stern, R. 2001, "The six hyaluronidase-like genes in the 
human and mouse genomes", Matrix biology : journal of the International Society for 
Matrix Biology, vol. 20, no. 8, pp. 499-508. 
Cui, X., Xu, H., Zhou, S., Zhao, T., Liu, A., Guo, X., Tang, W. & Wang, F. 2009, 
"Evaluation of angiogenic activities of hyaluronan oligosaccharides of defined 
minimum size", Life Sciences, vol. 85, no. 15-16, pp. 573-577. 
da Costa Prando, E., Cavalli, L.R. & Rainho, C.A. 2011, "Evidence of epigenetic 
regulation of the tumor suppressor gene cluster flanking RASSF1 in breast 
cancer cell lines", Epigenetics : official journal of the DNA Methylation Society, vol. 6, 
no. 12, pp. 1413-1424. 
Dang, S., Peng, Y., Ye, L., Wang, Y., Qian, Z., Chen, Y., Wang, X., Lin, Y., Zhang, X., 
Sun, X., Wu, Q., Cheng, Y., Nie, H., Jin, M. & Xu, H. 2013, "Stimulation of TLR4 
by LMW-HA induces metastasis in human papillary thyroid carcinoma through 
CXCR7", Clinical & developmental immunology, vol. 2013, pp. 712561. 
Day, A.J. & Prestwich, G.D. 2002, "Hyaluronan-binding proteins: tying up the giant", 
The Journal of biological chemistry, vol. 277, no. 7, pp. 4585-4588. 
de Kok, J.B., Roelofs, R.W., Giesendorf, B.A., Pennings, J.L., Waas, E.T., Feuth, T., 
Swinkels, D.W. & Span, P.N. 2005, "Normalization of gene expression 
53 
 
 
 
measurements in tumor tissues: comparison of 13 endogenous control genes", 
Laboratory investigation; a journal of technical methods and pathology, vol. 85, no. 1, 
pp. 154-159. 
de la Motte, C., Nigro, J., Vasanji, A., Rho, H., Kessler, S., Bandyopadhyay, S., 
Danese, S., Fiocchi, C. & Stern, R. 2009, "Platelet-derived hyaluronidase 2 cleaves 
hyaluronan into fragments that trigger monocyte-mediated production of 
proinflammatory cytokines", The American journal of pathology, vol. 174, no. 6, pp. 
2254-2264. 
Deen, A.J., Rilla, K., Oikari, S., Karna, R., Bart, G., Hayrinen, J., Bathina, A.R., 
Ropponen, A., Makkonen, K., Tammi, R.H. & Tammi, M.I. 2014, "Rab10-
mediated endocytosis of the hyaluronan synthase HAS3 regulates hyaluronan 
synthesis and cell adhesion to collagen", The Journal of biological chemistry, vol. 
289, no. 12, pp. 8375-8389. 
Della Pepa, C., Tonini, G., Santini, D., Losito, S., Pisano, C., Di Napoli, M., Cecere, 
S.C., Gargiulo, P. & Pignata, S. 2015, "Low Grade Serous Ovarian Carcinoma: 
from the molecular characterization to the best therapeutic strategy", Cancer 
treatment reviews, vol. 41, no. 2, pp. 136-143. 
Diaz-Padilla, I., Malpica, A.L., Minig, L., Chiva, L.M., Gershenson, D.M. & Gonzalez-
Martin, A. 2012, "Ovarian low-grade serous carcinoma: a comprehensive 
update", Gynecologic oncology, vol. 126, no. 2, pp. 279-285. 
Ding, Y., Tong, M., Liu, S., Moscow, J.A. & Tai, H.H. 2005, "NAD+-linked 15-
hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor 
suppressor in lung cancer", Carcinogenesis, vol. 26, no. 1, pp. 65-72. 
du Bois, A., Reuss, A., Pujade-Lauraine, E., Harter, P., Ray-Coquard, I. & Pfisterer, J. 
2009, "Role of surgical outcome as prognostic factor in advanced epithelial 
ovarian cancer: a combined exploratory analysis of 3 prospectively randomized 
phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische 
Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe 
d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO)", 
Cancer, vol. 115, no. 6, pp. 1234-1244. 
Duggan, B.D., Felix, J.C., Muderspach, L.I., Tourgeman, D., Zheng, J. & Shibata, D. 
1994, "Microsatellite instability in sporadic endometrial carcinoma", Journal of the 
National Cancer Institute, vol. 86, no. 16, pp. 1216-1221. 
Dumaresq-Doiron, K., Edjekouane, L., Orimoto, A.M., Yoffou, P.H., Gushulak, L., 
Triggs-Raine, B. & Carmona, E. 2012, "Hyal-1 but not hyal-3 deficiency has an 
impact on ovarian folliculogenesis and female fertility by altering the 
54 
 
 
 
follistatin/activin/Smad3 pathway and the apoptotic process", Journal of cellular 
physiology, vol. 227, no. 5, pp. 1911-1922. 
Edge, S.B., Byrd, D.R., Compton, C.C., Fritz, A.G., Greene, F.L. & Trotti, A. 2010a, 
"AJCC Cancer Staging Manual: Corpus Uteri" in , 7th ed. edn, New York, NY: 
Springer-Verlag;, , pp. 403. 
Edge, S.B., Byrd, D.R., Compton, C.C., Fritz, A.G., Greene, F.L. & Trotti, A. 2010b, 
"Ovary and primary peritoneal carcinoma." in AJCC Cancer Staging Manual, 7th 
ed. edn, New York, NY: Springer-Verlag;, , pp. 493-506. 
Eissa, S., Zohny, S.F., Shehata, H.H., Hegazy, M.G., Salem, A.M. & Esmat, M. 2012, 
"Urinary retinoic acid receptor-beta2 gene promoter methylation and 
hyaluronidase activity as noninvasive tests for diagnosis of bladder cancer", 
Clinical biochemistry, vol. 45, no. 6, pp. 402-407. 
Enegd, B., King, J.A., Stylli, S., Paradiso, L., Kaye, A.H. & Novak, U. 2002, 
"Overexpression of hyaluronan synthase-2 reduces the tumorigenic potential of 
glioma cells lacking hyaluronidase activity", Neurosurgery, vol. 50, no. 6, pp. 
1311-1318. 
Evanko, S.P., Tammi, M.I., Tammi, R.H. & Wight, T.N. 2007, "Hyaluronan-
dependent pericellular matrix", Advanced Drug Delivery Reviews, vol. 59, no. 13, 
pp. 1351-1365. 
Fieber, C., Baumann, P., Vallon, R., Termeer, C., Simon, J.C., Hofmann, M., Angel, P., 
Herrlich, P. & Sleeman, J.P. 2004, "Hyaluronan-oligosaccharide-induced 
transcription of metalloproteases", Journal of cell science, vol. 117, no. Pt 2, pp. 
359-367. 
Fiolka, R., Zubor, P., Janusicova, V., Visnovsky, J., Mendelova, A., Kajo, K., 
Lasabova, Z., Plank, L. & Danko, J. 2013, "Promoter hypermethylation of the 
tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer", 
Oncology reports, vol. 30, no. 6, pp. 2878-2886. 
Fuchs, K., Hippe, A., Schmaus, A., Homey, B., Sleeman, J.P. & Orian-Rousseau, V. 
2013, "Opposing effects of high- and low-molecular weight hyaluronan on 
CXCL12-induced CXCR4 signaling depend on CD44", Cell death & disease, vol. 4, 
pp. e819. 
Gao, F., Liu, Y., He, Y., Yang, C., Wang, Y., Shi, X. & Wei, G. 2010, "Hyaluronan 
oligosaccharides promote excisional wound healing through enhanced 
angiogenesis", Matrix biology : journal of the International Society for Matrix Biology, 
vol. 29, no. 2, pp. 107-116. 
55 
 
 
 
Geels, Y.P., Pijnenborg, J.M., van den Berg-van Erp, S.H., Snijders, M.P., Bulten, J. & 
Massuger, L.F. 2013, "Absolute depth of myometrial invasion in endometrial 
cancer is superior to the currently used cut-off value of 50%", Gynecologic 
oncology, vol. 129, no. 2, pp. 285-291. 
Ghatak, S., Misra, S. & Toole, B.P. 2002, "Hyaluronan oligosaccharides inhibit 
anchorage-independent growth of tumor cells by suppressing the 
phosphoinositide 3-kinase/Akt cell survival pathway", The Journal of biological 
chemistry, vol. 277, no. 41, pp. 38013-38020. 
Girish, K.S. & Kemparaju, K. 2007, "The magic glue hyaluronan and its eraser 
hyaluronidase: a biological overview", Life Sciences, vol. 80, no. 21, pp. 1921-1943. 
Gomez, C.S., Gomez, P., Knapp, J., Jorda, M., Soloway, M.S. & Lokeshwar, V.B. 2009, 
"Hyaluronic acid and HYAL-1 in prostate biopsy specimens: predictors of 
biochemical recurrence", The Journal of urology, vol. 182, no. 4, pp. 1350-1356. 
Grigsby, P.W., Perez, C.A., Kuten, A., Simpson, J.R., Garcia, D.M., Camel, H.M., Kao, 
M.S. & Galakatos, A.E. 1992, "Clinical stage I endometrial cancer: prognostic 
factors for local control and distant metastasis and implications of the new FIGO 
surgical staging system", International journal of radiation oncology, biology, physics, 
vol. 22, no. 5, pp. 905-911. 
Grisham, R.N., Iyer, G., Garg, K., DeLair, D., Hyman, D.M., Zhou, Q., Iasonos, A., 
Berger, M.F., Dao, F., Spriggs, D.R., Levine, D.A., Aghajanian, C. & Solit, D.B. 
2013, "BRAF mutation is associated with early stage disease and improved 
outcome in patients with low-grade serous ovarian cancer", Cancer, vol. 119, no. 
3, pp. 548-554. 
Gushulak, L., Hemming, R., Martin, D., Seyrantepe, V., Pshezhetsky, A. & Triggs-
Raine, B. 2012, "Hyaluronidase 1 and beta-hexosaminidase have redundant 
functions in hyaluronan and chondroitin sulfate degradation", The Journal of 
biological chemistry, vol. 287, no. 20, pp. 16689-16697. 
Hamalainen, K., Kosma, V.M., Eloranta, M.L., Tammi, R., Tammi, M., Leppanen, M., 
Leppanen, M., Heinonen, S. & Anttila, M. 2010, "Downregulated CD44 and 
hyaluronan expression in vulvar intraepithelial neoplasia and squamous cell 
carcinomas", Acta Obstetricia et Gynecologica Scandinavica, vol. 89, no. 1, pp. 108-
119. 
Hankinson, S.E., Hunter, D.J., Colditz, G.A., Willett, W.C., Stampfer, M.J., Rosner, B., 
Hennekens, C.H. & Speizer, F.E. 1993, "Tubal ligation, hysterectomy, and risk of 
ovarian cancer. A prospective study", JAMA : the journal of the American Medical 
Association, vol. 270, no. 23, pp. 2813-2818. 
56 
 
 
 
Hautmann, S.H., Lokeshwar, V.B., Schroeder, G.L., Civantos, F., Duncan, R.C., 
Gnann, R., Friedrich, M.G. & Soloway, M.S. 2001, "Elevated tissue expression of 
hyaluronic acid and hyaluronidase validates the HA-HAase urine test for 
bladder cancer", The Journal of urology, vol. 165, no. 6 Pt 1, pp. 2068-2074. 
Hayes, M.P. & Ellenson, L.H. 2010, "Molecular alterations in uterine serous 
carcinoma", Gynecologic oncology, vol. 116, no. 2, pp. 286-289. 
Heintz, A.P., Odicino, F., Maisonneuve, P., Quinn, M.A., Benedet, J.L., Creasman, 
W.T., Ngan, H.Y., Pecorelli, S. & Beller, U. 2006, "Carcinoma of the ovary. FIGO 
26th Annual Report on the Results of Treatment in Gynecological Cancer", 
International journal of gynaecology and obstetrics: the official organ of the 
International Federation of Gynaecology and Obstetrics, vol. 95 Suppl 1, pp. S161-92. 
Heldin, P., Basu, K., Kozlova, I. & Porsch, H. 2014, "HAS2 and CD44 in breast 
tumorigenesis", Advances in Cancer Research, vol. 123, pp. 211-229. 
Heldin, P., Basu, K., Olofsson, B., Porsch, H., Kozlova, I. & Kahata, K. 2013, 
"Deregulation of hyaluronan synthesis, degradation and binding promotes 
breast cancer", Journal of Biochemistry, vol. 154, no. 5, pp. 395-408. 
Hemming, R., Martin, D.C., Slominski, E., Nagy, J.I., Halayko, A.J., Pind, S. & Triggs-
Raine, B. 2008, "Mouse Hyal3 encodes a 45- to 56-kDa glycoprotein whose 
overexpression increases hyaluronidase 1 activity in cultured cells", Glycobiology, 
vol. 18, no. 4, pp. 280-289. 
Hennessy, B.T., Coleman, R.L. & Markman, M. 2009, "Ovarian cancer", Lancet, vol. 
374, no. 9698, pp. 1371-1382. 
Hiltunen, E.L., Anttila, M., Kultti, A., Ropponen, K., Penttinen, J., Yliskoski, M., 
Kuronen, A.T., Juhola, M., Tammi, R., Tammi, M. & Kosma, V.M. 2002, 
"Elevated hyaluronan concentration without hyaluronidase activation in 
malignant epithelial ovarian tumors", Cancer research, vol. 62, no. 22, pp. 6410-
6413. 
Hirvikoski, P., Tammi, R., Kumpulainen, E., Virtaniemi, J., Parkkinen, J.J., Tammi, 
M., Johansson, R., Agren, U., Karhunen, J. & Kosma, V.M. 1999, "Irregular 
expression of hyaluronan and its CD44 receptor is associated with metastatic 
phenotype in laryngeal squamous cell carcinoma", Virchows Archiv : an 
international journal of pathology, vol. 434, no. 1, pp. 37-44. 
Ho, C.L., Kurman, R.J., Dehari, R., Wang, T.L. & Shih, I. 2004, "Mutations of BRAF 
and KRAS precede the development of ovarian serous borderline tumors", 
Cancer research, vol. 64, no. 19, pp. 6915-6918. 
57 
 
 
 
Holcomb, K., Delatorre, R., Pedemonte, B., McLeod, C., Anderson, L. & Chambers, J. 
2002, "E-cadherin expression in endometrioid, papillary serous, and clear cell 
carcinoma of the endometrium", Obstetrics and gynecology, vol. 100, no. 6, pp. 
1290-1295. 
Horn, L.C., Schnurrbusch, U., Bilek, K., Hentschel, B. & Einenkel, J. 2004, "Risk of 
progression in complex and atypical endometrial hyperplasia: clinicopathologic 
analysis in cases with and without progestogen treatment", International journal 
of gynecological cancer : official journal of the International Gynecological Cancer 
Society, vol. 14, no. 2, pp. 348-353. 
Hosono, K., Nishida, Y., Knudson, W., Knudson, C.B., Naruse, T., Suzuki, Y. & 
Ishiguro, N. 2007, "Hyaluronan oligosaccharides inhibit tumorigenicity of 
osteosarcoma cell lines MG-63 and LM-8 in vitro and in vivo via perturbation of 
hyaluronan-rich pericellular matrix of the cells", The American journal of 
pathology, vol. 171, no. 1, pp. 274-286. 
Howlader, N., Noone, A.M., Krapcho, M., Neyman, N., Aminou, R. & Waldron, W. 
(eds) 2011, SEER cancer statistics review, 1975–2008, 
[http://seer.cancer.gov/csr/1975_2008/, National Cancer Institute, Bethesda, MD. 
Huang, Z., Zhao, C., Chen, Y., Cowell, J.A., Wei, G., Kultti, A., Huang, L., 
Thompson, C.B., Rosengren, S., Frost, G.I. & Shepard, H.M. 2014, "Recombinant 
human hyaluronidase PH20 does not stimulate an acute inflammatory response 
and inhibits lipopolysaccharide-induced neutrophil recruitment in the air pouch 
model of inflammation", Journal of immunology (Baltimore, Md.: 1950), vol. 192, 
no. 11, pp. 5285-5295. 
Itano, N. & Kimata, K. 2002, "Mammalian hyaluronan synthases", IUBMB life, vol. 54, 
no. 4, pp. 195-199. 
Itano, N., Sawai, T., Yoshida, M., Lenas, P., Yamada, Y., Imagawa, M., Shinomura, T., 
Hamaguchi, M., Yoshida, Y., Ohnuki, Y., Miyauchi, S., Spicer, A.P., McDonald, 
J.A. & Kimata, K. 1999, "Three isoforms of mammalian hyaluronan synthases 
have distinct enzymatic properties", The Journal of biological chemistry, vol. 274, 
no. 35, pp. 25085-25092. 
Itano, N. & Kimata, K. 2008, "Altered hyaluronan biosynthesis in cancer 
progression", Seminars in cancer biology, vol. 18, no. 4, pp. 268-274. 
Jacobetz, M.A., Chan, D.S., Neesse, A., Bapiro, T.E., Cook, N., Frese, K.K., Feig, C., 
Nakagawa, T., Caldwell, M.E., Zecchini, H.I., Lolkema, M.P., Jiang, P., Kultti, A., 
Thompson, C.B., Maneval, D.C., Jodrell, D.I., Frost, G.I., Shepard, H.M., Skepper, 
58 
 
 
 
J.N. & Tuveson, D.A. 2013, "Hyaluronan impairs vascular function and drug 
delivery in a mouse model of pancreatic cancer", Gut, vol. 62, no. 1, pp. 112-120. 
Jacobson, A., Rahmanian, M., Rubin, K. & Heldin, P. 2002, "Expression of 
hyaluronan synthase 2 or hyaluronidase 1 differentially affect the growth rate of 
transplantable colon carcinoma cell tumors", International journal of cancer, vol. 
102, no. 3, pp. 212-219. 
Jadin, L., Bookbinder, L.H. & Frost, G.I. 2012, "A comprehensive model of 
hyaluronan turnover in the mouse", Matrix biology : journal of the International 
Society for Matrix Biology, vol. 31, no. 2, pp. 81-89. 
Jadin, L., Wu, X., Ding, H., Frost, G.I., Onclinx, C., Triggs-Raine, B. & Flamion, B. 
2008, "Skeletal and hematological anomalies in HYAL2-deficient mice: a second 
type of mucopolysaccharidosis IX?", FASEB journal : official publication of the 
Federation of American Societies for Experimental Biology, vol. 22, no. 12, pp. 4316-
4326. 
Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E. & Forman, D. 2011, "Global 
cancer statistics", CA: a cancer journal for clinicians, vol. 61, no. 2, pp. 69-90. 
Jokela, T.A., Makkonen, K.M., Oikari, S., Karna, R., Koli, E., Hart, G.W., Tammi, 
R.H., Carlberg, C. & Tammi, M.I. 2011, "Cellular content of UDP-N-
acetylhexosamines controls hyaluronan synthase 2 expression and correlates 
with O-linked N-acetylglucosamine modification of transcription factors YY1 
and SP1", The Journal of biological chemistry, vol. 286, no. 38, pp. 33632-33640. 
Jordan, S.J., Siskind, V., C Green, A., Whiteman, D.C. & Webb, P.M. 2010, 
"Breastfeeding and risk of epithelial ovarian cancer", Cancer causes & control : 
CCC, vol. 21, no. 1, pp. 109-116. 
Karousou, E., Kamiryo, M., Skandalis, S.S., Ruusala, A., Asteriou, T., Passi, A., 
Yamashita, H., Hellman, U., Heldin, C.H. & Heldin, P. 2010, "The activity of 
hyaluronan synthase 2 is regulated by dimerization and ubiquitination", The 
Journal of biological chemistry, vol. 285, no. 31, pp. 23647-23654. 
Karvinen, S., Kosma, V.M., Tammi, M.I. & Tammi, R. 2003, "Hyaluronan, CD44 and 
versican in epidermal keratinocyte tumours", The British journal of dermatology, 
vol. 148, no. 1, pp. 86-94. 
Kindelberger, D.W., Lee, Y., Miron, A., Hirsch, M.S., Feltmate, C., Medeiros, F., 
Callahan, M.J., Garner, E.O., Gordon, R.W., Birch, C., Berkowitz, R.S., Muto, 
M.G. & Crum, C.P. 2007, "Intraepithelial carcinoma of the fimbria and pelvic 
59 
 
 
 
serous carcinoma: Evidence for a causal relationship", The American Journal of 
Surgical Pathology, vol. 31, no. 2, pp. 161-169. 
King, M.C., Marks, J.H., Mandell, J.B. & New York Breast Cancer Study Group 2003, 
"Breast and ovarian cancer risks due to inherited mutations in BRCA1 and 
BRCA2", Science (New York, N.Y.), vol. 302, no. 5645, pp. 643-646. 
Knudson, W., Casey, B., Nishida, Y., Eger, W., Kuettner, K.E. & Knudson, C.B. 2000, 
"Hyaluronan oligosaccharides perturb cartilage matrix homeostasis and induce 
chondrocytic chondrolysis", Arthritis and Rheumatism, vol. 43, no. 5, pp. 1165-
1174. 
Kobayashi, N., Miyoshi, S., Mikami, T., Koyama, H., Kitazawa, M., Takeoka, M., 
Sano, K., Amano, J., Isogai, Z., Niida, S., Oguri, K., Okayama, M., McDonald, 
J.A., Kimata, K., Taniguchi, S. & Itano, N. 2010, "Hyaluronan deficiency in tumor 
stroma impairs macrophage trafficking and tumor neovascularization", Cancer 
research, vol. 70, no. 18, pp. 7073-7083. 
Kong, D., Suzuki, A., Zou, T.T., Sakurada, A., Kemp, L.W., Wakatsuki, S., 
Yokoyama, T., Yamakawa, H., Furukawa, T., Sato, M., Ohuchi, N., Sato, S., Yin, 
J., Wang, S., Abraham, J.M., Souza, R.F., Smolinski, K.N., Meltzer, S.J. & Horii, 
A. 1997, "PTEN1 is frequently mutated in primary endometrial carcinomas", 
Nature genetics, vol. 17, no. 2, pp. 143-144. 
Kosaki, R., Watanabe, K. & Yamaguchi, Y. 1999, "Overproduction of hyaluronan by 
expression of the hyaluronan synthase Has2 enhances anchorage-independent 
growth and tumorigenicity", Cancer research, vol. 59, no. 5, pp. 1141-1145. 
Kosunen, A., Ropponen, K., Kellokoski, J., Pukkila, M., Virtaniemi, J., Valtonen, H., 
Kumpulainen, E., Johansson, R., Tammi, R., Tammi, M., Nuutinen, J. & Kosma, 
V.M. 2004, "Reduced expression of hyaluronan is a strong indicator of poor 
survival in oral squamous cell carcinoma", Oral oncology, vol. 40, no. 3, pp. 257-
263. 
Koyama, H., Hibi, T., Isogai, Z., Yoneda, M., Fujimori, M., Amano, J., Kawakubo, M., 
Kannagi, R., Kimata, K., Taniguchi, S. & Itano, N. 2007, "Hyperproduction of 
hyaluronan in neu-induced mammary tumor accelerates angiogenesis through 
stromal cell recruitment: possible involvement of versican/PG-M", The American 
journal of pathology, vol. 170, no. 3, pp. 1086-1099. 
Koyama, H., Kobayashi, N., Harada, M., Takeoka, M., Kawai, Y., Sano, K., Fujimori, 
M., Amano, J., Ohhashi, T., Kannagi, R., Kimata, K., Taniguchi, S. & Itano, N. 
2008, "Significance of tumor-associated stroma in promotion of intratumoral 
60 
 
 
 
lymphangiogenesis: pivotal role of a hyaluronan-rich tumor microenvironment", 
The American journal of pathology, vol. 172, no. 1, pp. 179-193. 
Kramer, M.W., Escudero, D.O., Lokeshwar, S.D., Golshani, R., Ekwenna, O.O., 
Acosta, K., Merseburger, A.S., Soloway, M. & Lokeshwar, V.B. 2011, 
"Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) 
with bladder cancer diagnosis and prognosis", Cancer, vol. 117, no. 6, pp. 1197-
1209. 
Kramer, M.W., Golshani, R., Merseburger, A.S., Knapp, J., Garcia, A., Hennenlotter, 
J., Duncan, R.C., Soloway, M.S., Jorda, M., Kuczyk, M.A., Stenzl, A. & 
Lokeshwar, V.B. 2010, "HYAL-1 hyaluronidase: a potential prognostic indicator 
for progression to muscle invasion and recurrence in bladder cancer", European 
urology, vol. 57, no. 1, pp. 86-93. 
Kryczek, I., Wei, S., Keller, E., Liu, R. & Zou, W. 2007, "Stroma-derived factor (SDF-
1/CXCL12) and human tumor pathogenesis", American journal of physiology.Cell 
physiology, vol. 292, no. 3, pp. C987-95. 
Kuhn, E., Kurman, R.J., Vang, R., Sehdev, A.S., Han, G., Soslow, R., Wang, T.L. & 
Shih, I. 2012, "TP53 mutations in serous tubal intraepithelial carcinoma and 
concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal 
relationship of the two lesions", The Journal of pathology, vol. 226, no. 3, pp. 421-
426. 
Kultti, A., Zhao, C., Singha, N.C., Zimmerman, S., Osgood, R.J., Symons, R., Jiang, P., 
Li, X., Thompson, C.B., Infante, J.R., Jacobetz, M.A., Tuveson, D.A., Frost, G.I., 
Shepard, H.M. & Huang, Z. 2014, "Accumulation of extracellular hyaluronan by 
hyaluronan synthase 3 promotes tumor growth and modulates the pancreatic 
cancer microenvironment", BioMed research international, vol. 2014, pp. 817613. 
Kuppusamy, H., Ogmundsdottir, H.M., Baigorri, E., Warkentin, A., Steingrimsdottir, 
H., Haraldsdottir, V., Mant, M.J., Mackey, J., Johnston, J.B., Adamia, S., Belch, 
A.R. & Pilarski, L.M. 2014, "Inherited polymorphisms in hyaluronan synthase 1 
predict risk of systemic B-cell malignancies but not of breast cancer", PloS one, 
vol. 9, no. 6, pp. e100691. 
Kurman, R.J., Carcangiu, M.L., Herrington, C.S. & Young, R.H. (eds) 2003, WHO 
Classification of Tumours of Female Reproductive Organs, Fourth Edition edn, IARC, 
Lyon. 
Kurman, R.J. 2013, "Origin and molecular pathogenesis of ovarian high-grade serous 
carcinoma", Annals of Oncology : Official Journal of the European Society for Medical 
Oncology / ESMO, vol. 24 Suppl 10, pp. x16-21. 
61 
 
 
 
Kurman, R.J., Vang, R., Junge, J., Hannibal, C.G., Kjaer, S.K. & Shih, I. 2011, 
"Papillary tubal hyperplasia: the putative precursor of ovarian atypical 
proliferative (borderline) serous tumors, noninvasive implants, and 
endosalpingiosis", The American Journal of Surgical Pathology, vol. 35, no. 11, pp. 
1605-1614. 
Lagarda, H., Catasus, L., Arguelles, R., Matias-Guiu, X. & Prat, J. 2001, "K-ras 
mutations in endometrial carcinomas with microsatellite instability", The Journal 
of pathology, vol. 193, no. 2, pp. 193-199. 
Langevin, S.M., Koestler, D.C., Christensen, B.C., Butler, R.A., Wiencke, J.K., Nelson, 
H.H., Houseman, E.A., Marsit, C.J. & Kelsey, K.T. 2012, "Peripheral blood DNA 
methylation profiles are indicative of head and neck squamous cell carcinoma: 
an epigenome-wide association study", Epigenetics : official journal of the DNA 
Methylation Society, vol. 7, no. 3, pp. 291-299. 
Laurent, T.C. & Fraser, J.R. 1992, "Hyaluronan", FASEB journal : official publication of 
the Federation of American Societies for Experimental Biology, vol. 6, no. 7, pp. 2397-
2404. 
Laurent, U.B., Dahl, L.B. & Reed, R.K. 1991, "Catabolism of hyaluronan in rabbit skin 
takes place locally, in lymph nodes and liver", Experimental physiology, vol. 76, 
no. 5, pp. 695-703. 
Lax, S.F., Kendall, B., Tashiro, H., Slebos, R.J. & Hedrick, L. 2000, "The frequency of 
p53, K-ras mutations, and microsatellite instability differs in uterine 
endometrioid and serous carcinoma: evidence of distinct molecular genetic 
pathways", Cancer, vol. 88, no. 4, pp. 814-824. 
Li, R., Todd, N.W., Qiu, Q., Fan, T., Zhao, R.Y., Rodgers, W.H., Fang, H.B., Katz, R.L., 
Stass, S.A. & Jiang, F. 2007, "Genetic deletions in sputum as diagnostic markers 
for early detection of stage I non-small cell lung cancer", Clinical cancer research : 
an official journal of the American Association for Cancer Research, vol. 13, no. 2 Pt 1, 
pp. 482-487. 
Li, Y. & Heldin, P. 2001, "Hyaluronan production increases the malignant properties 
of mesothelioma cells", British journal of cancer, vol. 85, no. 4, pp. 600-607. 
Lipponen, P., Aaltomaa, S., Tammi, R., Tammi, M., Agren, U. & Kosma, V.M. 2001, 
"High stromal hyaluronan level is associated with poor differentiation and 
metastasis in prostate cancer", European journal of cancer (Oxford, England : 1990), 
vol. 37, no. 7, pp. 849-856. 
62 
 
 
 
Liu, N., Gao, F., Han, Z., Xu, X., Underhill, C.B. & Zhang, L. 2001, "Hyaluronan 
synthase 3 overexpression promotes the growth of TSU prostate cancer cells", 
Cancer research, vol. 61, no. 13, pp. 5207-5214. 
Lokeshwar, V.B., Cerwinka, W.H., Isoyama, T. & Lokeshwar, B.L. 2005, "HYAL1 
hyaluronidase in prostate cancer: a tumor promoter and suppressor", Cancer 
research, vol. 65, no. 17, pp. 7782-7789. 
Lokeshwar, V.B., Cerwinka, W.H. & Lokeshwar, B.L. 2005, "HYAL1 hyaluronidase: a 
molecular determinant of bladder tumor growth and invasion", Cancer research, 
vol. 65, no. 6, pp. 2243-2250. 
Lokeshwar, V.B., Estrella, V., Lopez, L., Kramer, M., Gomez, P., Soloway, M.S. & 
Lokeshwar, B.L. 2006, "HYAL1-v1, an alternatively spliced variant of HYAL1 
hyaluronidase: a negative regulator of bladder cancer", Cancer research, vol. 66, 
no. 23, pp. 11219-11227. 
Lokeshwar, V.B., Gomez, P., Kramer, M., Knapp, J., McCornack, M.A., Lopez, L.E., 
Fregien, N., Dhir, N., Scherer, S., Klumpp, D.J., Manoharan, M., Soloway, M.S. & 
Lokeshwar, B.L. 2008, "Epigenetic regulation of HYAL-1 hyaluronidase 
expression. identification of HYAL-1 promoter", The Journal of biological 
chemistry, vol. 283, no. 43, pp. 29215-29227. 
Lokeshwar, V.B., Rubinowicz, D., Schroeder, G.L., Forgacs, E., Minna, J.D., Block, 
N.L., Nadji, M. & Lokeshwar, B.L. 2001, "Stromal and epithelial expression of 
tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer", 
The Journal of biological chemistry, vol. 276, no. 15, pp. 11922-11932. 
Lokeshwar, V.B., Schroeder, G.L., Carey, R.I., Soloway, M.S. & Iida, N. 2002, 
"Regulation of hyaluronidase activity by alternative mRNA splicing", The Journal 
of biological chemistry, vol. 277, no. 37, pp. 33654-33663. 
Lokeshwar, V.B. & Selzer, M.G. 2000, "Differences in hyaluronic acid-mediated 
functions and signaling in arterial, microvessel, and vein-derived human 
endothelial cells", The Journal of biological chemistry, vol. 275, no. 36, pp. 27641-
27649. 
Lowe, K.A., Chia, V.M., Taylor, A., O'Malley, C., Kelsh, M., Mohamed, M., Mowat, 
F.S. & Goff, B. 2013, "An international assessment of ovarian cancer incidence 
and mortality", Gynecologic oncology, vol. 130, no. 1, pp. 107-114. 
Lu, K.H. & Broaddus, R.R. 2005, "Gynecologic Cancers in Lynch 
Syndrome/HNPCC", Familial cancer, vol. 4, no. 3, pp. 249-254. 
63 
 
 
 
Lu, K.H. & Daniels, M. 2013, "Endometrial and ovarian cancer in women with Lynch 
syndrome: update in screening and prevention", Familial cancer, vol. 12, no. 2, 
pp. 273-277. 
Lu, P., Weaver, V.M. & Werb, Z. 2012, "The extracellular matrix: a dynamic niche in 
cancer progression", The Journal of cell biology, vol. 196, no. 4, pp. 395-406. 
Lucenteforte, E., Talamini, R., Montella, M., Dal Maso, L., Pelucchi, C., Franceschi, S., 
La Vecchia, C. & Negri, E. 2009, "Family history of cancer and the risk of 
endometrial cancer", European journal of cancer prevention : the official journal of the 
European Cancer Prevention Organisation (ECP), vol. 18, no. 2, pp. 95-99. 
Lynch, H.T. & de la Chapelle, A. 2003, "Hereditary colorectal cancer", The New 
England journal of medicine, vol. 348, no. 10, pp. 919-932. 
Machin, P., Catasus, L., Pons, C., Munoz, J., Matias-Guiu, X. & Prat, J. 2002, 
"CTNNB1 mutations and beta-catenin expression in endometrial carcinomas", 
Human pathology, vol. 33, no. 2, pp. 206-212. 
Malpica, A., Deavers, M.T., Lu, K., Bodurka, D.C., Atkinson, E.N., Gershenson, D.M. 
& Silva, E.G. 2004, "Grading ovarian serous carcinoma using a two-tier system", 
The American Journal of Surgical Pathology, vol. 28, no. 4, pp. 496-504. 
Martin, D.C., Atmuri, V., Hemming, R.J., Farley, J., Mort, J.S., Byers, S., Hombach-
Klonisch, S., Csoka, A.B., Stern, R. & Triggs-Raine, B.L. 2008, "A mouse model of 
human mucopolysaccharidosis IX exhibits osteoarthritis", Human molecular 
genetics, vol. 17, no. 13, pp. 1904-1915. 
Matias-Guiu, X. & Prat, J. 2013, "Molecular pathology of endometrial carcinoma", 
Histopathology, vol. 62, no. 1, pp. 111-123. 
Maxwell, C.A., McCarthy, J. & Turley, E. 2008, "Cell-surface and mitotic-spindle 
RHAMM: moonlighting or dual oncogenic functions?", Journal of cell science, vol. 
121, no. 7, pp. 925-932. 
McAtee, C.O., Barycki, J.J. & Simpson, M.A. 2014, "Emerging roles for hyaluronidase 
in cancer metastasis and therapy", Advances in Cancer Research, vol. 123, pp. 1-34. 
Mell, L.K., Meyer, J.J., Tretiakova, M., Khramtsov, A., Gong, C., Yamada, S.D., 
Montag, A.G. & Mundt, A.J. 2004, "Prognostic significance of E-cadherin protein 
expression in pathological stage I-III endometrial cancer", Clinical cancer research : 
an official journal of the American Association for Cancer Research, vol. 10, no. 16, pp. 
5546-5553. 
64 
 
 
 
Miller, A.D. 2008, "Hyaluronidase 2 and its intriguing role as a cell-entry receptor for 
oncogenic sheep retroviruses", Seminars in cancer biology, vol. 18, no. 4, pp. 296-
301. 
Misra, S., Ghatak, S., Zoltan-Jones, A. & Toole, B.P. 2003, "Regulation of multidrug 
resistance in cancer cells by hyaluronan", The Journal of biological chemistry, vol. 
278, no. 28, pp. 25285-25288. 
Monzon, M.E., Fregien, N., Schmid, N., Falcon, N.S., Campos, M., Casalino-Matsuda, 
S.M. & Forteza, R.M. 2010a, "Reactive oxygen species and hyaluronidase 2 
regulate airway epithelial hyaluronan fragmentation", The Journal of biological 
chemistry, vol. 285, no. 34, pp. 26126-26134. 
Monzon, M.E., Fregien, N., Schmid, N., Falcon, N.S., Campos, M., Casalino-Matsuda, 
S.M. & Forteza, R.M. 2010b, "Reactive oxygen species and hyaluronidase 2 
regulate airway epithelial hyaluronan fragmentation", The Journal of biological 
chemistry, vol. 285, no. 34, pp. 26126-26134. 
Monzon, M.E., Manzanares, D., Schmid, N., Casalino-Matsuda, S.M. & Forteza, R.M. 
2008, "Hyaluronidase expression and activity is regulated by pro-inflammatory 
cytokines in human airway epithelial cells", American journal of respiratory cell and 
molecular biology, vol. 39, no. 3, pp. 289-295. 
Moreno-Bueno, G., Hardisson, D., Sarrio, D., Sanchez, C., Cassia, R., Prat, J., 
Herman, J.G., Esteller, M., Matias-Guiu, X. & Palacios, J. 2003, "Abnormalities of 
E- and P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression 
in endometrial cancer and endometrial atypical hyperplasia", The Journal of 
pathology, vol. 199, no. 4, pp. 471-478. 
Morrison, C., Zanagnolo, V., Ramirez, N., Cohn, D.E., Kelbick, N., Copeland, L., 
Maxwell, G.L. & Fowler, J.M. 2006, "HER-2 is an independent prognostic factor 
in endometrial cancer: association with outcome in a large cohort of surgically 
staged patients", Journal of clinical oncology : official journal of the American Society 
of Clinical Oncology, vol. 24, no. 15, pp. 2376-2385. 
Mukherjee, S. 2010, The emperor of all maladies: A biography of cancer, 1st edn, Scribner, 
New York. 
Murali, R., Soslow, R.A. & Weigelt, B. 2014, "Classification of endometrial carcinoma: 
more than two types", The Lancet.Oncology, vol. 15, no. 7, pp. e268-78. 
Mutter, G.L., Lin, M.C., Fitzgerald, J.T., Kum, J.B., Baak, J.P., Lees, J.A., Weng, L.P. & 
Eng, C. 2000, "Altered PTEN expression as a diagnostic marker for the earliest 
65 
 
 
 
endometrial precancers", Journal of the National Cancer Institute, vol. 92, no. 11, 
pp. 924-930. 
Naor, D., Sionov, R.V. & Ish-Shalom, D. 1997, "CD44: structure, function, and 
association with the malignant process", Advances in Cancer Research, vol. 71, pp. 
241-319. 
Nishida, Y., Knudson, W., Knudson, C.B. & Ishiguro, N. 2005, "Antisense inhibition 
of hyaluronan synthase-2 in human osteosarcoma cells inhibits hyaluronan 
retention and tumorigenicity", Experimental cell research, vol. 307, no. 1, pp. 194-
203. 
Orlichenko, L.S. & Radisky, D.C. 2008, "Matrix metalloproteinases stimulate 
epithelial-mesenchymal transition during tumor development", Clinical & 
experimental metastasis, vol. 25, no. 6, pp. 593-600. 
Pirinen, R., Tammi, R., Tammi, M., Hirvikoski, P., Parkkinen, J.J., Johansson, R., 
Bohm, J., Hollmen, S. & Kosma, V.M. 2001, "Prognostic value of hyaluronan 
expression in non-small-cell lung cancer: Increased stromal expression indicates 
unfavorable outcome in patients with adenocarcinoma", International journal of 
cancer, vol. 95, no. 1, pp. 12-17. 
Pirinen, R.T., Tammi, R.H., Tammi, M.I., Paakko, P.K., Parkkinen, J.J., Agren, U.M., 
Johansson, R.T., Viren, M.M., Tormanen, U., Soini, Y.M. & Kosma, V.M. 1998, 
"Expression of hyaluronan in normal and dysplastic bronchial epithelium and in 
squamous cell carcinoma of the lung", International journal of cancer, vol. 79, no. 3, 
pp. 251-255. 
Porsch, H., Bernert, B., Mehic, M., Theocharis, A.D., Heldin, C.H. & Heldin, P. 2013, 
"Efficient TGFbeta-induced epithelial-mesenchymal transition depends on 
hyaluronan synthase HAS2", Oncogene, vol. 32, no. 37, pp. 4355-4365. 
Prat, J. 2004, "Prognostic parameters of endometrial carcinoma", Human pathology, 
vol. 35, no. 6, pp. 649-662. 
Provenzano, P.P., Cuevas, C., Chang, A.E., Goel, V.K., Von Hoff, D.D. & Hingorani, 
S.R. 2012, "Enzymatic targeting of the stroma ablates physical barriers to 
treatment of pancreatic ductal adenocarcinoma", Cancer cell, vol. 21, no. 3, pp. 
418-429. 
Puissant, E., Gilis, F., Dogne, S., Flamion, B., Jadot, M. & Boonen, M. 2014, 
"Subcellular trafficking and activity of Hyal-1 and its processed forms in murine 
macrophages", Traffic (Copenhagen, Denmark), vol. 15, no. 5, pp. 500-515. 
66 
 
 
 
Rilla, K., Pasonen-Seppanen, S., Karna, R., Karjalainen, H.M., Torronen, K., 
Koistinen, V., Tammi, M.I., Tammi, R.H., Teravainen, T. & Manninen, A. 2012, 
"HAS3-induced accumulation of hyaluronan in 3D MDCK cultures results in 
mitotic spindle misorientation and disturbed organization of epithelium", 
Histochemistry and cell biology, vol. 137, no. 2, pp. 153-164. 
Rilla, K., Oikari, S., Jokela, T.A., Hyttinen, J.M.T., Kärnä, R., Tammi, R.H. & Tammi, 
M.I. 2013, "Hyaluronan Synthase 1 (HAS1) Requires Higher Cellular UDP-
GlcNAc Concentration than HAS2 and HAS3", Journal of Biological Chemistry, 
vol. 288, no. 8, pp. 5973-5983. 
Risch, H.A., McLaughlin, J.R., Cole, D.E., Rosen, B., Bradley, L., Fan, I., Tang, J., Li, 
S., Zhang, S., Shaw, P.A. & Narod, S.A. 2006, "Population BRCA1 and BRCA2 
mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, 
Canada", Journal of the National Cancer Institute, vol. 98, no. 23, pp. 1694-1706. 
Rock, K., Meusch, M., Fuchs, N., Tigges, J., Zipper, P., Fritsche, E., Krutmann, J., 
Homey, B., Reifenberger, J. & Fischer, J.W. 2012, "Estradiol protects dermal 
hyaluronan/versican matrix during photoaging by release of epidermal growth 
factor from keratinocytes", The Journal of biological chemistry, vol. 287, no. 24, pp. 
20056-20069. 
Rodgers, L.S., Lalani, S., Hardy, K.M., Xiang, X., Broka, D., Antin, P.B. & Camenisch, 
T.D. 2006, "Depolymerized hyaluronan induces vascular endothelial growth 
factor, a negative regulator of developmental epithelial-to-mesenchymal 
transformation", Circulation research, vol. 99, no. 6, pp. 583-589. 
Rudd, M.L., Price, J.C., Fogoros, S., Godwin, A.K., Sgroi, D.C., Merino, M.J. & Bell, 
D.W. 2011, "A unique spectrum of somatic PIK3CA (p110alpha) mutations 
within primary endometrial carcinomas", Clinical cancer research : an official 
journal of the American Association for Cancer Research, vol. 17, no. 6, pp. 1331-1340. 
Saito, T., Nishimura, M., Yamasaki, H. & Kudo, R. 2003, "Hypermethylation in 
promoter region of E-cadherin gene is associated with tumor dedifferention and 
myometrial invasion in endometrial carcinoma", Cancer, vol. 97, no. 4, pp. 1002-
1009. 
Sakuragi, N., Nishiya, M., Ikeda, K., Ohkouch, T., Furth, E.E., Hareyama, H., Satoh, 
C. & Fujimoto, S. 1994, "Decreased E-cadherin expression in endometrial 
carcinoma is associated with tumor dedifferentiation and deep myometrial 
invasion", Gynecologic oncology, vol. 53, no. 2, pp. 183-189. 
Samuel, S.K., Hurta, R.A., Spearman, M.A., Wright, J.A., Turley, E.A. & Greenberg, 
A.H. 1993, "TGF-beta 1 stimulation of cell locomotion utilizes the hyaluronan 
67 
 
 
 
receptor RHAMM and hyaluronan", The Journal of cell biology, vol. 123, no. 3, pp. 
749-758. 
Sato, N., Tsunoda, H., Nishida, M., Morishita, Y., Takimoto, Y., Kubo, T. & Noguchi, 
M. 2000, "Loss of heterozygosity on 10q23.3 and mutation of the tumor 
suppressor gene PTEN in benign endometrial cyst of the ovary: possible 
sequence progression from benign endometrial cyst to endometrioid carcinoma 
and clear cell carcinoma of the ovary", Cancer research, vol. 60, no. 24, pp. 7052-
7056. 
Sattar, A., Rooney, P., Kumar, S., Pye, D., West, D.C., Scott, I. & Ledger, P. 1994, 
"Application of angiogenic oligosaccharides of hyaluronan increases blood 
vessel numbers in rat skin", The Journal of investigative dermatology, vol. 103, no. 4, 
pp. 576-579. 
Schmaus, A., Bauer, J. & Sleeman, J.P. 2014, "Sugars in the microenvironment: the 
sticky problem of HA turnover in tumors", Cancer metastasis reviews, vol. 33, no. 
4, pp. 1059-1079. 
Schmaus, A. & Sleeman, J.P. 2015, "Hyaluronidase-1 expression promotes lung 
metastasis in syngeneic mouse tumor models without affecting accumulation of 
small hyaluronan oligosaccharides in tumor interstitial fluid", Glycobiology, vol. 
25, no. 3, pp. 258-268. 
Setala, L.P., Tammi, M.I., Tammi, R.H., Eskelinen, M.J., Lipponen, P.K., Agren, U.M., 
Parkkinen, J., Alhava, E.M. & Kosma, V.M. 1999, "Hyaluronan expression in 
gastric cancer cells is associated with local and nodal spread and reduced 
survival rate", British journal of cancer, vol. 79, no. 7-8, pp. 1133-1138. 
Shih, I. & Kurman, R.J. 2004, "Ovarian tumorigenesis: a proposed model based on 
morphological and molecular genetic analysis", The American journal of pathology, 
vol. 164, no. 5, pp. 1511-1518. 
Siegel, R., Naishadham, D. & Jemal, A. 2013, "Cancer statistics, 2013", CA: a cancer 
journal for clinicians, vol. 63, no. 1, pp. 11-30. 
Siiskonen, H., Poukka, M., Tyynela-Korhonen, K., Sironen, R. & Pasonen-Seppanen, 
S. 2013, "Inverse expression of hyaluronidase 2 and hyaluronan synthases 1-3 is 
associated with reduced hyaluronan content in malignant cutaneous 
melanoma", BMC cancer, vol. 13, pp. 181-2407-13-181. 
Sillanpaa, S., Anttila, M.A., Voutilainen, K., Tammi, R.H., Tammi, M.I., Saarikoski, 
S.V. & Kosma, V.M. 2003, "CD44 expression indicates favorable prognosis in 
68 
 
 
 
epithelial ovarian cancer", Clinical cancer research : an official journal of the 
American Association for Cancer Research, vol. 9, no. 14, pp. 5318-5324. 
Silverberg, S.G., Bell, D.A., Kurman, R.J., Seidman, J.D., Prat, J., Ronnett, B.M., 
Copeland, L., Silva, E., Gorstein, F. & Young, R.H. 2004, "Borderline ovarian 
tumors: key points and workshop summary", Human pathology, vol. 35, no. 8, pp. 
910-917. 
Simpson, M.A., Wilson, C.M., Furcht, L.T., Spicer, A.P., Oegema, T.R.,Jr & McCarthy, 
J.B. 2002, "Manipulation of hyaluronan synthase expression in prostate 
adenocarcinoma cells alters pericellular matrix retention and adhesion to bone 
marrow endothelial cells", The Journal of biological chemistry, vol. 277, no. 12, pp. 
10050-10057. 
Simpson, M.A., Wilson, C.M. & McCarthy, J.B. 2002, "Inhibition of prostate tumor 
cell hyaluronan synthesis impairs subcutaneous growth and vascularization in 
immunocompromised mice", The American journal of pathology, vol. 161, no. 3, pp. 
849-857. 
Singer, G., Oldt, R.,3rd, Cohen, Y., Wang, B.G., Sidransky, D., Kurman, R.J. & Shih, I. 
2003, "Mutations in BRAF and KRAS characterize the development of low-grade 
ovarian serous carcinoma", Journal of the National Cancer Institute, vol. 95, no. 6, 
pp. 484-486. 
Sironen, R.K., Tammi, M., Tammi, R., Auvinen, P.K., Anttila, M. & Kosma, V.M. 
2011, "Hyaluronan in human malignancies", Experimental cell research, vol. 317, 
no. 4, pp. 383-391. 
Soegaard, M., Frederiksen, K., Jensen, A., Hogdall, E., Hogdall, C., Blaakaer, J., 
Ramus, S.J., Gayther, S.A. & Kjaer, S.K. 2009, "Risk of ovarian cancer in women 
with first-degree relatives with cancer", Acta Obstetricia et Gynecologica 
Scandinavica, vol. 88, no. 4, pp. 449-456. 
Soslow, R.A. 2008, "Histologic subtypes of ovarian carcinoma: an overview", 
International journal of gynecological pathology : official journal of the International 
Society of Gynecological Pathologists, vol. 27, no. 2, pp. 161-174. 
Spicer, A.P., Seldin, M.F., Olsen, A.S., Brown, N., Wells, D.E., Doggett, N.A., Itano, 
N., Kimata, K., Inazawa, J. & McDonald, J.A. 1997, "Chromosomal localization of 
the human and mouse hyaluronan synthase genes", Genomics, vol. 41, no. 3, pp. 
493-497. 
Stern, R. 2004, "Hyaluronan catabolism: a new metabolic pathway", European journal 
of cell biology, vol. 83, no. 7, pp. 317-325. 
69 
 
 
 
Stern, R. & Jedrzejas, M.J. 2006, "Hyaluronidases: their genomics, structures, and 
mechanisms of action", Chemical reviews, vol. 106, no. 3, pp. 818-839. 
Stern, R., Kogan, G., Jedrzejas, M.J. & Soltes, L. 2007, "The many ways to cleave 
hyaluronan", Biotechnology Advances, vol. 25, no. 6, pp. 537-557. 
Stern, R. 2008a, "Association between cancer and “acid mucopolysaccharides”: An 
old concept comes of age, finally", Seminars in cancer biology, vol. 18, no. 4, pp. 
238-243. 
Stern, R. 2008b, "Hyaluronan in Cancer Biology", Seminars in cancer biology, vol. 18, 
no. 4, pp. 237. 
Sugahara, K.N., Hirata, T., Hayasaka, H., Stern, R., Murai, T. & Miyasaka, M. 2006, 
"Tumor cells enhance their own CD44 cleavage and motility by generating 
hyaluronan fragments", The Journal of biological chemistry, vol. 281, no. 9, pp. 
5861-5868. 
Sundstrom, G., Dahl, I.M., Hultdin, M., Lundstrom, B., Wahlin, A. & Engstrom-
Laurent, A. 2005, "Bone marrow hyaluronan distribution in patients with acute 
myeloid leukemia", Medical oncology (Northwood, London, England), vol. 22, no. 1, 
pp. 71-78. 
Sussmann, M., Sarbia, M., Meyer-Kirchrath, J., Nusing, R.M., Schror, K. & Fischer, 
J.W. 2004, "Induction of hyaluronic acid synthase 2 (HAS2) in human vascular 
smooth muscle cells by vasodilatory prostaglandins", Circulation research, vol. 94, 
no. 5, pp. 592-600. 
Tammi, R.H., Passi, A.G., Rilla, K., Karousou, E., Vigetti, D., Makkonen, K. & 
Tammi, M.I. 2011, "Transcriptional and post-translational regulation of 
hyaluronan synthesis", The FEBS journal, vol. 278, no. 9, pp. 1419-1428. 
Tammi, R.H., Kultti, A., Kosma, V., Pirinen, R., Auvinen, P. & Tammi, M.I. 2008, 
"Hyaluronan in human tumors: Pathobiological and prognostic messages from 
cell-associated and stromal hyaluronan", Seminars in cancer biology, vol. 18, no. 4, 
pp. 288-295. 
Tan, J.X., Wang, X.Y., Li, H.Y., Su, X.L., Wang, L., Ran, L., Zheng, K. & Ren, G.S. 
2011a, "HYAL1 overexpression is correlated with the malignant behavior of 
human breast cancer", International journal of cancer, vol. 128, no. 6, pp. 1303-1315. 
Tan, J.X., Wang, X.Y., Su, X.L., Li, H.Y., Shi, Y., Wang, L. & Ren, G.S. 2011b, 
"Upregulation of HYAL1 expression in breast cancer promoted tumor cell 
70 
 
 
 
proliferation, migration, invasion and angiogenesis", PloS one, vol. 6, no. 7, pp. 
e22836. 
Tashiro, H., Isacson, C., Levine, R., Kurman, R.J., Cho, K.R. & Hedrick, L. 1997, "P53 
Gene Mutations are Common in Uterine Serous Carcinoma and Occur Early in 
their Pathogenesis", The American journal of pathology, vol. 150, no. 1, pp. 177-185. 
Thankamony, S.P. & Knudson, W. 2006, "Acylation of CD44 and its association with 
lipid rafts are required for receptor and hyaluronan endocytosis", The Journal of 
biological chemistry, vol. 281, no. 45, pp. 34601-34609. 
Thiery, J.P. 2003, "Epithelial-mesenchymal transitions in development and 
pathologies", Current opinion in cell biology, vol. 15, no. 6, pp. 740-746. 
Tian, X., Azpurua, J., Hine, C., Vaidya, A., Myakishev-Rempel, M., Ablaeva, J., Mao, 
Z., Nevo, E., Gorbunova, V. & Seluanov, A. 2013, "High-molecular-mass 
hyaluronan mediates the cancer resistance of the naked mole rat", Nature, vol. 
499, no. 7458, pp. 346-349. 
Tien, J.Y. & Spicer, A.P. 2005, "Three vertebrate hyaluronan synthases are expressed 
during mouse development in distinct spatial and temporal patterns", 
Developmental dynamics : an official publication of the American Association of 
Anatomists, vol. 233, no. 1, pp. 130-141. 
Tolg, C., Hamilton, S.R., Nakrieko, K.A., Kooshesh, F., Walton, P., McCarthy, J.B., 
Bissell, M.J. & Turley, E.A. 2006, "Rhamm-/- fibroblasts are defective in CD44-
mediated ERK1,2 motogenic signaling, leading to defective skin wound repair", 
The Journal of cell biology, vol. 175, no. 6, pp. 1017-1028. 
Tone, A.A., Begley, H., Sharma, M., Murphy, J., Rosen, B., Brown, T.J. & Shaw, P.A. 
2008, "Gene expression profiles of luteal phase fallopian tube epithelium from 
BRCA mutation carriers resemble high-grade serous carcinoma", Clinical cancer 
research : an official journal of the American Association for Cancer Research, vol. 14, 
no. 13, pp. 4067-4078. 
Toole, B.P. 2004, "Hyaluronan: from extracellular glue to pericellular cue", Nature 
reviews.Cancer, vol. 4, no. 7, pp. 528-539. 
Toole, B.P. 2009, "Hyaluronan-CD44 Interactions in Cancer: Paradoxes and 
Possibilities", Clinical Cancer Research, vol. 15, no. 24, pp. 7462-7468. 
Triggs-Raine, B., Salo, T.J., Zhang, H., Wicklow, B.A. & Natowicz, M.R. 1999, 
"Mutations in HYAL1, a member of a tandemly distributed multigene family 
encoding disparate hyaluronidase activities, cause a newly described lysosomal 
71 
 
 
 
disorder, mucopolysaccharidosis IX", Proceedings of the National Academy of 
Sciences of the United States of America, vol. 96, no. 11, pp. 6296-6300. 
Tuhkanen, H., Anttila, M., Kosma, V.M., Yla-Herttuala, S., Heinonen, S., Kuronen, 
A., Juhola, M., Tammi, R., Tammi, M. & Mannermaa, A. 2004, "Genetic 
alterations in the peritumoral stromal cells of malignant and borderline 
epithelial ovarian tumors as indicated by allelic imbalance on chromosome 3p", 
International journal of cancer, vol. 109, no. 2, pp. 247-252. 
Uchiyama, T., Sakuta, T. & Kanayama, T. 2005, "Regulation of hyaluronan synthases 
in mouse uterine cervix", Biochemical and biophysical research communications, vol. 
327, no. 3, pp. 927-932. 
Udabage, L., Brownlee, G.R., Nilsson, S.K. & Brown, T.J. 2005a, "The over-expression 
of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer", 
Experimental cell research, vol. 310, no. 1, pp. 205-217. 
Udabage, L., Brownlee, G.R., Waltham, M., Blick, T., Walker, E.C., Heldin, P., 
Nilsson, S.K., Thompson, E.W. & Brown, T.J. 2005b, "Antisense-mediated 
suppression of hyaluronan synthase 2 inhibits the tumorigenesis and 
progression of breast cancer", Cancer research, vol. 65, no. 14, pp. 6139-6150. 
Urakawa, H., Nishida, Y., Knudson, W., Knudson, C.B., Arai, E., Kozawa, E., 
Futamura, N., Wasa, J. & Ishiguro, N. 2012, "Therapeutic potential of hyaluronan 
oligosaccharides for bone metastasis of breast cancer", Journal of orthopaedic 
research : official publication of the Orthopaedic Research Society, vol. 30, no. 4, pp. 
662-672. 
Vigdorovich, V., Miller, A.D. & Strong, R.K. 2007, "Ability of hyaluronidase 2 to 
degrade extracellular hyaluronan is not required for its function as a receptor for 
jaagsiekte sheep retrovirus", Journal of virology, vol. 81, no. 7, pp. 3124-3129. 
Vigetti, D., Clerici, M., Deleonibus, S., Karousou, E., Viola, M., Moretto, P., Heldin, 
P., Hascall, V.C., De Luca, G. & Passi, A. 2011, "Hyaluronan synthesis is 
inhibited by adenosine monophosphate-activated protein kinase through the 
regulation of HAS2 activity in human aortic smooth muscle cells", The Journal of 
biological chemistry, vol. 286, no. 10, pp. 7917-7924. 
Vigetti, D., Deleonibus, S., Moretto, P., Karousou, E., Viola, M., Bartolini, B., Hascall, 
V.C., Tammi, M., De Luca, G. & Passi, A. 2012, "Role of UDP-N-
acetylglucosamine (GlcNAc) and O-GlcNAcylation of hyaluronan synthase 2 in 
the control of chondroitin sulfate and hyaluronan synthesis", The Journal of 
biological chemistry, vol. 287, no. 42, pp. 35544-35555. 
72 
 
 
 
Vigetti, D., Genasetti, A., Karousou, E., Viola, M., Clerici, M., Bartolini, B., Moretto, 
P., De Luca, G., Hascall, V.C. & Passi, A. 2009, "Modulation of hyaluronan 
synthase activity in cellular membrane fractions", The Journal of biological 
chemistry, vol. 284, no. 44, pp. 30684-30694. 
Vigetti, D. & Passi, A. 2014, "Hyaluronan synthases posttranslational regulation in 
cancer", Advances in Cancer Research, vol. 123, pp. 95-119. 
Vigetti, D., Viola, M., Karousou, E., De Luca, G. & Passi, A. 2014, "Metabolic control 
of hyaluronan synthases", Matrix biology : journal of the International Society for 
Matrix Biology, vol. 35, pp. 8-13. 
Visnovsky, J., Fiolka, R., Kudela, E., Slavik, P., Krkoska, M., Lasabova, Z. & Danko, J. 
2013, "Hypermethylation of selected genes in endometrial carcinogenesis", Neuro 
endocrinology letters, vol. 34, no. 7, pp. 675-680. 
Voelcker, V., Gebhardt, C., Averbeck, M., Saalbach, A., Wolf, V., Weih, F., Sleeman, 
J., Anderegg, U. & Simon, J. 2008, "Hyaluronan fragments induce cytokine and 
metalloprotease upregulation in human melanoma cells in part by signalling via 
TLR4", Experimental dermatology, vol. 17, no. 2, pp. 100-107. 
Voigt, L.F., Weiss, N.S., Chu, J., Daling, J.R., McKnight, B. & van Belle, G. 1991, 
"Progestagen supplementation of exogenous oestrogens and risk of endometrial 
cancer", Lancet, vol. 338, no. 8762, pp. 274-277. 
Voutilainen, K., Anttila, M., Sillanpaa, S., Tammi, R., Tammi, M., Saarikoski, S. & 
Kosma, V.M. 2003, "Versican in epithelial ovarian cancer: relation to hyaluronan, 
clinicopathologic factors and prognosis", International journal of cancer, vol. 107, 
no. 3, pp. 359-364. 
Wang, A. & Hascall, V.C. 2004, "Hyaluronan structures synthesized by rat mesangial 
cells in response to hyperglycemia induce monocyte adhesion", The Journal of 
biological chemistry, vol. 279, no. 11, pp. 10279-10285. 
Wang, C., Tammi, M., Guo, H. & Tammi, R. 1996, "Hyaluronan distribution in the 
normal epithelium of esophagus, stomach, and colon and their cancers", The 
American journal of pathology, vol. 148, no. 6, pp. 1861-1869. 
Wang, F., Grigorieva, E.V., Li, J., Senchenko, V.N., Pavlova, T.V., Anedchenko, E.A., 
Kudryavtseva, A.V., Tsimanis, A., Angeloni, D., Lerman, M.I., Kashuba, V.I., 
Klein, G. & Zabarovsky, E.R. 2008, "HYAL1 and HYAL2 inhibit tumour growth 
in vivo but not in vitro", PloS one, vol. 3, no. 8, pp. e3031. 
73 
 
 
 
Wei, W., Dizon, D., Vathipadiekal, V. & Birrer, M.J. 2013, "Ovarian cancer: genomic 
analysis", Annals of Oncology : Official Journal of the European Society for Medical 
Oncology / ESMO, vol. 24 Suppl 10, pp. x7-15. 
Weigel, P.H. & Baggenstoss, B.A. 2012, "Hyaluronan synthase polymerizing activity 
and control of product size are discrete enzyme functions that can be uncoupled 
by mutagenesis of conserved cysteines", Glycobiology, vol. 22, no. 10, pp. 1302-
1310. 
Weigel, P.H. & DeAngelis, P.L. 2007, "Hyaluronan synthases: a decade-plus of novel 
glycosyltransferases", The Journal of biological chemistry, vol. 282, no. 51, pp. 
36777-36781. 
West, D.C. & Kumar, S. 1989, "Hyaluronan and angiogenesis", Ciba Foundation 
symposium, vol. 143, pp. 187-201; discussion 201-7, 281-5. 
Wiegand, K.C., Shah, S.P., Al-Agha, O.M., Zhao, Y., Tse, K., Zeng, T., Senz, J., 
McConechy, M.K., Anglesio, M.S., Kalloger, S.E., Yang, W., Heravi-Moussavi, 
A., Giuliany, R., Chow, C., Fee, J., Zayed, A., Prentice, L., Melnyk, N., Turashvili, 
G., Delaney, A.D., Madore, J., Yip, S., McPherson, A.W., Ha, G., Bell, L., Fereday, 
S., Tam, A., Galletta, L., Tonin, P.N., Provencher, D., Miller, D., Jones, S.J., 
Moore, R.A., Morin, G.B., Oloumi, A., Boyd, N., Aparicio, S.A., Shih, I., Mes-
Masson, A.M., Bowtell, D.D., Hirst, M., Gilks, B., Marra, M.A. & Huntsman, D.G. 
2010, "ARID1A mutations in endometriosis-associated ovarian carcinomas", The 
New England journal of medicine, vol. 363, no. 16, pp. 1532-1543. 
Win, A.K., Reece, J.C. & Ryan, S. 2015, "Family History and Risk of Endometrial 
Cancer: A Systematic Review and Meta-analysis", Obstetrics and gynecology, vol. 
125, no. 1, pp. 89-98. 
Wong, K.K., Tsang, Y.T., Deavers, M.T., Mok, S.C., Zu, Z., Sun, C., Malpica, A., Wolf, 
J.K., Lu, K.H. & Gershenson, D.M. 2010, "BRAF mutation is rare in advanced-
stage low-grade ovarian serous carcinomas", The American journal of pathology, 
vol. 177, no. 4, pp. 1611-1617. 
Yabushita, H., Kishida, T., Fusano, K., Kanyama, K., Zhuo, L., Itano, N., Kimata, K. & 
Noguchi, M. 2005, "Role of hyaluronan and hyaluronan synthase in endometrial 
cancer", Oncology reports, vol. 13, no. 6, pp. 1101-1105. 
Yabushita, H., Noguchi, M., Kishida, T., Fusano, K., Noguchi, Y., Itano, N., Kimata, 
K. & Noguchi, M. 2004, "Hyaluronan synthase expression in ovarian cancer", 
Oncology reports, vol. 12, no. 4, pp. 739-743. 
74 
 
 
 
Yamada, Y., Itano, N., Narimatsu, H., Kudo, T., Morozumi, K., Hirohashi, S., Ochiai, 
A., Ueda, M. & Kimata, K. 2004, "Elevated transcript level of hyaluronan 
synthase1 gene correlates with poor prognosis of human colon cancer", Clinical 
& experimental metastasis, vol. 21, no. 1, pp. 57-63. 
Yang, B., Yang, B.L., Savani, R.C. & Turley, E.A. 1994, "Identification of a common 
hyaluronan binding motif in the hyaluronan binding proteins RHAMM, CD44 
and link protein", The EMBO journal, vol. 13, no. 2, pp. 286-296. 
Yang, C., Cao, M., Liu, H., He, Y., Xu, J., Du, Y., Liu, Y., Wang, W., Cui, L., Hu, J. & 
Gao, F. 2012, "The high and low molecular weight forms of hyaluronan have 
distinct effects on CD44 clustering", The Journal of biological chemistry, vol. 287, 
no. 51, pp. 43094-43107. 
Yang, J., Mani, S.A., Donaher, J.L., Ramaswamy, S., Itzykson, R.A., Come, C., 
Savagner, P., Gitelman, I., Richardson, A. & Weinberg, R.A. 2004, "Twist, a 
master regulator of morphogenesis, plays an essential role in tumor metastasis", 
Cell, vol. 117, no. 7, pp. 927-939. 
Yang, R., Pfutze, K., Zucknick, M., Sutter, C., Wappenschmidt, B., Marme, F., Qu, B., 
Cuk, K., Engel, C., Schott, S., Schneeweiss, A., Brenner, H., Claus, R., Plass, C., 
Bugert, P., Hoth, M., Sohn, C., Schmutzler, R., Bartram, C.R. & Burwinkel, B. 
2015, "DNA methylation array analyses identified breast cancer-associated 
HYAL2 methylation in peripheral blood", International journal of cancer, vol. 136, 
no. 8, pp. 1845-1855. 
Yoffou, P.H., Edjekouane, L., Meunier, L., Tremblay, A., Provencher, D.M., Mes-
Masson, A.M. & Carmona, E. 2011, "Subtype specific elevated expression of 
hyaluronidase-1 (HYAL-1) in epithelial ovarian cancer", PloS one, vol. 6, no. 6, 
pp. e20705. 
Yuan, H., Tank, M., Alsofyani, A., Shah, N., Talati, N., LoBello, J.C., Kim, J.R., 
Oonuki, Y., de la Motte, C.A. & Cowman, M.K. 2013, "Molecular mass 
dependence of hyaluronan detection by sandwich ELISA-like assay and 
membrane blotting using biotinylated hyaluronan binding protein", 
Glycobiology, vol. 23, no. 11, pp. 1270-1280. 
Zaino, R.J., Kurman, R., Herbold, D., Gliedman, J., Bundy, B.N., Voet, R. & Advani, 
H. 1991, "The significance of squamous differentiation in endometrial carcinoma. 
Data from a Gynecologic Oncology Group study", Cancer, vol. 68, no. 10, pp. 
2293-2302. 
75 
 
 
 
Zeng, C., Toole, B.P., Kinney, S.D., Kuo, J.W. & Stamenkovic, I. 1998, "Inhibition of 
tumor growth in vivo by hyaluronan oligomers", International journal of cancer, 
vol. 77, no. 3, pp. 396-401. 
Zhang, S., Chang, M.C., Zylka, D., Turley, S., Harrison, R. & Turley, E.A. 1998, "The 
hyaluronan receptor RHAMM regulates extracellular-regulated kinase", The 
Journal of biological chemistry, vol. 273, no. 18, pp. 11342-11348. 
Zhang, W., Watson, C.E., Liu, C., Williams, K.J. & Werth, V.P. 2000, "Glucocorticoids 
induce a near-total suppression of hyaluronan synthase mRNA in dermal 
fibroblasts and in osteoblasts: a molecular mechanism contributing to organ 
atrophy", The Biochemical journal, vol. 349, no. Pt 1, pp. 91-97. 
Zoltan-Jones, A., Huang, L., Ghatak, S. & Toole, B.P. 2003, "Elevated hyaluronan 
production induces mesenchymal and transformed properties in epithelial 
cells", The Journal of biological chemistry, vol. 278, no. 46, pp. 45801-45810. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Publications of the University of Eastern Finland
Dissertations in Health Sciences
isbn 978-952-61-1814-7
Publications of the University of Eastern Finland
Dissertations in Health Sciences
d
issertatio
n
s | 28
9 | T
im
o
 K
. N
yk
o
pp | E
xp
ression
 of H
yalu
ron
a
n
 S
yn
th
a
ses a
n
d H
yalu
ron
id
a
ses in
 G
yn
ecological M
align
a
n
cies
Timo K. Nykopp
Expression of Hyaluronan
Synthases and Hyaluronidases
in Gynecological Malignancies Timo K. Nykopp
Expression of Hyaluronan 
Synthases and Hyaluronidases 
in Gynecological Malignancies
Hyaluronan is an abundant high-mo-
lecular weight polysaccharide in the 
extracellular matrix. Its accumulation 
is observed in several types of malig-
nancies. In this study, the mechanism 
of hyaluronan accumulation was 
clarified by analyzing the expression 
of hyaluronan synthesis (HAS1-3) 
and degradation (HYAL1-2) enzymes 
in normal, precancerous and can-
cerous states of human ovaries and 
endometria. Decreased HYAL1 levels 
were associated with increased tu-
moral hyaluronan content in ovarian 
and endometrial carcinomas. Fur-
thermore the decreased expression 
of HYAL1 was associated with more 
aggressive type of endometrial car-
cinoma and predicted early disease 
recurrence.
